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Abstract 
The classical immunoglobulin family of cell adhesion molecules, known as the IgCAMs, 
have been characterised as having an important adhesive function at areas of cell-cell 
contact and from cell to extracellular matrix. Members of this family have been shown 
to participate in signal transduction and increasingly it seems that this could be a 
general feature of the IgCAM family rather than the exception. We aimed to determine 
whether IgCAMs that undergo retrograde axonal transport in neurons contribute to 
neuronal viability and co-operate with neurotrophin signalling.  
Activated Leukocyte Cell Adhesion Molecule (ALCAM) was identified in cells of 
immune system as the binding partner of the T-cell glycoprotein CD6, where it 
contributes to normal T-cell activation. Additionally ALCAM has been shown to have an 
important role in the nervous system, where it is involved in neuron pathfinding and 
development of the neuromuscular junction. 
We identified ALCAM as a protein associated with the axonal retrograde transport 
compartment containing neurotrophins and their receptors in primary ventral horn 
neurons. I found that ALCAM is bidirectionally transported in neurons, and 
predominantly cotransported with the neurotrophin receptor p75NTR toward the cell 
body. Furthermore, I found ALCAM could specifically potentiate neurotrophic signalling. 
ALCAM overexpression resulted in extension of longer neuritic processes in PC12 cells 
treated with nerve growth factor (NGF). The extracellular domain is both necessary and 
sufficient to potentiate NGF-induced neurite outgrowth, while the transmembrane and 
cytoplasmic domain have no effect. ALCAM overexpression only potentiated specific 
growth factor stimuli but had no effect on other pathways leading to differentiation or on 
undifferentiated PC12 cell morphology.  
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In conclusion, ALCAM appears to synergise with NGF signalling to induce neuronal 
differentiation and may have a role in the nervous system not only as an adhesion 
molecule but also in neurotrophin signalling.  
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Chapter 1. Introduction 
The human brain is estimated to contain around 100 billion neurons and each one is 
required to make the necessary connections with other neurons or target tissues to 
build the networks required for life. Further complexity arises, as individual neurons are 
specialised cells with a highly polarised architecture and specific function. Neurons 
have a cell body that contains the nucleus, a dendritic compartment consisting of many 
dendrites that receive synaptic input, and a long axon that transmits electrical signals 
to target cells. The cell body contains only a fraction of the total cellular cytoplasm and 
organelles (1-10%), whilst the remaining proportion is localised in the dentritic tree and 
axon, possibly at great distances from the nucleus. This arrangement presents unique 
challenges to neuronal cells during development and maintenance of the nervous 
system.  
The development of the nervous system was classically described as being dependent 
on soluble long-distance cues and membrane bound short-distance signposts. It was 
proposed that distinct molecules mediated these two guidance mechanisms. In recent 
years however, it has become increasingly apparent that not only do long and short-
distance cues cooperate with each other, but that important players can actually have 
dual functions and participate in both pathways. In this thesis, I aimed to investigate 
whether activated leukocyte cell adhesion molecule (ALCAM) found in an axonal 
retrograde signalling endosome of ventral horn neurons, cooperated with 
neurotrophins, mediators of long-range signalling during development. 
Chapter 1. Introduction 
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1.1 Neurotrophins, their receptors and retrograde signalling 
The first neurotrophin to be described was nerve growth factor (NGF) discovered by 
Rita Levi-Montalcini as a result of work started in the 1950s (Aloe, 2004). Studies of the 
chick limb in Victor Hamburger’s lab led to the observation that neurons were 
overproduced in development, and their subsequent survival depended on the 
presence of target tissues. While in Hamburger’s lab, Levi-Montalcini noticed that 
mouse tumours implanted in the chick limb resulted in hyperinnervation of resident 
internal organs. She suggested that this unusual observation was because the tumours 
produced a diffusible agent stimulating neuron growth and differentiation (Levi-
Montalcini and Hamburger, 1951). In 1960, Levi-Montalcini isolated the secreted 
protein, named NGF, in collaboration with Stanley Cohen, for which both shared the 
1986 Nobel Prize for Physiology or Medicine. Since the initial identification of NGF, 
many studies on neurotrophins have shown that distinct neuronal populations use 
specific neurotrophin signalling pathways for axon guidance and cell survival during 
development (reviewed in Zweifel et al., 2005). To date, many other growth factors 
have been discovered and they are currently under intensive investigation since they 
provide potential therapies for many neurodegenerative conditions. 
In addition to NGF there are 3 other members of the neurotrophin family: Brain derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT3) and neurotrophin-4/5 (NT4/5). 
Neurotrophins bind to two types of receptors. They bind with ligand specificity to 
tropomyosin receptor kinases (Trk); NGF binds to TrkA, BDNF and NT4/5 bind TrkB, 
while NT3 binds to TrkC (Figure 1.1). Trk receptors dimerise on ligand binding, 
autophosphorylate, and this in turn activates downstream signalling cascades including 
the serine/threonine protein kinase (Akt) and mitogen-activated protein kinase (MAPK). 
On the other hand, all the neurotrophins as well as their immature forms 
Chapter 1. Introduction 
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(proneurotrophins) can bind the p75NTR receptor. The p75NTR receptor is a member of 
the tumour necrosis family (TNF) receptor superfamily and has no intrinsic catalytic 
activity but through associations with other membrane partners it can elicit downstream 
signalling. Activation of the receptor can lead to diverse responses depending on the 
ligand bound and the co-receptor engaged (reviewed in Schecterson and Bothwell, 
2010) and (Vilar et al., 2009). For example, p75NTR activation can lead to apoptosis 
when it binds proneurotrophins in complex with sortilin, can promote cell survival in the 
presence of TrkA, and can induce growth cone collapse when associated with the nogo 
receptor (Schecterson and Bothwell, 2010). The complexity and diversity of the 
interactions between neurotrophins and their receptors is important when considering 
the widespread and varied function of these factors during development that is tightly 
regulated in time and space. 
The neurotrophin hypothesis states that neurons are overproduced during 
development and only those that successfully compete for limited target-derived factors 
survive (reveiwed in Zweifel et al., 2005). Critical to this proposal is the implication that 
retrograde signals need to be transmitted from target tissues to the neuron cell body. 
Initial evidence that neurons were indeed engaged in retrograde signalling was that 
neurotrophins could undergo retrograde transport e.g. radiolabelled NGF applied in the 
periphery was found in the neuron cell body (Hendry et al., 1974). More recently, 
signalling endosomes have been proposed to mediate the transport of activated 
neurotrophin receptors and the neurotrophins themselves to maintain neuron survival 
(reviewed in Ibanez, 2007). Introduction of neurotrophins directly into the cytoplasm of 
the PC12 cells did not sustain survival, and suggested that neurotrophins need to bind 
to membrane receptors to elicit the survival response (Heumann et al., 1981). 
Subsequent studies found that the receptors had to undergo internalisation and 
transport to sustain survival and that following transport at least some receptors need 
Chapter 1. Introduction 
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to remain bound to their ligand to fulfil their trophic function (Watson et al., 1999, Ye et 
al., 2003). 
Another important aspect of long-distance growth factor signalling in neurons is that 
ligand and receptor have to undergo the appropriate sorting upon internalisation and 
entry into the endocytic system. TrkA has been reported to undergo both clathrin-
dependent and clathrin-independent mechanisms of endocytosis, and following NGF 
stimulation has been predominantly found in multivesicular bodies and within 
compartments associated with the small GTPases Rab5 and Rab7 (reviewed in Moises 
et al., 2007). The Rab family of small GTPases are regulators of intracellular trafficking 
events, and they recycle between a predominantly cytosolic GDP-bound form and an 
active GTP-bound membrane-associated form (reveiwed by Ng and Tang, 2008). 
Dominant-negative mutants of dynamin and Rab7 show that Trk internalisation is 
important in regulating neurotrophin signalling, cell survival and differentiation (Saxena 
et al., 2005, Zhang et al., 2000).  
Although common themes are emerging, the exact nature of the signalling endosome 
as it undergoes axonal transport remains controversial, because findings change 
depending on the cell type and stimulation paradigm used (reviewed by Ibanez, 2007 
and Cosker, 2008 #214). Although most studies investigating TrkA endocytosis have 
been conducted in cell lines, similar endocytic proteins have been observed associated 
with neurotrophin receptor-containing endosomes in primary neurons (e.g. Rab5 and 
Rab7) (Ibanez, 2007). In Deinhardt (2006b) the p75NTR neurotrophin receptor was 
found to undergo constitutive clathrin-independent endocytosis, recycling back to the 
plasma membrane in basal conditions and only in the presence of NGF was p75NTR 
directed into a clathrin-dependent endocytic pathway linked to the retrograde transport 
route (Deinhardt et al., 2007). This illustrates that the fate of the receptor depends on 
Chapter 1. Introduction 
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the presence of ligand and its type. Endosomes undergoing microtubule associated 
fast axonal transport in neurons have been reported to travel at rates ranging from 0.5-
5 μm/s. The speeds of axon transport observed in vitro are consistent with, and could 
account for, the observed times taken between neurotrophin exposure at axon 
terminals and their appearance in cell bodies in vivo, e.g. 2.5 mm/hour (Hendry et al., 
1974).  
Interestingly, following retrograde transport, the signalling cascades activated in the 
cell body can be distinct to that observed after direct activation of the soma. Local 
application of NGF to cell bodies or axons in compartmentalised chambers activated 
both extracellular-signal-regulated kinases 1/2 (ERK1/2) and ERK5 MAPK pathways 
(Watson et al., 2001). However, upon NGF stimulation of distal axons, only ERK5 was 
phosphorylated in the cell soma and this was necessary for survival and the 
phosphorylation of transcription factors e.g. cyclic-AMP response element binding 
protein (CREB) (Watson et al., 2001). 
It is noted that other retrograde signalling mechanisms, independent of signalling 
endosomes, have been proposed in recent years (reviewed in Ibanez, 2007). Firstly, it 
has been suggested that lateral propagation of receptor phosphorylation at the cell 
surface and waves of increased intracellular calcium could transmit quick retrograde 
signals. However evidence is currently lacking on whether these mechanisms are 
relevant to neuronal signal transduction where propagation has to travel for long 
distances, and it is unresolved how the directionality of the signal could be maintained. 
Secondly, there is evidence for direct association of signalling molecules with the 
transport machinery, independent of signalling endosomes. After injury, Fainzilber and 
colleagues found that axonal importins bind cytoplasmic dynein and retrogradely 
transport various proteins with nuclear localisation sequences (reviewed in Hanz and 
Chapter 1. Introduction 
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Fainzilber, 2006). Nevertheless, it appears that retrograde transport is an important 
aspect of delivering signals from the periphery to the cell body. 
Chapter 1. Introduction 
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Figure 1.1 Neurotrophins and their receptors 
Two TrkA receptors are depicted binding an NGF dimer to activate downstream 
signalling for survival, growth and differentiation. The other Trk receptors and their 
relative preference for neurotrophins are shown, with BDNF and NT4/5 binding TrkB, 
while NT3 binds TrkC. The p75NTR receptor can interact with Trk receptors and 
contributes to survival signalling as indicated (dotted arrow). The p75NTR receptor can 
also bind proneurotrophins (ProNT) in complex with sortilin to activate apoptosis and 
cell death pathways, or bind to the Nogo receptor (NgR) complex to induce growth 
cone collapse.  
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1.2 Axonal transport 
The unique architecture of neurons results in the majority of their cytoplasm being 
contained within their axon and dendrites, some at great distance from the cell soma. 
For example for a motor neuron, whose cell body is around 50 μm in diameter, its axon 
could reach over 1 metre in humans, e.g. for those innervating the lower limb muscles 
– which is equivalent to 20,000 times the diameter of the cell body. This makes 
neurons particularly dependent on active transport, since organelles, proteins, energy 
and signals are required to travel over great distances (reviewed in Salinas et al., 2008, 
Perlson et al., 2010). A schematic illustrating the process of axonal transport is shown 
in Figure 1.2. Newly synthesised material is transported anterogradely, away from the 
cell body towards the cell periphery, e.g. protein and membrane components, 
mitochondria and mRNAs required for local translation. Simultaneously, proteins and 
organelles targeted for degradation are transported back to the soma. Importantly, as 
well as maintaining synthetic and degradative processes, axonal transport is involved 
in regulating cell signalling. For example, as explained in section 1.1, neurotrophins 
secreted from target tissues need to be retrogradely transported to the cell body to 
elicit their full survival response. Axonal transport requires molecular motors to move 
along the cytoskeleton using energy from ATP hydrolysis. Anterograde axonal 
transport is predominantly associated with kinesin motors that move towards the plus 
ends of microtubules, while cytoplasmic dynein is the main retrograde motor and 
travels towards the microtubule minus ends. In axons, unlike dendrites, microtubules 
are almost all oriented so that the plus ends are located at the nerve terminal while the 
minus ends are toward the cell body (reviewed in Salinas et al., 2008) 
Disruption in axonal transport has been associated with many neurodegenerative 
conditions supporting the view that this process is of particular importance to neuronal 
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survival (reviewed by De Vos et al., 2008). Mutations in the kinesin motors KIF5a and 
KIF1B have been associated with neurodegeneration in families with hereditary 
spastic paraplegia and charcot-marie-tooth type 2A neuropathy respectively (Xia et al., 
2003, Zhao et al., 2001). Furthermore, mutations in the p150Glued subunit of dynactin, a 
component of the retrograde dynein motor complex, cause spinal and bulbar muscular 
atrophy (SBMA) in human patients (Puls et al., 2005).  
Further evidence from animal models suggests that mutations disrupting axonal 
transport are sufficient to cause neurodegeneration. Defects in axonal transport have 
been observed in affected neurons in Drosophila and mouse models of Huntington’s 
disease following overexpression of mutant huntingtin, a motor-associated protein 
(Gunawardena et al., 2003, Her and Goldstein, 2008). Mice that express a dominant 
negative form of dynactin, known to disrupt dynein function, have progressive motor 
neuron loss (LaMonte et al., 2002), and mice with mutations within the heavy chain of 
cytoplasmic dynein (cra and loa), show axonal transport defects and a sensory neuron 
degenerative phenotype (Hafezparast et al., 2003, Chen et al., 2007).  
Defects in axonal transport have also been observed in neurodegenerative conditions 
even when the primary causative mutation is not directly linked to axonal transport. A 
defect in retrograde axonal transport is one of the earliest pathogenic events observed 
in the SODG93A mouse model of amyotrophic lateral sclerosis (Williamson and 
Cleveland, 1999, Kieran et al., 2005, Bilsland et al., 2010). This suggests that 
disruption of axonal transport is a common contributing factor to neurodegeneration. 
When SODG93A mice are crossed with loa mice, with a mutation in cytoplasmic dynein, 
the axonal transport deficits are no longer observed and the mice survive significantly 
longer than their SODG93A littermates (Kieran et al., 2005). Although the mechanism by 
which the dynein mutation alleviated SODG93A neurodegeneration remains unknown, it 
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has recently been associated with alleviation of the SODG93A mitochondrial pathology 
(El-Kadi et al., 2010). The study by Kieran et al (2005) indicates that axonal transport is 
directly involved in the disease process since improvement in transport correlated with 
delayed disease progression.  
It has not yet been determined how defects in axonal transport can lead to 
neurodegeneration but it is likely to involve several pathways (reviewed by Perlson et 
al., 2010). As illustrated in Figure 1.2, axonal transport is required to balance general 
house keeping functions between the periphery and cell body. Evidence of aberrant 
mitochondrial transport and localisation in neurodegenerative diseases suggest that 
the energy supply of neurons is disrupted (De Vos et al., 2007). As well as aberrant 
energy supplies, there is evidence of disruption in degradation of proteins and 
organelles in neurodegenerative conditions. Defects in the distribution and transport of 
lysosomes has been observed e.g. in a model of motor neuron disease (Chevalier-
Larsen et al., 2008). Mice with loss of autophagy (a process for bulk protein 
degradation) specifically in neurons have poly-ubiquitinated protein accumulations and 
show neurodegeneration (Komatsu et al., 2006).  
Since neurotrophic signalling requires retrograde transport to maintain neuronal 
survival, defects in axonal transport are likely to result in misregulation of signalling.  In 
mouse models of neurodegeneration exogenous supply of growth factors can only 
delay, but cannot prevent, disease progression (Dodge et al., 2010) and neurotrophins 
have had limited success in treatment of human disease (Thoenen and Sendtner, 
2002). This would suggest that additional signals to neurotrophic factors are required 
for motor neuron survival. Similar defects in axonal transport were observed in 
embryonic neurons from two distinct mouse models of neurodegeneration with very 
different rates of disease progression (Kieran et al., 2005), and this can be partially 
Chapter 1. Introduction 
 25 
explained by differences in the transport of death signals in the two models (Perlson et 
al., 2010). However, neurodegenerative conditions do not only concern pathological 
processes within neurons, but also involve interactions with their environment through 
non-cell autonomous processes e.g. that involve the surrounding glial cells (Boillee et 
al., 2006). In view of the complexity of neurodegenerative diseases, which involve 
multiple cell types and pathological mechanisms, it is likely that other retrograde factors 
that contribute to neuron viability and function have yet to be identified. 
Axonal transport was initially studied in squid giant axoplasm preparations, where the 
movement of motors along microtubules could be recorded in the presence of various 
inhibitors and pathogenic proteins (for example Brady et al., 1993). However, this 
system is limited in its physiological relevance since it is quite far removed from the 
environment of a mammalian intact axon. To follow retrograde transport in vivo, the 
endogenous properties of infective viruses and bacterial toxins known to undergo 
internalisation and transport to the central nervous system, have been used (reviewed 
by Salinas et al., 2010). Alternatively, protein and organelle accumulation can be 
examined both proximally and distally to nerve ligations. This has been used to 
examine the transport of anterograde and retrograde cargoes in vivo and to determine 
the relative transport efficiency in various pathological states (for a recent study see 
Perlson et al., 2009). However, these methods inferred transport by analysing the 
accumulation of labelled toxin, virus or protein of interest ex vivo, rather than directly 
measuring transport dynamics. More recently, cellular and molecular biology 
techniques have allowed analysis of transport in living neurons in vitro e.g. transport of 
TrkB and NgCAM cell adhesion molecule using fluorescent tags or antibodies to these 
proteins (Ascano et al., 2009, Yap et al., 2008). However, in these studies the proteins 
of interest were transfected into differentiated neuronal cell lines and primary neurons 
that could potentially alter endogenous trafficking processes. In our laboratory, we 
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have taken advantage of the endogenous properties of the binding fragment of the 
tetanus toxin to make a fluorescent probe that allows axonal retrograde transport to be 
examined in living neurons in vitro and in vivo (Lalli and Schiavo, 2002, Bilsland et al., 
2010). 
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Figure 1.2 Axonal transport and its functions 
The dendrites and cell body of a typical neuron are shown on the left, with the axon 
projecting to the target synapse on the right. Newly synthesised proteins, mitochondria, 
mRNA, and proteins from the dendritic plasma membrane (indicated by Transcytosis1) 
and are all transported anterogradely toward the target synapse (blue arrows). 
Mitochondria, proteins targeted for degradation and retrograde signals are transported 
from the synapse to the cell body (red arrows). Once in the soma the retrograde 
cargoes are sorted to their next destination. This could be to the nucleus to activate 
transcription, e.g. CREB transcription, or activate signalling in the cytosol. Cargoes 
could be targeted to lysosomes for degradation (Lys), or transcytosed to the plasma 
membrane (Transcytosis2).  
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1.3 The binding fragment of the tetanus toxin labels a 
retrograde axonal transport compartment 
Toxigenic strains of bacteria of the genus Clostridia produce the tetanus toxin (TeNT) 
and the seven serotypes of botulinum toxins (BoNT). These neurotoxins bind neurons 
with high affinity and cause spastic or flaccid paralysis respectively (reviewed in Lalli et 
al., 2003a). Both TeNT and BoNT are internalised in motor neurons at the 
neuromuscular junction (NMJ). Several serotypes of BoNT bind to proteins of synaptic 
vesicles, such as synaptotagmin and SV2A-C and remain at the NMJ where they 
cleave soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor 
(SNARE) proteins and block exocytosis of acetylcholine. In certain circumstances 
BoNT/A was shown to undergo retrograde transport and reach distant sites in the 
central nervous system (CNS) (Antonucci et al., 2008). Following clathrin-dependent 
endocytosis (Deinhardt et al., 2006a) TeNT is not retained at the NMJ but directed to a 
long-range transport pathway to the motor neuron cell body in the spinal cord. Here, 
TeNT is transcytosed to inhibitory interneurons where it cleaves the SNARE protein 
VAMP/synaptobrevin and blocks neurotransmission. This results in the excessive 
stimulation of motor neurons, which in turn causes spastic paralysis in their target 
muscles. The route of internalisation and transport of TeNT is shown in Figure 1.3. It is 
known that the carboxy-terminal fragment (Hc) of clostridial neurotoxins are 
responsible for neuron binding specificity and therefore members of our laboratory 
previously designed this atoxic Hc fragment to follow the internalisation and retrograde 
transport route used by the TeNT holotoxin (reviewed by Lalli et al., 2003a). 
The Hc fragment has been engineered with several molecular tags i.e. a vesicular 
stomatitis virus protein G epitope (VSVG) (Herreros et al., 2000) and a cysteine-rich 
region (Lalli et al., 2003b). This allows for the atoxic toxin fragment to be easily and 
Chapter 1. Introduction 
 29 
specifically modified with fluorophores, such as Alexa Fluor dyes, to visualise the 
transport of Hc in live neurons in live-cell imaging experiments (Lalli and Schiavo, 
2002). The Hc-containing endosome undergoes long-range retrograde axonal transport 
that is dependent on dynein function and the myosin Va motor (Lalli et al., 2003b). 
Further studies found that the Hc-labelled endosome also contained neurotrophins 
such as BDNF and NGF, and neurotrophin receptors p75NTR and TrkB (Lalli and 
Schiavo, 2002, Deinhardt et al., 2006b). This retrograde axonal transport compartment 
is considered to be a non-degradative compartment as it is non-acidic (Bohnert and 
Schiavo, 2005), and does not label with LysoTracker (Lalli and Schiavo, 2002). The 
Hc-containing endosome associates with Rab5 and Rab7 GTPases (Deinhardt et al., 
2006b), which as discussed in section 1.1, are associated with neurotrophin signalling 
endosomes. It is thought that this is a sequential process, with Rab5 involved in the 
early steps of internalisation, while Rab7 activity is required for long-distance vectorial 
transport along the axon (Deinhardt et al., 2006b). Interestingly, mutations in Rab7 are 
associated with Charcot-Marie-Tooth type 2B neuropathy (Verhoeven et al., 2003), 
consistent with the idea that this small GTPase has an important role in neurons. 
In our laboratory a method to purify the axonal retrograde transport compartment using 
the Hc fragment conjugated to monocrystalline iron oxide nanoparticles (MION) was 
developed (Deinhardt et al., 2006b). It was shown that the Hc-MION undergo 
endocytosis and transport in living ventral horn neurons in culture. By harvesting the 
neurons in the absence of detergent and mechanically breaking the plasma membrane 
it was possible to purify the endosomes containing Hc-MION by passing post-nuclear 
supernatants through a magnet. A schematic illustrating the experiment is shown in 
Figure 1.4. Using this technique, it was demonstrated biochemically that the Hc-
labelled endosome contained the neurotrophin receptor p75NTR and the small GTPases 
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Rab5 and Rab7, confirming the associations observed in live-cell imaging experiments 
(Deinhardt et al., 2006b).  
In a similar experiment performed by K. Deinhardt in our laboratory, these purified Hc-
labelled organelles were analysed by mass spectrometry (unpublished data). This 
allowed for large-scale analysis of the proteins associated with the axonal retrograde 
transport compartment. Several proteins found in this proteomic analysis were known 
to be associated with the Hc endosome by western blot and live-cell imaging, and 
served as positive controls. These included several motor complexes, such as myosins 
and cytoplasmic dynein subunits, as well as the small GTPases Rab5 and Rab7. Of 
the 348 proteins identified, the majority (216) were classified as cytoplasmic/membrane 
proteins, i.e. not mitochondrial, nuclear or ribosomal. Of the cytoplasmic/membrane 
proteins, around 12% were plasma membrane proteins, which included ion channels 
and transporters and many cell recognition molecules. All the major classes of cell 
adhesion molecules (CAM) were represented including selectins, integrins, and 
members of the immunoglobulin cell adhesion molecule (IgCAM) superfamily. Although 
cadherins were not directly identified, junction plakoglobin, an intracellular protein 
associated with the E-cadherin/catenin complex, was found in the mass-spectrometry 
proteomic analysis. Additionally cadherin13 had been identified in a previous proteomic 
screen undertaken in the laboratory, of proteins that immunoprecipitated with Hc within 
lipid raft fractions (unpublished data). Table 1 provides a list of the cell recognition 
molecules identified in the Hc proteome.  
I was particularly interested in whether the CAMs present in the Hc-labelled axonal 
retrograde transport compartment were undergoing long-range transport, and if so 
whether these were distinct carriers from the neurotrophin containing endosomes. 
Considering that in recent years CAMs have been shown to have diverse roles in 
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signalling, I also wanted to see whether the CAMs present in the axonal transport 
compartment are involved in the modulation of neurotrophin signal regulation.  
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Figure 1.3 TeNT Hc internalisation and transport 
TeNT Hc is endocytosed from the plasma membrane at the neuromuscular junction 
and is retrogradely transported along microtubules (brown) to the cell soma, where it is 
transcytosed to inhibitory interneurons to block their exocytosis. Hc binds to polysialo-
gangliosides on the cell surface, as well as some GPI-anchored (e.g. Thy1.1) and 
transmembrane receptors (yellow) (Herreros et al., 2000). In the retrograde transport 
compartment neurotrophin receptors TrkA and p75NTR and their ligands (antibodies (Y) 
or neurotrophins, NGF blue circle) are found (lower inset). The retrograde axonal 
compartment is also associated with the GTPases Rab5 and Rab7 and the retrograde 
motor complex dynein and dynactin (upper inset). 
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Figure 1.4 Endosome purification using Hc-MIONs 
This scheme shows the binding and subsequent internalisation of Hc-coupled MIONs. 
Cells were then homogenised, samples clarified by centrifugation and postnuclear 
supernatant separated using a magnetic column. Protein eluted from the beads was 
used for mass-spectrometry or western blot. Samples were compared to the flow 
through that contains proteins not associated with the beads. 
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Protein Accession 
Number 
Score 
(peptide 
number) 
Confirmation 
Integrin, beta-1 precursor  P09055 93.13   
Integrin, beta 6 Q6AYF4 39.01   
E-selectin ligand 1 Q61543 64.08   
Junction plakoglobin 
(Desmoplakin-3) (Desmoplakin III)  
Q02257 38.08 RP, IF 
Neural cell adhesion molecule 1, 
140 kDa isoform precursor 
P13596 63.28 RP, IF 
Coxsackievirus and adenovirus 
receptor homolog precursor (CAR) 
P97792 43.66 LC, IF, WB 
Poliovirus receptor-related protein 
2 precursor (Murine herpesvirus 
entry protein B) (Nectin-2) 
P32507 35.89   
CD166 antigen precursor 
(Activated leukocyte cell 
adhesion molecule) 
O35112 51.14   
CD147 antigen; Basigin precursor 
(OX-47 antigen) (Glycoprotein 
CE9); 
P26453 41.22   
Reticulon-4 (Neurite outgrowth 
inhibitor) (Nogo protein) 
Q9JK11 97.98   
Nidogen-1 precursor (Entactin);  P10493 56.94   
Erythrocyte band 7 integral 
membrane protein (Stomatin) 
(Protein 7.2b)  
P54116 38.54   
Glypican-4 precursor (K-glypican);  P51655 54.2   
Table 1 Cell surface proteins associated with the Hc-labelled axonal 
retrograde transport compartment 
Components of integrin, selectin and cadherin binding complexes are coloured in 
orange, green and yellow respectively. IgCAM superfamily members are coloured in 
blue and ALCAM, which has been investigated in this thesis, is in bold. Other cell 
membrane proteins identified are also shown (uncoloured) and include reticulon-4 a 
protein associated with neurite outgrowth inhibition. NCAM, CAR and junction 
plakoglobin had already been confirmed by other techniques to associate with the Hc-
endosome (RP- Hc-raft proteome; LC live-cell imaging; IF immunofluorescence; WB 
western blot).  
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1.4 Cell adhesion molecules (CAM) 
Cell adhesion molecules (CAMs) are critical for the development and maintenance of 
tissue architecture necessary for multicellular life. These cell surface proteins are 
responsible for cell to cell, and cell to extracellular matrix interactions and comprise of 
the cadherin, integrin, selectin and immunoglobulin (Ig) families. None of these proteins 
have intrinsic enzymatic activity and therefore were not defined as receptors. However, 
extensive evidence now exists that CAMs are capable of signalling and have important 
roles in growth factor signalling regulation (reviewed in Schmid and Maness, 2008, 
Maness and Schachner, 2007). 
The IgCAM superfamily, are transmembrane proteins with large extracellular domains 
and shorter cytoplasmic tails responsible for interactions with the cytoskeleton. It is one 
of the largest protein families. For example, over 1% of the predicted genes in the 
Drosophila genome are Ig-domain-containing proteins suggesting that they have 
important, diverse, though perhaps redundant functions (Kamiguchi and Lemmon, 
2000). L1 and neural cell adhesion molecule (NCAM) are two prototypical proteins from 
this family and are the best characterised (reviewed in Schmid and Maness, 2008). 
The properties of these two proteins as examples of the diverse interactions and 
functions that members of the IgCAM superfamily have are discussed below. Figure 
1.5 is a schematic representing the protein structures and some of their known 
properties. 
NCAM was the first identified cell adhesion molecule in the nervous system (reviewed 
in Maness and Schachner, 2007). The three major NCAM isoforms have identical 
extracellular domains that contain 5 Ig domains, followed by 2 fibronectin type-III (FN 
III) repeats. There are two transmembrane isoforms of NCAM that differ by a 261 
amino acid insertion in the cytoplasmic domain (NCAM-140 and NCAM-180 without 
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and with the insert respectively) and a Glycosylphosphatidylinositol (GPI) anchored 
form (NCAM-120) that is expressed predominantly on glial cells. The relative 
expression of these isoforms changes throughout development, with the 180 kDa form 
increasing with age and being associated with the stabilisation of synapses. Post-
translational modification generates an alternative NCAM form that is glycosylated on 
its 5th Ig domain with poly-sialylated acid side chains (PSA). This is thought to inhibit 
homophilic interactions causing decreased adhesion. NCAM-PSA is also 
developmentally regulated, and decreases in adulthood when it is only found at sites of 
neuritogenesis and where it has been linked to synaptic plasticity.   
Apart from its role in cell adhesion, NCAM has been shown to have diverse functions in 
growth factor signalling and its regulation. NCAM interacts with the fibroblast growth 
factor receptor (FGFR) signalling pathways in several ways. NCAM homophilic binding 
can potentiate neurite outgrowth in a FGFR-dependent manner, the mechanism of 
which is not yet fully understood (Saffell et al., 1997). NCAM can also bind directly to 
FGFR, and peptides either interfering or mimicking NCAM-FGFR binding can inhibit or 
activate FGFR downstream signalling respectively, leading to changes in differentiation 
and survival (Neiiendam et al., 2004, Anderson et al., 2005). Interestingly their co-
signalling is context-dependent; NCAM signalling in neurite outgrowth is independent 
of FGFR when resident in lipid rafts, while FGFR-dependent when in non-raft 
membranes (reviewed in Maness and Schachner, 2007). Furthermore, NCAM can act 
as the co-receptor for GDNF in the presence of GDNF family receptor alpha (GFR), 
and acts as an alternative co-receptor in GDNF signalling in cells that do not express 
the classical GDNF receptor RET (Paratcha et al., 2003). Recently the intracellular 
domain of NCAM has been shown to interact directly with the kinase domain of TrkB 
(Cassens et al., 2010). The authors of this study found that TrkB activation results in 
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NCAM phosphorylation, which in turn regulates NCAM-mediated neurite outgrowth, 
suggesting that a functional relationship exists between NCAM and TrkB signalling.  
The L1-CAM family consists of L1, Close-Homolog of L1 (CHL1), NrCAM and 
Neurofascin. All members have 6 Ig domains, followed by 4 or 5 FN III domains, which 
only show around 35-45% overall homology, but are more highly conserved within their 
cytoplasmic tails. L1 is known to bind several proteins in the cytoplasm, which are 
important for its function. L1 binds to ankyrin via a conserved FIGQ/AY motif that is 
responsible for anchorage to the actin cytoskeleton. Tyrosine phosphorylation within 
the L1 motif inhibits ankyrin binding and interactions with the cytoskeleton, which in 
turn increases migration and neurite outgrowth (Whittard et al., 2006). L1 also plays a 
role in axon guidance, where it can mediate growth cone collapse by acting as a co-
receptor for Semaphorin 3a with Neuropilin-1 (Castellani et al., 2002). Similarly to 
NCAM, L1 can cooperate with growth factor signalling cascades, for example 
transfection of L1 increased sustained ERK1/2 activation in response to serum or 
Platelet derived growth factor (PDGF) (Silletti et al., 2004).  
Both L1 and NCAM cooperate with integrin signalling. Integrins are another family of 
CAMs important for cell to extracellular matrix interactions and are capable of inside-
out and outside-in signalling (reviewed in Ivaska and Heino, 2010). L1 has a conserved 
arginyl-glycyl-aspartic acid (RGD) motif in its extracellular 6th Ig with which it interacts 
with v5-integrin (Mechtersheimer et al., 2001). A second motif in the 3rd FN III 
domain can also recruit integrins in a non-RGD-dependent manner (Silletti et al., 
2000). Interactions between integrins and L1 have also been shown to cooperate with 
growth factor signalling. Phosphorylation of the L1 cytoplasmic domain can alter its 
extracellular conformation (Chen et al., 2010). These alternative L1 extracellular 
domain conformations show differential binding to specific integrins, and in turn this 
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has been associated with altered L1 proteolysis and migration (Chen et al., 2010). The 
way in which NCAM interacts with integrins is less well resolved but they have been 
shown to converge on the same downstream MAPK pathway and this ability depends 
on FYN and FAK kinases downstream of NCAM (Maness and Schachner, 2007). 
Integrin functions are intimately linked to their endocytic recycling (Caswell et al., 
2009). In Pellinen et al (2006) integrins were found to associate directly with the Rab 
GTPase Rab21. Rab21 activity regulated integrin internalisation, which in turn altered 
integrin mediated adhesion and migration. Similarly, evidence suggests that 
endocytosis also contributes to IgCAM function and regulation. The neuron specific 
isoform of L1 encodes a RSLE motif that recruits the AP2 clathrin adaptor, which is 
required for endocytosis of L1 at the growth cone and is important for axon growth 
(Kamiguchi et al., 1998). This interaction is also regulated by the phosphorylation state 
of the tyrosine residue immediately adjacent to the AP2 binding motif (YRSLE) 
(Schaefer et al., 2002). On dephosphorylation, L1 is preferentially endocytosed at 
specific areas of cell-cell contact e.g. rear of the growth cone and its endocytosis is 
necessary for neurite outgrowth on L1 substrate. NCAM can also undergo regulated 
endocytosis in neurites. NCAM was shown to be endocytosed after antibody-induced 
clustering on the plasma membrane of cell bodies followed by recycling back to the 
plasma membrane (Diestel et al., 2007). In this study the authors found NCAM in a 
mono-ubiquitinated form on the plasma membrane after antibody clustering and 
suggested that this could be the endocytosis signal. It is noted that this study was 
performed using transfected protein in primary neurons and cell lines, and that the 
process has yet to be reported in vivo. Interestingly, NCAM was found to be associated 
with the Hc axonal retrograde transport vesicle by mass spectrometry (see Table 1), as 
well as in the Hc-associated raft proteomic screen, which may suggest that 
endogenous NCAM undergoes endocytosis in ventral horn neurons. 
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There is growing evidence to suggest that IgCAMs can undergo a specialisation of the 
endocytic pathway known as transcytosis, where proteins can be transported from the 
plasma membrane of one compartment and travel to another. Transcytosis has been 
characterised in endothelial cells where proteins are transported from basolateral 
membrane to the apical membrane or vice versa. In neurons a similar process has 
been observed for proteins transcytosed from the plasma membrane of the dendritic 
compartment to the axon and vice versa (see Figure 1.2 for examples). Work by 
Winckler and colleagues have shown that the chick homolog of L1, NgCAM, undergoes 
a regulated process of transcytosis, whereby the protein is targeted to the 
soma/dendritic compartment plasma membrane before internalisation and targeting to 
the axon (Wisco et al., 2003). It is suggested that transcytosis is important for the 
maintenance of the compartmentalisation of proteins within the polarised architecture 
of the neuron. Indeed, it has been found that the process is regulated by the neuron-
enriched endosomal protein of 21 kDa (NEEP21), and if this is disrupted, L1 loses its 
restriction to the axon and is also erroneously found within the plasma membrane of 
the dendritic compartment (Yap et al., 2008). Transcytosis is of particular interest in the 
context of the Hc-labelled axonal retrograde transport compartment, because 
transcytosis has been observed for neurotrophins, neurotrophin receptors and the 
tetanus toxin itself (Rind et al., 2005, Ascano et al., 2009), and could be a destination 
of other endogenous proteins within the Hc-positive endosome. 
Another important property of L1 and NCAM is that both proteins are substrates for 
disintegrin and metalloprotease (ADAM) membrane proteolysis. Ectodomain shedding 
can downregulate CAM dependent migration and adhesion but can also result in 
autocrine stimulation. NCAM ectodomain shedding has been shown to inhibit cortical 
neuron outgrowth, while it stimulates hippocampal neuron outgrowth (Hubschmann et 
al., 2005, Hinkle et al., 2006). This again illustrates the context-dependence of IgCAM 
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signalling. L1 is not only cleaved by ADAM17 and ADAM10 but also undergoes 
regulated intramembrane proteolysis by -secretase, to produce an intracellular 
cytoplasmic domain (Maretzky et al., 2005). In this study, upon inhibition of L1 
shedding, neurite outgrowth of cerebellar neurons from explants grown on an L1-
substrate was also decreased. Interestingly, the authors found that ADAM10 was 
responsible for constitutive L1 cleavage, as well as in response to a glutamate receptor 
agonist, while ADAM17 was responsible for L1 cleavage to different stimuli, including 
cholesterol depletion or phorbol ester stimulation (PMA). It should also be noted that in 
the explant experiments used in this study, ADAM17 inhibition had a greater effect than 
ADAM10 inhibition, suggesting that other ADAM17 substrates, including the growth 
factor receptors p75NTR and TrkA (Ahmed et al., 2006, Diaz-Rodriguez et al., 1999), 
could contribute to the decreased neurite outgrowth observed.  
The importance of L1 and NCAM in the maintenance of tissue integrity and growth 
factor signalling is illustrated by their associations with disease. L1 and NCAM are both 
upregulated in brain tumours (Schmid and Maness, 2008) and mutations in both 
proteins are associated with neuropsychological conditions. L1 is mutated in an X-
linked form of mental retardation and NCAM misregulation has been associated with 
schizophrenia and bipolar disorder (reviewed by Schmid and Maness, 2008). However 
it is noted that there is considerable redundancy within the IgCAM superfamily, 
illustrated by the mild phenotypes observed in knockout mice. For instance both the 
NCAM and L1-CAM knockout mice are viable and fertile (Cremer et al., 1994, Cohen et 
al., 1998). Mice lacking L1 expression show defects in corticospinal tract development 
and hyperfasciculation in the brain (Wiencken-Barger et al., 2004). NCAM knockout 
mice also have subtle defects including learning difficulties and alterations in 
neurotransmitter release at the neuromuscular junction (Polo-Parada et al., 2001).  
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In summary, members of the IgCAM superfamily are involved in a diverse array of 
functions by interacting with many different partners as co-receptors, or co-operating 
with common signalling cascades. IgCAM endocytosis and regulated proteolysis are 
common properties involved in regulating their function, as well as their interaction with 
other signalling pathways. In this thesis, I examined ALCAM, a protein found among 
the associated IgCAMs in the proteomic screen of the Hc-positive compartment Table 
1. As a member of the IgCAM superfamily and possessing some of the interesting 
properties outlined in this section, ALCAM was a good candidate to investigate for a 
novel role in neurotrophic signalling. 
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Figure 1.5 IgCAM interactions with growth factor signalling 
Structurally, NCAM and L1 contain fibronectin type-III domains (dark blue boxes) and 
Ig domains (green circles). Sites of metalloprotease cleavage are indicated by scissors 
in the NCAM and L1 juxtamembrane regions. NCAM is known to interact with GDNF 
family receptor  (GFR) as a co-receptor for GDNF and activates neuronal survival, 
growth and differentiation. NCAM can also activate downstream signalling on its own 
via its intracellular interaction with FYN and FAK kinases. L1 is depicted interacting 
with neuropilin, with which it mediates repellent sema3a signalling and induces growth 
cone collapse. Intracellularly, L1 binds the AP2 clathrin adaptor to mediate endocytosis 
and ankyrin (ANK) through which it interacts with the actin cytoskeleton. NCAM and L1 
both cooperate with integrin and growth factor signalling pathways (e.g. EGF and 
FGF). This can happen via direct interactions with these receptors at the membrane or 
by activating the same downstream signalling cascades and therefore potentiating their 
response (large arrow).  
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1.5 Activated Leukocyte Cell Adhesion Molecule (ALCAM) 
ALCAM is a classical IgCAM, that is a member of the subfamily defined by having 5 
extracellular domains, two variable type Ig domains and 3 constant type-2 domains 
(i.e.V1V2C1C2C3), followed by a transmembrane region and a cytoplasmic tail (Figure 
1.6). ALCAM is expressed in many different tissues, for instance in the nervous 
system, the immune system and in haematopoietic stem cells (reviewed in Swart, 
2002). ALCAM expression is highly temporally and spatially regulated and is found on 
cells undergoing dynamic cellular interactions, e.g. neurons during axonal outgrowth, 
immune cells during T-cell activation and cancer cells during migration (reviewed in 
Swart, 2002). ALCAM has been independently found in different species and tissues. 
Its synonyms include BEN/MuSC in mice, CD166/ALCAM in humans, DM-GRASP/SC1 
in chick, and neurolin in fish to name but a few (for an extensive list see Swart, 2002). 
Throughout this thesis, I will refer to the protein as ALCAM.  
The other members of the V1V2C1C2C3 subfamily are BCAM/lutheran (basal cell 
adhesion molecule/lutheran blood group antigen), a laminin receptor, and 
MUC18/CD146. BCAM and MUC18 show low similarity with the ALCAM sequence 
(34.7% and 37.4% respectively). The greatest homology between the three receptors 
is in their extracellular domains, while similarities are lost in their cytoplasmic domains 
(Swart, 2002). ALCAM has a very short cytoplasmic domain of only 34 amino acids, 
while BCAM and MUC18 have bigger cytoplasmic domains. This is an important 
consideration in the study of ALCAM because so far no interaction motifs have been 
identified in its cytoplasmic tail and there is only limited evidence for intracellular 
interactors, such as actin (Te Riet et al., 2007) and ubiquitin (Thelen et al., 2008). 
Within higher vertebrates, ALCAM is strongly conserved, with around 95% similarity 
between mouse, rat, rabbit and human (Swart, 2002). This suggests that ALCAM may 
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have similar functions across these species. This is important in the context of my 
thesis where both mouse and rat cells were examined.  
Three isoforms of human ALCAM have been reported and are shown schematically in 
Figure 1.6. ALCAM-1 and ALCAM-2 are products of alternative splicing, with ALCAM-2 
missing a short 13 amino acid sequence in the juxtamembrane region. No functional 
differences have been reported for the two isoforms. A third ALCAM variant, consisting 
of just the most distal extracellular V1 domain, has been isolated from endothelial cells 
and is suggested to be the product of alternative splicing (Ikeda and Quertermous, 
2004). In this study, it was shown that the soluble isoform could inhibit ALCAM 
homophilic interactions and could increase cell migration in both an ALCAM-dependent 
and independent manner. The equivalent splicing region of exon 3 is present in the 
ALCAM locus of the mouse genome and a transcript coding for soluble ALCAM was 
found by 3’-rapid amplification from mouse endothelial cell cDNA suggesting that this 
isoform is conserved between humans and mice. 
ALCAM was identified as the heterophilic binding partner of the glycoprotein CD6 
expressed on lymphocytes (Bowen et al., 1995, Skonier et al., 1997). Mapping studies       
have shown that the N-terminal V1 domain of ALCAM binds to the membrane proximal 
scavenger receptor cysteine rich (SRCR) domain of CD6, as illustrated in Figure 1.7 
(Skonier et al., 1997, Bowen et al., 1997). Their interaction is important for the 
stabilisation of the immunological synapse, and is required to elicit T-cell activation 
(Zimmerman et al., 2006, Gimferrer et al., 2004). The interaction of ALCAM and CD6 is 
highly conserved and displays cross-species binding with mouse and human ALCAM 
both capable of binding mouse and human CD6 (Bowen et al., 1997). ALCAM can also 
engage in homophilic interactions (Bowen et al., 1995). Structure-function analysis 
using antibodies to specific ALCAM domains and N-terminal truncated mutants 
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identified that the most distal ALCAM domains are responsible for ligand binding in 
trans, whereas the membrane proximal domains are responsible for ALCAM binding in 
cis, and leads to clustering (van Kempen et al., 2001). 
Surface-plasmon-resonance experiments determined that the ALCAM-CD6 complex 
has a 100 fold higher affinity than the homotypic interaction between two ALCAM 
proteins (Hassan et al., 2004). ALCAM interactions have been further characterised 
using single-molecule force spectroscopy to compare homophilic binding and the 
heterophilic interaction to CD6 (Te Riet et al., 2007). The two interactions show very 
different properties, the ALCAM-CD6 interaction having a 100 fold lower dissociation 
rate and greater resistance to mechanical stress (i.e. more resistant to applied force), 
while the homotypic interaction displayed greater lability (Te Riet et al., 2007). The 
homophilic bonds lability could have functional importance because ALCAM is often 
expressed in migrating cells.  
The ALCAM transmembrane region and cytoplasmic domain interact with the 
cytoskeleton. ALCAM co-immunoprecipitates with -actin and interestingly disruption of 
the cytoskeleton enhances ALCAM avidity without affecting the affinity (Te Riet et al., 
2007). These findings are consistent with data from Nelissen et al (2000), where 
cytochalasin D treatment (which inhibits actin polymerisation) resulted in increased 
ALCAM lateral mobility, clustering and cell adhesion. Since ALCAM adhesion is 
modulated by cytoskeletal rearrangements it was examined whether, similar to integrin 
and cadherin adhesion, Rho-like GTPases were involved. However, it was found that 
ALCAM adhesion regulation is independent of these proteins and is instead associated 
with PKC activity (Zimmerman et al., 2004). 
Interestingly, a second ALCAM soluble form, lacking the transmembrane and 
cytoplasmic domains is produced as a product of metalloprotease cleavage and 
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ALCAM was identified in a proteomic screen as a substrate for ADAM17 (Bech-Serra 
et al., 2006). Furthermore, the soluble ALCAM extracellular domain was 
immunoprecipitated from growth medium of epithelial ovarian cancer cells in culture 
and evidence of the cleaved fragment was found in vivo from patient ascites and sera 
(Rosso et al., 2007). In this study, the authors found that ALCAM cleavage was 
stimulated by EGF receptor activation and was ADAM-dependent. This has important 
implications for cancer, because inhibitors of ADAM cleavage decreased motility of 
these cells. Recently it has been proposed that targeting of ADAM17 cleavage and 
inhibiting of soluble ALCAM release may be a promising cancer therapy (Nuti et al., 
2010). This is of particular interest considering that ADAM17 has been also shown to 
cleave the neurotrophin receptors p75NTR and TrkA as well as L1 (Ahmed et al., 2006, 
Diaz-Rodriguez et al., 1999, Maretzky et al., 2005). 
Alterations in ALCAM expression as well as cleavage have been associated with many 
forms of cancer, poor prognosis and with tumour progression and metastasis (reviewed 
by Ofori-Acquah and King, 2008). Swart and colleagues have suggested that ALCAM 
may function as a cell density sensor and may act at the interface between growth and 
metastasis (Swart et al., 2005). As described earlier, ALCAM can bind homophilically in 
trans or in cis, and these authors propose that the resulting ALCAM network is 
important in sensing cell-cell interactions. A schematic representation of this model is 
shown in Figure 1.8. Upon expression of an amino-terminal truncated ALCAM (N-
ALCAM) mutant, the ALCAM network is disrupted and this interferes with cell adhesion 
without effecting soluble ligand binding (van Kempen et al., 2001). Further work on the 
N-ALCAM showed that expression in adherent melanoma cells inhibited 
metalloprotease activation in 2D and 3D cultures, as well as in ex vivo tumours from 
mice (Lunter et al., 2005). These experiments found that despite the inhibition of 
metalloprotease activity, there was an increase in metastasis, which interestingly 
Chapter 1. Introduction 
 47 
invalidated the previous assumption that metastasis is always accompanied with 
increased metalloprotease activity.  
Swart’s group has since compared truncated ALCAM expression with its soluble 
ALCAM form (V1 domain alone)(van Kilsdonk et al., 2008). This study revealed that 
although both ALCAM forms could disrupt the ALCAM network (Figure 1.8), they had 
both similar and opposite consequences. Expression of soluble ALCAM inhibited 
metalloprotease activity similarly to N-ALCAM, but in contrast to N-ALCAM, it 
actually decreased migration and metastasis (van Kilsdonk et al., 2008). The difference 
in metastatic potential was reflected by concomitant changes in L1-CAM expression 
and it was proposed that this could account for the differential effect on metastasis. L1-
CAM was increased in N-ALCAM cells but decreased in soluble ALCAM expressing 
cells, suggesting L1 expression was linked to metastatic potential.  
As well as undergoing regulated proteolysis and having a regulatory role in 
metalloprotease activity, another interesting property of ALCAM is that it has also been 
shown to undergo endocytosis (Piazza et al., 2005). In this study, full-length ALCAM 
was identified as a potential therapeutic target for antibody-based immunotherapy in 
cancer. In a phage display library screen, human single chain antibody fragments were 
selected on the basis of whether they could be internalised in ovarian cancer cell lines 
(Piazza et al., 2005). The authors found that upon ligand binding (either CD6-Fc or I/F8 
minibody) ALCAM was internalised in a clathrin-dependent compartment and recycled 
back to the plasma membrane. Furthermore, stimulation of ALCAM endocytosis 
increases epithelial ovarian cancer cell migration in a wound-healing assay (Rosso et 
al., 2007). Since ALCAM can undergo ligand-dependent internalisation in cancer cells, 
it was a good candidate to investigate its internalisation and axonal transport in 
neurons. 
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ALCAM is expressed in the nervous system and its expression is developmentally 
regulated (Dillon et al., 2005, Fournier-Thibault et al., 1999). It is associated with axon 
fasciculation and neurite outgrowth in several systems. In lower vertebrates, it was 
shown that ALCAM is important for motor neuron outgrowth and fasciculation. In fish, 
antibodies blocking ALCAM adhesion result in the misprojection and defasciculation of 
axons that express ALCAM as they exit the spinal cord (Ott et al., 2001). In chick, DM-
GRASP, the orthologue of ALCAM, was shown to support neurite extension from 
distinct subsets of neurons by homophilic interactions (DeBernardo and Chang, 1995). 
Furthermore, using affinity chromatography, DM-GRASP was shown to interact with 
NgCAM (L1 chick orthologue) and antibodies blocking this interaction inhibited neurite 
extension on an NgCAM substrate (DeBernardo and Chang, 1996).  
DM-GRASP expression is dynamically regulated during neuromuscular junction 
formation in the chick limb (Fournier-Thibault et al., 1999). The authors found that 
ALCAM is expressed on muscle cells and fibres and is downregulated upon innervation 
with motor neurons that also express ALCAM. In the mature limb ALCAM expression is 
only localised to the neuromuscular junction, but interestingly, this process is 
reversible. After muscle dennervation ALCAM is re-expressed on mature muscle fibres, 
as well as in regenerating motor neurons. Upon reinnervation, ALCAM expression is 
again confined to the neuromuscular junction (Fournier-Thibault et al., 1999). These 
results suggest that ALCAM homophilic interactions are important in neuromuscular 
junction maintenance, which is of particular interest in my investigation of CAMs 
contained in the axonal retrograde transport compartment in motor neurons. It is 
possible that ALCAM homophilic interactions between axon terminal and muscle could 
provide a muscle contact signal. 
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Further studies on DM-GRASP in chick have focussed on its role in the retina, where 
ALCAM expression is also spatiotemporally regulated. Avci et al (2004) found ALCAM 
is concentrated on retinal ganglion cell (RGC) axons during their outgrowth from the 
retina. RGCs showed a preference to grow along DM-GRASP/laminin substrates and 
this was inhibited by addition of blocking antibody fragments to ALCAM of its 
heterophilic binding partner NgCAM. In flatmount retina cultures, antibodies to DM-
GRASP resulted in misprojections of the RGC axons at the point of the optic fissure 
where the axons grow into the optic nerve (Avci et al., 2004), suggesting that DM-
GRASP adhesion is important in RGC outgrowth from the retina. More recent work 
from Pollerberg and colleagues reported that DM-GRASP is endocytosed at RGC 
growth cones (Thelen et al., 2008). They found that DM-GRASP endocytosis is 
clathrin-dependent and dynein-dependent, and is altered upon inhibition of MAPK and 
PI3K activity. In this study, a yeast-2-hybrid screen was conducted to look for 
interactors with the DM-GRASP cytoplasmic domain that could drive endocytosis. The 
authors found evidence that DM-GRASP’s cytoplasmic domain has ubiquitin-binding 
activity, and is also a site of ubiquitination. The details of this interaction, however has 
not been clarified, and it has not been resolved whether DM-GRASP ubiquitination 
alters DM-GRASP internalisation or function (Thelen et al., 2008).  
In the mouse, ALCAM expression has also been identified in the nervous system 
during development e.g. ALCAM specifically labels a subset of cranial sensory ganglia 
(Sekine-Aizawa et al., 1998). ALCAM is downregulated at points of defasciculation of 
primary vestibulo-cerebellar afferents and ALCAM substrates promote axonal 
outgrowth of these cells (Kawauchi et al., 2003). In further studies, it has been shown 
that ALCAM specifically labels spinal accessory motor neurons and their axons from 
E9.5-E12.5 and subsequently is also expressed in motor neurons in the ventral horn of 
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the spinal cord (Dillon et al., 2005). This suggests that ALCAM may be expressed on 
motor neurons in the ventral horn neuron cultures used in our experiments. 
Since ALCAM is expressed in many cells of the murine nervous system, immune 
system and haematopoietic stem cells, it is perhaps surprising that mice lacking 
endogenous ALCAM (ALCAM-/-) do not have an overt phenotype (Weiner et al., 2004). 
The mice are viable and fertile, and show only subtle defects in the nervous system. 
Problems with fasciculation are observed in their motor thoracic nerves and their RGCs 
(Weiner et al., 2004). RGCs have also been shown to misproject in the optic tectum of 
ALCAM-/- mice (Buhusi et al., 2009). The authors of this study suggest that ALCAM in 
the tectum is required for the successful targeting of RGC expressing L1, and is 
consistent with the finding that the two proteins interact (DeBernardo and Chang, 
1996).  
In summary, ALCAM possesses properties that make it of particular interest to study as 
a candidate protein transported in the axonal retrograde transport compartment and 
that could have a function related to neurotrophic signalling in neurons. Firstly, it is 
expressed in motor neurons during development and its expression is regulated by 
innervation of target muscles. Secondly, ALCAM is endocytosed and can be cleaved 
by metalloproteases and these properties are important in the ability of L1 and NCAM 
to cooperate in growth factor signalling. In this thesis, I examine whether ALCAM 
undergoes retrograde axonal transport in neurons and whether ALCAM, similarly to 
other IgCAMs, cooperates with neurotrophic signalling in the nervous system.  
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Figure 1.6 ALCAM forms in human and mouse 
All reported ALCAM forms are shown (Accession numbers: human, underlined and 
mouse, italics). ALCAM consists of five extracellular domains, two variable 
immunoglobulin (IgG) domains (V1 and V2) and three constant type-2 IgG domains (C1-
3). ALCAM-2 has 13 amino acids removed in the juxtamembrane region by alternative 
splicing (indicated by the wedge). The soluble form is the V1 domain alone, while 
another soluble form consisting of the entire extracellular domain is produced as a 
result of juxtamembrane cleavage by the disintegrin and metalloprotease, ADAM17 
(scissors).  
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Figure 1.7 ALCAM engages in both homophilic and heterophilic 
interactions 
Homophilic ALCAM binding can occur both in cis interactions via domain C1-3 and in 
trans via V1 and V2. ALCAM heterophilic binding to the juxtamembrane scavenger 
receptor cysteine rich (SRCR) domain of T-cell glycoprotein CD6 is mediated by its V1 
domain. The two forms of binding have very different properties, homophilic binding 
increases with avidity and has high lability, while heterophilic binding is of much higher 
affinity.   
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Figure 1.8 Model of ALCAM function  
ALCAM can engage in homophilic interactions both in trans and cis, and thus forming 
an ALCAM network between two ALCAM expressing cells as shown in A. It has been 
proposed by Swart and colleagues that ALCAM lacking V1 and V2 (N-ALCAM), 
disrupts formation of the network by disrupting binding in trans. However N-ALCAM 
expression would still promote binding in cis and may partially compensate for loss of 
the network. In contrast, expression of soluble ALCAM would disrupt network formation 
without promoting cis interactions. The schematic illustrates the various ways in which 
ALCAM network formation can be interfered with and may explain differences in the 
effects of expressing mutant ALCAM constructs. (modified from (van Kilsdonk et al., 
2008) 
 .
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Laboratory chemicals were obtained from Sigma, Invitrogen, BDH-Prolabo or Fischer 
Scientific unless otherwise stated. Molecular biology reagents were obtained from 
Qiagen and restriction enzymes and DNA enzymes were from New England Biolabs. 
Fluorophore-conjugated secondary antibodies and LysoTracker Red DND-99 were 
supplied by Molecular Probes, while horseradish peroxidase (HRP)-coupled secondary 
antibodies were all from DAKO. Reagents for western blot visualisation by enhanced 
chemiluminescence (ECL) were supplied from GE Healthcare, while Kodak provided 
autoradiographic films.  
2.1.2 Cell lines 
Rat pheochromocytoma (PC12) cells were obtained from Dr T. B. Rogers, University of 
Washington USA (Herreros et al., 2000). Rat mammary adenocarcinoma (MTLN3) 
cells were a kind gift from Prof. E. Sahai, CRUK’s London Research Institute (LRI). 
U251MG astrocytoma cells and mouse neuroblastoma (Neuro2A) were obtained in 
house from LRI cell services.  
2.1.3 Bacteria 
XL1Blue, TG1, BL21 competent bacteria were from LRI stocks and made in house. 
XL10-gold® ultracompetent bacteria were from Stratagene. 
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2.1.4 Vectors and expression plasmids 
The pDendra-2N vector was obtained from Evrogen. The His6-tag containing vector, 
pET30b-hERCC1 was a kind gift from Prof. N. McDonald, LRI. The CD8-CI-MPR 
pIRES-neo2 vector was the kind gift of Prof. M. Seaman, University of Cambridge. 
2.1.5 Recombinant Proteins 
The following proteins were obtained from R&D systems: 
Rat GDNF family receptor alpha Fc chimera (GFRa-1/GDNF Ra-1 Fc chimera)  
Mouse ALCAM/CD166 Fc Chimera (ALCAM-Fc) 
Mouse CD6 Fc Chimera (CD6-Fc) 
Human immunoglobulin IgG1 Fc (Hu-Fc) 
Fluorescently labelled canine adenovirus serotype 2 (CAV-2-cy3) was a kind gift 
provided by Prof. E. Kremer, Institut de Génétique Moléculaire de Montpellier and was 
used in live-cell imaging experiments as described in (Salinas et al., 2009). 
2.1.6 Primers for construct insert amplification 
Table 2 lists the primers used for cloning ALCAM constructs in this study. 
2.1.7 Antibodies 
See Table 3 for primary antibodies used for immunofluorescence, western blot and 
live-cell imaging. 
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Table 2 Primers used for cloning 
 
Insert Name Primers Digest 
ALCAM-FL MNP278ALCAMxho1start 
AAACTCGAGACCATGGCATCTAAGGTGTCC 
MNP285ALCAMbamh1stop 
AAAGGATCCTCGGCTTCTGTTTTGTGATT 
Xho1 
BamH1 
Signal 
sequence 
MNP278ALCAMxho1start 
AAACTCGAGACCATGGCATCTAAGGTGTCC 
MNP301_revpEcoR1_ssAL 
AAAAGAATTCACAGTGTACCATCCAAGGCCTGG 
Xho1 
EcoR1 
D1-ALCAM MNP303_forpDeltaD1_AL 
AAAGTGAATTCTCCTACCCTAGTCAAGGTGTT 
MNP285ALCAMbamh1stop 
AAAGGATCCTCGGCTTCTGTTTTGTGATT 
EcoR1 
BamH1 
D1D2-
ALCAM 
MNP304_forpDeltaD1D2_AL 
AAAGTGAATTCTCCTACAGAGCAGGTGACA 
MNP285ALCAMbamh1stop 
AAAGGATCCTCGGCTTCTGTTTTGTGATT 
EcoR1 
BamH1 
C-ALCAM MNP278ALCAMxho1start 
AAACTCGAGACCATGGCATCTAAGGTGTCC 
MNP302_revpDeltaCYMKK_AL 
AAAGGATCCTCCTTCTTCATGTACAGCCAGTAG 
Xho1 
BamH1 
CD8Ec MNP323_CD8startXho1 
AAACTCGAGACCATGGCCTTACCAGTGACC 
MNP324_CD8revEcoR1 
AAAGAATTCCCCCTCGTGTGCACTGCGCC 
Xho 
EcoR1 
Ec-ALCAM MNP309_forpDeltaEc_AL 
AAAGTGAATTCTGACCAGGCAAAACTGATT 
MNP285ALCAMbamh1stop 
AAAGGATCCTCGGCTTCTGTTTTGTGATT 
EcoR1 
BamH1 
ALCAM-Ec MNP288_alcam_d1d5_Sfo1f 
AAGGCGCCATGGGATGGTACACTGTCAAC 
MNP282_alcam_d1d5_Xho1 
AAACTCGAGTTTTGCCTGGTCATTCACCTT 
Sfo1 
Xho1 
ALCAM-C MNP283alcam_cyt_Nde1 
AAACATATGTACATGAAGAAGTCCAAAACTGCA 
MNP284alcam_cyt_Xho1 
AAACTCGAGGGCTTCTGTTTTGTGATTGTT 
Nde1 
Xho1 
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Table 3 Primary antibodies 
Dilutions for western blot (WB), immunofluorescence (IF), -cell imaging (LC). 
 
Antigen Name & Supplier Species Dilution 
ALCAM (mouse 
extracellular 
domain) 
AF1172, R&D 
Systems 
Goat WB 1:500 
IF 1:150 
LC 1:500 
ALCAM (mouse 
cytoplasmic 
domain) 
In house ALCAM-C 
4682 
Rabbit WB 1:250 (serum) 
or 1:100 (IgG) 
IF 1:600 
ALCAM (mouse 
cytoplasmic 
domain) 
In house ALCAM-C 
4683 
Rabbit WB 1:250 (serum) 
Dendra2 AB822, Evrogen  Rabbit WB 1:10,000 
His6 6X His tag® HRP 
ab1187, Abcam 
Rabbit WB 1:1000 
Kidins 220 In house 1F8 
(Bracale et al., 
2007)  
Mouse IF 1:400 
LAMP2 A L-93, BD 
PharmingenTM 
Rat IF 1:500 
P44/42 MAPK 
(ERK1/2) 
Cell Signalling Cat 
No 9102 
Rabbit WB 1:1000 
Phospho-p44/42 
MAPK (ERK1/2) 
Cell Signalling Cat 
No 9106 
Mouse WB 1:1000-1:2000 
NCAMic Cat 556323, BD 
PharmingenTM  
Rat IF 1:400 
Thy1.1 MRC OX-7 BD 
PharmingenTM 
Mouse WB 1:1000 
PanTrk C-14, Santa Cruz Rabbit WB 1:500 
PanTrk B-3, Santa Cruz Mouse WB 1:500 
Phospho-TrkA Cell Signalling Cat 
No 9141 
Rabbit WB 1:1000 
Tubulin Tuj1, Covance Mouse WB 1:10,000 
p75NTREc In house 
(Deinhardt et al., 
2006b) 
Rabbit WB 1:1000 
IF 1:1000 
LC 1:500 
p75NTRIc In house 
(Deinhardt et al., 
2006b) 
Rabbit WB 1:1000 
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2.2 Methods 
2.2.1 DNA techniques and cloning 
I designed ALCAM constructs tagged with Dendra (Gurskaya et al., 2006), a 
photoactivatable fluorescent protein for expression experiments in mammalian cells. I 
also designed His6-tagged ALCAM protein fragments to be expressed in bacteria and 
the protein purified. The cloning strategies used to produce the ALCAM-Dendra and 
ALCAM-His6 constructs are illustrated in Figure 2.1 and Figure 2.2 respectively. 
2.2.1.1 Amplification of DNA fragments 
Primers were designed to amplify full length ALCAM or its fragments from the image 
clone IMGCLO3501215, or the CD8 fragment from the CD8-CIMPR vector, a kind gift 
of Prof. M. Seaman, University of Cambridge. For each reaction, 10 ng of template 
DNA was used with 200 μM deoxynucleoside triphosphates (dNTPs), 0.5 μM of the 
appropriate forward and reverse primers, 1 μl PfuTurbo DNA polymerase and made up 
to a final reaction volume of 40-50 μl with MilliQ water. 
The following PCR program was used adjusting the annealing temperature and 
elongation time according to what fragment was being amplified: 
1. 95°C for 2 min 
2. 95°C for 60 s 
3. Annealing temperature for 30 s (approximately 10°C less than the melting 
temperature of forward and reverse primers) 
4. 72°C for elongation time (approximated 60 s per Kb amplified) 
5. Back to step 2, 29 times 
6. 72°C for 10 min 
7. 12°C thereafter 
 
2.2.1.2 Insert and vector digests 
The amplified insert and 2-4 μg of vector were digested with appropriate restriction 
enzymes, enzyme buffer and 1% Bovine Serum Albumin (BSA) in MilliQ water as 
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required, for 2 h at 37°C followed by 20 min at 65°C to inactivate the restriction 
enzymes. Digested vector DNA was then incubated with alkaline phosphatase for 1 h 
at 37°C to remove the reactive 5’-phosphates from the DNA fragment ends to minimise 
potential self-annealing of the vector. 
To purify the DNA from the reaction mix, digested vectors were ran on 1% agarose 
gels, bands corresponding to the linearised vector were cut out and purified using the 
Qiagen QIAquick® Gel extraction kit. Inserts were purified directly after the digest using 
the Qiagen QIAquick® PCR purification kit.  
The ALCAM extracellular domain (ALCAM-Ec) DNA sequence contains an internal 
Nde1 restriction site therefore the Nde1 enzyme was avoided when digesting the 
insert. Instead the insert was cut with Sfo1, to produce a blunt-end. Therefore, the 
Nde1 digested vector underwent an additional step to convert the Nde1 sticky-end into 
a blunt-end so that the Sfo1 digested ALCAM-Ec insert could ligate with the vector. 
This was undertaken in sequential steps as shown in Figure 2.2 and the restriction 
sites are represented in Figure 2.3. The pET-ERCC1 vector was digested for 2 hours 
at 37°C with Nde1 and heat inactivated for 20 minutes at 65°C. The vector DNA was 
then incubated with 1 μl of T4 polymerase and 30 μM dNTPs for 30 minutes at 15°C. 
The polymerase fills in the 5’ overhang to convert the Nde1 sticky end into a blunt-end. 
The now blunt linearised vector was then purified using the Dyex® 2.0 Spin Kit and 
eluted in 35 μl required for the next digest with Xho1, BSA and its corresponding 
enzyme buffer for 2 h at 37°C, followed by heat inactivation at 65°C for 20 min. The 
pET Vector was separated from the ERCC1 insert on a 1% agarose gel, the digested 
vector band was cut out and vector DNA was purified using the Qiagen QIAquick® Gel 
extraction kit as before. The process is represented in Figure 2.2. 
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2.2.1.3 Ligation 
Digested insert and vector were ligated by T4-ligase overnight at 16°C with a vector to 
insert ratio of 1:3 to 1:5. All reactions were conducted with a control sample, containing 
vector alone without insert. 
2.2.1.4 Transformation of bacteria 
Bacteria were transformed by adding 2 μl ligation mix to 100 μl bacteria for 10 min then 
by electroporating the mix at 2.5 kV. Bacteria were recovered by adding 900 μl of 
Super Optimal broth with Catabolite repression (SOC) medium. Transformants were 
selected by plating the bacteria on agar plates containing 50 μg/ml Kanamycin or 100 
μg/ml Ampicillin, as appropriate.  
For the more complicated ligations (i.e. D1D2-ALCAM-D and CD8-ALCAM-D), 
supercompetent XL10-gold® bacteria were transformed by heat shock. Bacteria and 
ligation mix were incubated with -mercaptoethanol for 30 min, heat shocked for 30 s 
at 42°C, kept on ice for 2 min then recovered with NZY+ broth (10 g NZ amine, 5 g 
NaCl, 5 g yeast extract in 1 litre deionised water was obtained from LRI media services 
and supplemented with 12.5 mM MgCl2, 12.5 mM MgSO4 and 20% w/v glucose before 
use) for 1 hour at 37°C. Transformants were plated on agar plates, with appropriate 
resistance as above. 
2.2.1.5 Preparation of plasmid DNA 
Bacteria from picked colonies were grown in lysogeny broth (LB, from LRI media 
services) at 37°C overnight. Plasmid DNA was isolated using Qiaprep® spin miniprep 
or Qiafilter® plasmid maxi kits as appropriate.  Isolated plasmid DNA was analysed by 
diagnostic digests with restriction enzymes and ran on an agarose gel, followed by 
plasmid sequencing. 
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2.2.1.6 Plasmid sequencing 
Approximately 200-300 ng of plasmid DNA was added to 3.2-5 pM of appropriate 
primers spanning around 400 base pairs (bp), BigDye Terminator (BDT) reaction mix 
and made up to 20 μl with MilliQ to undergo a sequencing PCR reaction: 
1. 95°C for 2 min 
2. 95°C for 30 s 
3. 60°C for 4 min 
4. Back to step 2, 29 times 
5. 12°C thereafter 
 
Samples were then purified by Dyex® 2.0 Spin Kit and sent for sequencing (LRI 
equipment park). 
For all pDendra-2N constructs the following vector primers were used: 
MNP279pdendraNforward AGGCGTGTACGGTGGGAG 
MNP280pdendraNreverse GGTGTTCATGGTGGCGAC 
 
For sequencing ALCAM image clone and subsequent constructs the following internal 
primers were used as appropriate: 
MNP273ALCAMint1 GCATTCCGATCTTCTACGA 
MNP274ALCAMint2 GCCATTCACCTGTTCTGTG 
MNP275ALCAMint3 CGCGACTGTGGTGTGGATG 
MNP276ALCAMint4 CCAGAGCACGATGAGGCAG 
MNP277ALCAMint5 GCAGTTCATTCTACCAAGC 
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2.2.1.7 RNA isolation 
TRIzol® Reagent (Invitrogen) was used to isolate RNA from 35 mm cell culture plates 
according to the manufacturers instructions. Briefly, cells were directly lysed in 1 ml of 
TRIzol reagent and incubated for 5 min at room temperature for dissociation of 
nucleoprotein complexes. Then 0.2 ml of chloroform was added per sample, tubes 
were shaken, incubated at room temperature for a further 2 min before centrifugation at 
12,000 x g for 15 min at 4°C. The samples separated into two phases, a lower red 
phenol-chloroform phase and an upper aqueous phase that contains RNA. The 
aqueous phase was transferred to a new eppendorf and the RNA precipitated by 
mixing with 0.5 ml isopropanol at room temperature for 10 min followed by 
centrifugation at 12,000 x g 10 minutes at 4°C. The RNA pellet was washed in 1 ml 
75% ethanol, vortexed and centrifuged for 5 minutes at 7,500 x g 4°C. Finally, pellets 
were left to dry and then resuspended in water. The concentration and integrity of the 
RNA was verified using the Nanodrop 1000 spectrophotometer (Thermo Scientific). 
Absorbance is measured at 260 nm and 280 nm (represented as if recorded with a 
conventional 10mm light path). The absorbance ratio 260/280 is a measure of the RNA 
purity. Ideally the ratio should be ~2 for RNA, if it is lower it may indicate the presence 
of contaminants such as proteins. I also analysed RNA samples by electrophoresis on 
a 1% agarose gel where preserved RNA should resolve into 2 distinct bands. 
2.2.1.8 cDNA synthesis and analysis 
I used the Superscript® Vilo cDNA synthesis Kit (Invitrogen) to amplify cDNA samples 
from purified RNA. In subsequent PCR reactions 2 μl of the resulting cDNA preparation 
was used with the appropriate primers (ALCAM or CD6 forward and reverse primers) 
and MegaMix (Microzone Ltd). 
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ALCAM MNP274ALCAMint2  GCCATTCACCTGTTCTGTG 
  MNP308ALCAMin3_rev CACCACAGTCGCGTTCCTAC 
CD6   MNP338_CD6forwardprimer  GTGTGTAAGCAACTGAAGTG 
  MNP339_CD6revprimer  TGAGGGCGGGCTCCTGTCCT 
 
2.2.2 Mouse breeding and genotyping 
Mice lacking ALCAM were a kind gift from Dr. J. Weiner at the University of Iowa. The 
mice were generated using knock-in techniques, by homologous recombination, to 
introduce a GFP followed by a stop codon into the endogenous ALCAM locus (Weiner 
et al., 2004). There is no evidence of ALCAM transcription downstream of the insertion 
and there is no evidence of ALCAM protein expression in the knockout mice. In the 
original paper, the mice are named BEN-/- mutant mice. BEN is one of the many names 
used for the ALCAM protein (names are reviewed by Swart, 2002). Throughout this 
thesis I will refer to these mice as ALCAM knockout animals (ALCAM-/-).  
The colony is maintained by breeding heterozygous (ALCAM+/-) animals to generate all 
three genotypes; wild type, ALCAM+/- and ALCAM-/-. Mice and embryos are identified 
by genotyping with the following PCR program using DNA extracted from adult ear 
snips, tail snips or embryonic tissue, using Viagen DirectPCR® lysis reagent. The 
forward primer binds to the ALCAM locus upstream of the knockout insertion and 
differential reverse primers are used, which bind to the wild type sequence or the 
EGFP sequence in the knockout allele.  
Primers  BEN-SA:   5’ CTA AGG CGA GAC CCA CAA GCG 3’ 
  BEN-Leader-Rev2:  5’ GAT CAA GAG GCA GAA AAC CAG 3’ 
  EGFP-Rev   5’ GTC GTC CTT GAA GAA GAT GG 3’ 
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ALCAM genotyping PCR programme 
1. 95°C for 3 min 
2. 95°C for 30 s 
3. Annealing temperature 58°C for 30 s  
4. 72°C for elongation 45 s 
5. Back to step 2, 24 times 
6. 72°C for 10 min 
7. 12°C thereafter 
 
Genotyping was run as two separate reactions: BEN-SA + BEN-Leader-Rev2 for wild 
type and BEN-SA + EGFP-Rev for knockout reactions, using 2-5 pM of each primer, 
1.5 μl of DNA and 15 μl of MegaMix (Microzone Ltd). Samples were run on a 1.5% 
agarose gel to resolve a 150 bp wild type band and a 400 bp knockout allele (Weiner et 
al., 2004). 
2.2.3 Cell culture 
2.2.3.1 Primary ventral horn neuron cultures 
Pregnant CD1 female mice were euthanised using CO2 or intraperitoneal injection of 
pentobarbitone and E12.5-13.5 embryos were removed by hysterectomy. Embryonic 
spinal cords were dissected out and the meninges and dorsal root ganglia (DRG) were 
carefully removed. The dorsal portions of the spinal cords were cut away to isolate the 
ventral horn, which were dissociated by DNAase incubation and centrifugation at 370 x 
g through a 4% BSA cushion (Arce et al., 1999). Cells were resuspended in complete 
medium composed of Neurobasal medium (GIBCO®, Invitrogen), 2% B-27 
Supplement (Invitrogen), 2% horse serum, 0.5 mM glutamine (CRUK Cell Services), 
0.05% -mercaptoethanol, 10 ng/ml ciliary neurotrophic factor (CNTF) (Invitrogen), 0.1 
ng/ml glial cell-derived neurotrophic factor (GDNF) (Invitrogen), 50 units/ml penicillin, 
50 μg/ml streptomycin solution. Cells were plated onto poly-D,L-ornithine/laminin-
coated 35 mm glass-bottom dishes (MatTek) or coverslips at a density of 75,000-
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100,000 cells/plate and maintained in culture for 5-10 days at 37°C and 7.5% CO2. 
Ventral horn neuron cultures are enriched for motor neurons, but also contain 
interneurons and glia. Previous characterisation of ventral horn neuron cultures in the 
laboratory established by immunofluorescence that 30-40% of neurons in these 
cultures are motor neurons, using peripherin as a marker. No sensory neurons are 
present because the dorsal part of the spinal cord is removed.  
For dissections of ALCAM knockout litters an additional genotyping step from embryo 
tail and feet was carried out during isolation of the ventral horns. Ventral horns of the 
same genotype were then pooled before dissociation.  
2.2.3.2 Magnetic isolation of Hc retrograde carriers 
For Hc endosome purification Hc-MIONs were used, as previously described in 
(Deinhardt et al., 2006b) and is represented schematically in the Introduction, Figure 
1.3. Ventral horn neurons were isolated from 10 mouse embryos and plated on to 100 
mm dishes. Ventral horn neuron cultures were incubated with MION beads either for 
30 min on ice followed by two washes in Hanks buffered salt solution (HBSS - obtained 
from LRI media services) supplemented with 0.4% BSA and then shifted to 37°C for 1 
hr in complete medium, or added directly to ventral horn neuron cultures incubated at 
37°C in complete medium for 1-2 h. After cooling on ice, cells were scraped in HBSS 
supplemented with a protease inhibitor cocktail (Roche), and centrifuged at 170 x g for 
5 min at 4°C. Cells were resuspended in breaking buffer (0.25 M sucrose, 10 mM 
HEPES-KOH, pH 7.2, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM MgOAc, 
complete protease inhibitors). Ventral horn neurons were passed 15 times through a 
cell cracker (18 μm clearance; EMBL) and clarified at 690 x g for 10 min at 4°C to 
remove nuclear membranes. AS columns (Miltenyi Biotech) were equilibrated with 
breaking buffer supplemented with 0.4% BSA. The column was placed inside the 
magnetic field of the SuperMACS II (Miltenyi Biotech), and the postnuclear supernatant 
Chapter 2. Materials and Methods 
 66 
was loaded two times onto the column. After washing with 15 ml breaking buffer, the 
column was removed from the magnetic field and elution was carried out with 5.5 ml of 
breaking buffer containing 300 mM KCl. Proteins were precipitated (see 2.2.4.3) before 
solubilisation in Laemmli sample buffer. Proteins were separated by SDS-PAGE (4-
12%). 
2.2.3.3 Primary astrocyte cultures 
Astrocytes were isolated from decapitated CD1 neonate pups at 2 days after birth (P2). 
The spinal cord was isolated and meninges were removed then transferred to HBSS. 
Two working solutions, A and B were prepared and kept at 37°C: Solution A comprised 
of Eagle’s balanced salt solution (LRI media Services), supplemented with 1% 
penicillin/streptomycin, 0.3% BSA and 20 μg/ml DNAse. Solution B is comprised of 
solution A supplemented with 0.25 mg/ml trypsin and 0.15 mg/ml DNAse. 
Spinal cords were chopped into small pieces, then transferred to solution A and 
triturated. The suspension was centrifuged at 4°C for 5 min at 800 x g. The supernatant 
was discarded and the pellet resuspended in 10 ml of solution B and incubated for 10 
min at 37°C with 5% CO2, followed by a second centrifugation for 5 min at 800 x g. The 
supernatant was discarded and the pellet resuspended in solution A, followed by a final 
centrifugation for 5 min 800 x g.  The final pellet was resuspended in Dulbecco’s 
modified eagle medium (DMEM) (from LRI media services) supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. Before plating, the solution was 
passed through a N70 filter to remove large debris and aggregates. Cells were 
maintained in culture for 7 days at 37°C and 7.5% CO2 to reach confluency before 
preparing cell lysates. 
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2.2.3.4 PC12 cell culture 
PC12 cells were maintained in Dulbecco’s modified eagle medium (DMEM) (GIBCO®, 
Invitrogen) supplemented with 7.5% horse serum, 7.5% fetal bovine serum, 4 mM 
glutamine and 1% penicillin/streptomycin. PC12 cells were frozen in 45% horse serum, 
45% fetal bovine serum and 10% sterile dimethyl sulfoxide (DMSO), frozen at -80°C 
and stored in liquid nitrogen. 
2.2.3.5 PC12 cell transfection 
Cells were transfected at 30% confluency one day after plating on 0.1 mg/ml 
polylysine-coated coverslips. Lipofectamine 2000 transfection reagent was used at a 
ratio of 0.5 μg DNA to 1.5 μl lipofectamine per coverslip in a 12 well plate. After 5 min 
incubation of DNA and lipofectamine in 100 μl Optimem (GIBCO®, Invitrogen) 
respectively, DNA and transfection reagent were incubated for a further 20 min before 
addition dropwise to cells in DMEM free of antibiotics and serum. For transfections in 
30 mm dishes the amount of DNA and lipofectamine were scaled up 2.5 times, while in 
100 mm dishes 8 μg DNA and 24 μl of transfection reagent were diluted in 800 μl of 
Optimem respectively. After 4 h, the transfection medium was changed to 
differentiation medium alone (DMEM supplemented with 0.1% horse serum, 0.1% fetal 
bovine serum, 4 mM glutamine) or with the appropriate differentiation stimulus. Nerve 
growth factor (NGF) was used at 100 ng/ml, dibutyryl-cyclic adenosine monophosphate 
(dbcAMP) was used at 0.1 mM or 0.5 mM, while glial cell-derived neurotrophic factor 
(GDNF) was used at 100 ng/ml in the presence of 10 μg/ml the co-receptor GDNF 
family receptor alpha chimera (GFR-Fc). On addition of human Fc (Hu-Fc), CD6-Fc or 
ALCAM-Fc chimeras, they were used at a concentration of 1 μg/ml or 10 μg/ml 
2.2.3.6 PC12 Neurite outgrowth analysis 
Cells were fixed for 15 minutes in 4% paraformaldehyde (PFA) in phosphate buffered 
saline solution (PBS) at 3, 5 or 7 days after transfection depending on the 
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differentiation stimulus. Cells were then quenched with 50 mM NH4Cl in PBS pH 7.5 
for 10 minutes, rinsed in PBS and permeabilised in 0.1% Triton X-100 for 5 min. After 
rinsing in PBS cells were incubated with 1:2000 DRAQ5 (BioStatus Ltd) a cell 
permeant DNA probe to stain nuclei for 30 minutes, washed in PBS several times and 
mounted in 10% mowiol 4-88 solution. Pictures were taken on a Zeiss LSM 510 
confocal microscope using a 40x 1.3 NA Plan-NeoFluor oil-immersion objective. At 
least 10 random fields of view were selected per coverslip. An average of 48 cells were 
counted per condition in the original Dendra versus ALCAM-D neurite outgrowth 
experiments (see Chapter 5.1,) and in subsequent neurite outgrowth experiments a 
similar strategy was used. Cells were regarded as exhibiting neurite outgrowth if the 
longest neurite was at least two times the widest length of the soma. Data was 
analysed using 1-way ANOVA followed by a post-hoc Bonferroni’s test on selected 
groups or using an unpaired t-test as appropriate.  
2.2.4 Biochemical techniques 
2.2.4.1 Preparation of cell and tissue lysates 
Mouse brain was dissected and kept at 4°C in TNE lysis buffer (10 mM Tris-HCl pH 8, 
150 mM NaCl, 1 mM EDTA, 1% NP40). Brain was homogenized in lysis buffer 
supplemented with a protease inhibitor cocktail (Roche). Ventral horn neuron or 
astrocyte cultures were plated on 100 mm dishes. After approximately 7 days in vitro, 
cells were washed in PBS, scraped in HBSS supplemented with protease inhibitors, 
and centrifuged at 170 x g for 5 min at 4°C. Cells were resuspended in TNE lysis buffer 
supplemented with protease inhibitors. Brain or cell homogenate was incubated with 
agitation for 30 min at 4°C, then centrifuged at 17,000 x g for 15 min. Supernatants 
were used immediately or snap frozen and kept at -80°C. 
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For signalling experiments, which involved analyzing phosphorylated proteins, a high 
sodium dodecyl sulphate (SDS) lysis buffer was used (2% SDS, 0.05 Tris-HCl pH 6.8). 
Cells starved of serum and neurotrophins for 5 hours were stimulated with 100 ng/ml 
NGF for the times indicated. Cells were washed once with PBS then 100 μl of high 
SDS lysis buffer at 100°C was added to the cells directly. Cells were not scraped but 
triturated slowly up and down using a p200 Gilson pipette, and then put in a tube on 
ice. Samples were then sonicated 3 times for 10 s for disaggregation. Samples 
supplemented with Laemmli sample buffer without SDS (60 mM Tris-HCl pH 6.8, 10% 
glycerol, 5% -mercaptoethanol, 0.01% bromophenol blue) were then analysed by 
SDS-PAGE and western blot.  
2.2.4.2 Protein concentration 
The Bradford method was used to determine protein concentration (Bradford, 1976). A 
standard curve 0-10 μg of IgG was used with Biorad protein assay diluted in water and 
the samples were measured at 595 nm. Samples in high SDS lysis buffer were 
analysed using the BCATM protein assay (Thermoscientific). 
2.2.4.3 Protein precipitation 
Proteins were precipitated with 10% trichloroacetic acid (TCA) using 0.05% sodium 
deoxycholate as a carrier, centrifuged, washed with -20°C acetone and air dried before 
solubilisation in Laemmli sample buffer (60 mM Tris-HCl pH 6.8, 10% glycerol, 2% 
SDS, 5% -mercaptoethanol, 0.01% bromophenol blue). 
2.2.4.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were prepared in Laemmli sample buffer, boiled for 3-5 min or left for 
25 min at room temperature. For all SDS PAGE analysis NuPAGE 4-12% Bis-tris gels 
were run in Nupage MOPS running buffer unless otherwise stated. 
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2.2.4.5 Western blot analysis 
After SDS-PAGE separation, protein was transferred to methanol-activated 
polyvinylidene fluoride (PVDF) membrane. After blocking for 45 min in 5% milk or 5% 
BSA in PBS with 0.01% Tween 20 (PBST) as appropriate, membranes were incubated 
with the primary antibody in the same blocking buffer for 1 hour at room temperature or 
overnight at 4°C. Bound primary antibodies were visualised by appropriate HRP-
coupled secondary antibodies and enhanced chemiluminescence (ECL, Amersham 
Biosciences). In some experiments primary antibodies or serum were cross absorbed 
with purified protein, either 3 μg of CD6-Fc or 20 μg of ALCAM-C for 90 min in blocking 
solution before addition to the membrane. 
2.2.4.6 Densitometric quantification of western blots 
Quantification of phosphorylated protein by western blot was carried out using ImageJ 
software to measure band pixel intensity for the proteins of interest. The amount of 
phosphorylated protein was normalised according to the total protein in the sample 
(phosphorylated protein intensity multiplied by the ratio between the sample total 
protein and the average total protein per condition). Due to the limited transfection 
efficiency, the change in phosphorylation observed by western blot was expected to be 
small. To increase the power with which we could resolve differences statistically, we 
collaborated with Dr Gavin Kelly (LRI, Bioinformatics and Biostatistics Service). For this 
predicted intensity values were generated using a model that removed experiment and 
time-trend effects (i.e. variability introduced as an effect of the different cell 
preparations and times after NGF treatment). This allowed us to pool all the data 
obtained across all experiments and timepoints. We could then test whether there was 
a difference between the predicted values in our condition of interest i.e. if 
phosphorylation was different between ALCAM-D or Dendra-transfected cells. ANOVA 
was used to determine whether the difference between, the Dendra and ALCAM-D 
predicted phosphorylation values, was larger than that ascribable to noise.  
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2.2.4.7 Production of recombinant His6-tagged ALCAM 
BL21 bacteria transformed with ALCAM-His6 constructs were grown in 2 litres 2YT (LRI 
media services) supplemented with 50 μg/ml kanamycin. At A600 of 0.6-0.8 1 mM 
isopropyl -D-1-thiogalactopyranoside (IPTG) was added and bacteria were incubated 
for 6 h at 27°C to induce protein expression. The following steps were undertaken at 
4°C or on ice. Samples were centrifuged for 15 minutes at 5,000 rpm (JA-10 
Beckman), supernatant discarded and pellets washed in PBS-T. The samples were 
centrifuged again for 10 min at 10,000 rpm, discarding the supernatant. The bacterial 
pellet was then resuspended in Breaking Buffer (25 mM Tris/HCl pH 7.8, 300 mM KCl, 
2 μg/ml pepstatin A, 1mM phenylmethylsulfonyl fluoride (PMSF) and -
mercaptoethanol) and passed through the French Press (1300 PSI; MaxiCell; 2 times). 
The bacterial lysate was centrifuged at 20,000 rpm (JA-20 Beckman) for 15 minutes.  
The protein was then purified using a chromatographic method. Buffer A (50 mM Tris-
HCl pH 7.8, 600 mM KCl, 4 mM -mercaptoethanol and 20 mM imidazole) and Buffer B 
(50 mM Tris-HCl pH 7.8, 600 mM KCl, 4 mM -mercaptoethanol and 500 mM 
imidazole) were prepared. For each litre of bacterial culture, 3 ml of Qiagen Ni-NTA 
50% beads were used. Beads were washed with Buffer A, prior to adding the bacterial 
supernatant for 2 hours at 4°C on a rotor wheel. The bead suspension was then 
transferred to the column and allowed to pack. To elute the protein, a linear gradient of 
buffer B was run across the column (Biologic LP (BioRad), rate of 0.5 ml/min, fractions 
0-25 buffer A, fraction 25-85 linear gradient buffer B, collection started at fraction 25).  
10 μl of each fraction were treated with Laemmli sample buffer and analysed by SDS-
PAGE. Gels was then stained with Coomassie Blue (0.1% coomassie blue stain, 50% 
methanol, 10% acetic acid), before destaining and drying, or transferred to methanol 
activated PVDF membrane for western blot analysis with anti-His6 antibodies. 
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2.2.4.8 Production of recombinant atoxic fragment of the tetanus toxin (Hc) 
TG1 bacteria transformed with the triple tagged Hc vector pGEX3T-TeNTHc were 
grown in 2YT with 100 μg/ml ampicillin at 37°C until A600 ~ 0.8, whereupon 1 mM of 
IPTG was added, and incubation was continued for 4 hours. Bacteria were harvested 
by centrifugation at 5000 rpm, washed in PBST. After a further centrifugation, pellets 
were resuspended in Resuspension Buffer (0.05% PBST, protease inhibitors (Roche) 
and 1 mg/ml lysozyme). Samples were frozen in liquid nitrogen then thawed in a hot 
water bath; this was repeated twice to lyse the cells. Samples were then centrifuged 
28,000 rpm (Beckman Ti-70) at 4°C 20 min.  Supernatant was incubated with 2 ml of 
50% glutathione-agarose beads per litre of bacterial culture, for 2 hours with agitation 
at 4°C. As for His6-tagged protein purification (section 2.2.4.7), the sample plus beads 
were added to a column, allowed time for packing of the beads and then washed with 
PBST. To reduce sample contamination by chaperones and unfolded protein, pre-
warmed DNA-K elution buffer (10 mM MgSO4, 50 mM Tris-HCl pH 7.4, 2 mM ATP) was 
added to the resin. Cleavage was carried out by adding Thrombin cleavage buffer 
(TCB - 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.1% -mercaptoethanol) supplemented 
with 30 units of thrombin per litre of bacterial culture for 30 minutes on a rotorary wheel 
at room temperature. The supernatant was decanted, resin washed with TCB 
supplemented with 0.05 mM PMSF and then with TCB containing 0.5 M NaCl.  Protein 
was dialysed overnight at 4°C in dialysis buffer (20 mM Hepes-NaOH pH 7.5, 300 mM 
NaCl, 5% glycerol, 0.025 mM Dithiothreitol (DTT)). 
2.2.4.9 Hc and BSA-conjugated MIONs 
Amino-derivatised monocrystalline iron oxide nanoparticles (MION) were a kind gift of 
Prof. A. Moore, Harvard University, MA, USA. The beads were coupled to BSA or 
purified recombinant atoxic fragments of the tetanus toxin (Hc) as illustrated in Figure 
2.4. The Hc fragment is tagged with a VSVG epitope and cysteine-rich tag (Lalli et al., 
2003b), the latter of which is used to cross-link the peptide to the beads. MIONs were 
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initially incubated with 1 mM EDTA and 4 mM succinimidyl 4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate (SMCC) for 30 minutes at room temperature followed by 2 
hours at 4°C on a rotor wheel. This produces MIONs with maleimide-activated moieties 
that can react with sulfhydryls. MIONs were then purified through a pre-equilibrated 
PD10 column and divided into 2 batches, to label with 200 μg BSA or Hc previously 
treated with 1 mM Tris (2-carboxyethyl) phosphine (TCEP) for 30 min. Reaction mixes 
were incubated for 48 h at 4°C. The reaction was blocked by addition of 10 mM -
mercaptoethanol overnight. The Hc- or BSA-conjugated MIONs were purified by gel 
filtration using Sephacryl S100HR, using a flow rate 0.2 ml/min in PBS. 
2.2.4.10 Membrane stripping experiment 
For the membrane stripping experiment, ventral horn neuron cultures were scraped in 
HBSS containing protease inhibitors. Cells were diluted with equal volume of stripping 
buffer (0.2 M Na2CO3 (pH 11.2 with NaHCO3), 2 M KCl, 4 mM EDTA, 0.05% saponin 
(Sigma)), or alternatively mixed with 4 M KCl up to a 1 M final concentration. Samples 
were incubated for 30 min at 4°C and centrifuged at 100,000 x g for 30 min. Proteins in 
supernatants were TCA precipitated (see 2.2.4.3) and pellets were resuspended in 
loading Laemmli sample buffer.  
2.2.4.11 Deglycosylation experiment 
I used the enzymatic protein deglycosylation kit (sigma EDEGLY) following 
manufacturers recommendations, then analyse ventral horn neuron culture protein 
samples by SDS-PAGE and western blot. 
2.2.4.12 Immunoprecipitation experiments 
PC12 cells 2 to 3 days after transfection with full-length ALCAM tagged with Dendra 
(ALCAM-D) or Dendra (see Figure 2.1) were maintained in differentiation medium 
treated with or without NGF. Cells were washed two times with PBS on ice before 
addition of IP Lysis buffer (150 mM NaCl, 1% Nonidet P-40, 50 mM Tris-HCl, pH 8) 
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supplemented with fresh EDTA-free protease inhibitors. After 10 minutes rocking at 
4°C, cells were scraped on ice and clarified by centrifugation at 18,000 x g at 4°C for 
15 minutes. The protein concentration was determined using the Biorad assay. 1 mg of 
protein was used per immunoprecipitate. Either TrueblotTM anti-rabbit Ig IP beads 
(eBioscience) or Protein A-sepharose beads (Sigma) were used for ALCAM-D or 
tropomyosin receptor kinase A (TrkA) immunoprecipitation respectively. Cell lysates 
were precleared by incubation with beads alone for 30-60 minutes on a rotor wheel. 
Supernatants were transferred to new tubes and beads were sampled to analyse 
proteins that interact with the beads alone (preclear beads). Antibodies directed to 
ALCAM-D or TrkA (5 μg each) were added to the precleared supernatants for 1-2 
hours on a rotor wheel. Subsequently, the appropriate beads (Trueblot for ALCAM-D 
and protein A for TrkA immunoprecipitations respectively) were added to the tube for a 
further 2-3 hours. Tubes were centrifuged, exhausted supernatant removed and a 
sample taken for western blotting. Preclear and immunoprecipitate beads were washed 
3-5 times with IP buffer before elution of protein by direct addition of 30 μl of 2.5 x 
leammli sample buffer. Samples were run on a 4-12% NuPAGE, transferred to PVDF 
for further analysis of the membrane by standard western blotting. For experiments that 
utilised the Trueblot system, the appropriate Rabbit TrueblotTM:Horseradish 
Peroxidase (HRP) secondary antibody was used at 1:1000 (eBioscience).  
The U251MG immunoprecipitation, carried out by my colleague in the laboratory Claire 
Thomas, was conducted using 0.5 mg of lysate. Either 10 μg of 4682 antibody or rabbit 
IgG was bound to Protein A beads in PBS and lysate was precleared with beads alone 
for 2 h with rotation. Beads washed in TNE lysis buffer were mixed with precleared 
lysate for 3 hours on the rotor wheel. Supernatant was sampled, the beads washed 5 
times and the protein was eluted in 25 μl Laemmli sample buffer. Samples and beads 
were analysed by western blot. 
Chapter 2. Materials and Methods 
 75 
2.2.4.13 Detergent resistant membrane preparation 
PC12 cells transfected and differentiated in the presence of NGF for 3 days were 
washed with cold HBSS, excess wash was removed with a pipette before adding 1 ml 
1% Triton X-100 in HBSS supplemented with EDTA free protease inhibitors (Roche) at 
4°C. Cells were scraped on ice, then passed through a 25g needle 10 times, and left to 
solubilise on ice for 30 min. Samples (1 ml) were adjusted to 41% sucrose by adding 
pre-ground sucrose, vortexed and left to dissolve on a rotor wheel for 5-10 minutes. 
The samples were transferred to Beckman 9/16 x 3  inch tubes, and overlaid with 8.5 
ml 35% sucrose then 2.5 ml 16% sucrose both dissolved in HBSS supplemented with 
protease inhibitors. Samples were then separated by centrifugation at 35,000 rpm in 
SW40 Ti (154,693 x g av., 217,874 x g max) for 18 hours at 4˚C with 0 deceleration. 
Twelve or thirteen 1 ml samples were collected, and the protein precipitated with 0.1% 
sodium deoxycholate and 800 μl 15% TCA for 15 min on ice (see 2.2.4.3). Samples 
were centrifuged at 13,000 rpm 15 minutes at 4°C, pellets washed with -20°C acetone, 
and centrifugation repeated for 10 min, then pellets were allowed to air dry before 
adding 25 μl of 2.5 x Laemmli sample buffer. pH was adjusted with Tris-base, and 
loaded on SDS-PAGE for analysis. 
2.2.5 Visualisation and imaging techniques 
2.2.5.1 Immunofluorescence 
Ventral horn neurons or PC12 cells on coverslips were fixed in 4% PFA in PBS for 20 
min, quenched with NH4Cl: pH 7.5 for 10 min and washed with PBS. Neurons or PC12 
cells were permeabilised for 5 min with 0.1% Triton X-100 in PBS as necessary and 
were blocked in blocking solution (10% horse or goat serum according to the species 
of the secondary antibody to be used), 0.25% gelatin and 2% BSA). The cells were 
then incubated with primary antibodies for 30-60 min in blocking solution (see Table 3 
for primary antibodies used in these studies). After washing, cells were incubated for 
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30 min with appropriate secondary antibodies diluted in blocking solution. After 
extensive washing, cells were mounted in 10% mowiol 4-88 solution. Cells were 
visualized using the Zeiss LSM 510 confocal laser scanning microscope using either 
the 63x 1.4 NA Plan-Apochromat or the 40x 1.3 NA Plan-NeoFluor oil-immersion 
objectives. 
2.2.5.2 Conjugation of antibody 
The goat anti-mouse ALCAM (AF1172 R&D Systems) antibody or the anti-p75NTRCTD 
(Deinhardt et al., 2007) were labelled with the Alexa Fluor® 488 or 555 Monoclonal 
Antibody Labelling Kit (Invitrogen). 
2.2.5.3 Internalisation assay 
Ventral horn neuron cultures at 4°C or 37°C were exposed to the Alexa Fluor-
conjugated primary antibody directed against the extracellular domain of the cell-
surface molecule of interest (e.g. ALCAM or p75NTR). Ventral horn neurons were 
washed in medium to remove unbound antibody then incubated at 37°C for 1-2 hours 
to allow for internalisation and transport of the complex. Neurons were acid washed 
(100 mM Citrate-NaOH pH 2, 140 mM NaCl) to remove the fraction of antibody 
remaining on the surface, then fixed, permeabilised and processed in the same way as 
for standard immunofluorescence as described in 2.2.5.1. 
2.2.5.4 Measurement of axonal transport 
Ventral horn neurons were incubated with 1:500 to 1:1000 ALCAM-Alexa®488 
(ALCAM488) alone or in the presence of 40 nM Hc-AlexaFluor®555 (Hc-555) or anti-
p75NTR-AlexaFluor®555 (p75NTR555) in complete medium for 30 min at 37°C. Ventral 
horn neurons were then washed three times with imaging medium (Dulbecco’s 
minimum essential medium without phenol red (DMEM-), riboflavin, folic acid and 
penicillin/streptomycin, supplemented with 30 mM Hepes-NaOH pH 7.4). In some 
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experiments, ALCAM488 was incubated in the presence of 75 nM of LysoTracker 
Red DND-99. 
Ventral horn neurons were placed in a 37°C humidified chamber and an image taken 
every 5 s with a Zeiss LSM 510 confocal laser scanning microscope using a 63x 1.4 
NA Plan-Apochromat oil-immersion objective. Carrier tracking was performed on time-
lapse sequences using motion analysis software (AQM tracker). Only carriers that 
moved over 3 or more consecutive time points were analysed. Hc moves in the 
retrograde direction and this feature was used to determine the direction of transport in 
the axon during co-transport experiments. The distance covered by a carrier between 
two consecutive frames was used to calculate the speed (Bohnert and Schiavo, 2005). 
Speed distributions were plotted to show the relative frequency of single movements 
with identical speed and this was calculated per ventral horn neuron culture. In the 
speed distribution graphs, the mean relative frequency of carriers with a particular 
speed and the corresponding standard error of the mean (SEM) were plotted for all 
ventral horn neuron cultures analysed.  
The frequency of carriers was calculated per axon, dividing the total number of carriers 
tracked during a time-lapse movie by its duration in seconds. The average carrier 
frequency was calculated for each ventral horn neuron culture. The frequency data 
analysed are represented as box and whisker plots, an example of which is described 
in Figure 2.5. 
The proportion of carriers that paused during axonal transport was also quantified. An 
axonal carrier was defined as having paused if it moved more slowly than 0.01 μm/s 
between 2 consecutive frames in time-lapse sequences. This parameter was set 
according to the limitations imposed by the resolution of our live-cell imaging set-up i.e. 
smaller velocities are below the threshold of detection. The proportion of carriers that 
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paused was calculated by dividing the number of pausing carriers tracked by the total 
number of tracked carriers in a ventral horn neuron culture. The proportion of carriers 
that paused per ventral horn neuron culture are plotted on box and whisker diagrams 
similarly to the frequency analysis and as described in Figure 2.5. 
Kymograph correspondent to the transport experiments were assembled with the aid of 
MetaMorph®. Kymographs are a way in which a dynamic process e.g. axonal transport 
can be represented in both time and space in a two-dimensional image. An example of 
an ALCAM transport experiment represented as a kymograph is shown in Figure 2.6, 
accompanied by a description as to how they are generated. 
2.2.5.5 Measurement of axonal transport after binding on ice with or without the 
ALCAM ligand CD6 
ALCAM488 was incubated at 4°C alone, or in the presence of either 1 μg/ml CD6-
human Fc fusion protein or 1 μg/ml human Fc (Hu-Fc) in HBSS. Cells were then 
washed with imaging medium, then incubated for a further 30 min at 37°C. Cells were 
imaged and the data analysed as described in 2.2.5.4. In some cultures, neurons were 
exposed to both ALCAM488 and p75NTR555. In these co-transport experiments the 
transport of either probe was used to assess axonal viability. If neither probe was 
transported, the axon was not considered in the frequency analysis. 
For CD6-Fc exposed and control conditions, Gaussian curves, as a ‘best-fit’ for the 
instantaneous speeds observed for each axon, were generated with the help of Dr 
Gavin Kelly (LRI, Bioinformatics and Biostatistics Service). These curves were 
compared to the average speed distribution curves per ventral horn neuron culture and 
between the CD6 exposed and control conditions. No significant difference was 
detected between ventral horn neuron cultures, suggesting that transport did not differ 
between cell preparations isolated at different times. 
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2.2.6 Visualisation of axonal sprouting at skeletal muscle neuromuscular 
junctions (NMJ) in ALCAM-/- mice 
2.2.6.1 Botulinum Neurotoxin A (BoNT/A) treatment of the extensor digitorum 
longus (EDL) and Levator auris longus (LAL) 
Axonal sprouting in response to BoNT/A induced paralysis was compared in ALCAM-/- 
and their wild type littermates in two different skeletal muscles the EDL and LAL 
muscles. These experiments were undertaken with the help of Dr Bernadett Kalmar, a 
colleague in the laboratory, who carried out the BoNT/A intramuscular injections and 
removed the skeletal muscles from wild type and ALCAM-/- animals three weeks after 
the BoNT/A treatment.  
For EDL muscles, animals were anaesthetised with isoflurane and their left leg shaved. 
A longitudinal incision was made in the leg, the skin pulled open to expose the muscle, 
the EDL muscle was identified beneath the tibialis anterior muscle. A 3D representation 
of the mouse hindlimb and location of the EDL is illustrated in Figure 2.7. The muscle 
was injected midway along its length with 1 μl of 1 pg/μl BoNT/A diluted in 2 mg/ml 
mouse serum albumin in PBS. The skin was then closed with sutures before returning 
the mice to their cages. Animals were sacrificed and muscles removed 3 weeks after 
BoNT/A injection, pinned in a slightly stretched position in a sylgard-coated petri dish 
and then fixed for 6 h in muscle fixative (4% Formaldehyde, 10% CaCl2, 5% 
MgCl2.6H2O, 1% CdCl2.1/2H2O, in Veronal Acetate buffer). As a control EDL muscles 
were also removed from the uninjected leg of some animals. The muscles were kept in 
10% sucrose overnight and then mounted in Tissue-Tek® O.C.T.™ and cut into 40 nm 
sections using a Leica 4100 microtome at -20°C. Free-floating sections were 
processed using a combined silver-acetylcholinesterase stain, which allows for the 
simultaneous visualisation of nerve terminals and endplates (see 2.2.6.2) 
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For LAL muscles 2 μl of 0.25 pg/μl BoNT/A was injected subcutaneously on the left 
side of the head of each animal under isoflurane anaesthesia. After 3 weeks, both the 
left and right LAL muscles were removed, fixed for 2 hours in muscle fixative and 
transferred to 10% sucrose for 1 hour. The LAL muscle, as a whole mount preparation, 
was then stained using a combined acetylcholinesterase and silver stain as described 
in (Angaut-Petit et al., 1987). 
2.2.6.2 Acetylcholinesterase and silver staining 
Floating muscle sections washed in distilled water were cooled on ice and incubated 
for 20 min in cooled acetylcholine iodide solution (0.04% acetylcholine iodide, 59 mM 
sodium hydrogen maleate, 5 mM tri-sodium citrate, 3 mM copper sulphate, 0.45 mM 
potassium ferricyanide, 14% sucrose). Muscles were rinsed in distilled water and then 
immersed in potassium ferricyanide solution (7.6 mM potassium ferricyanide) for 10 
min at room temperature to stain endplates. Following 3 washes in distilled water, 
sections were immersed in absolute ethanol for 2 washes of 30 min each and 
subsequently washed in distilled water for a further 30 minutes.  
Nerve terminals were then stained by incubating sections in silver solution (0.1% 
CaCO3, 0.05% CuSO4.5H2O, 10% AgNO3) for 20-30 minutes at 37°C. Muscles were 
rinsed briefly in distilled water before being immersed in reducer solution (1% 
hydroquinone, 10% Na2SO3). When axons became visible, the reaction was stopped 
by washing several times in water. Sections were mounted on polylysine slides using a 
paintbrush and allowed to dry overnight at 37°C. Finally the sections were cleared by 
immersion in histoclear before mounting in DPX mountant (BDH) for microscopical 
analysis. For LAL muscles the same staining protocol was followed but wholemount 
muscle preparations were used rather than muscle sections. 
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2.2.6.3 Quantification of axonal sprouting at NMJs 
The number of sprouts per NMJ in BoNT/A injected muscles in wild type and ALCAM-/- 
littermates were counted. Uninjected muscles were also quantified as a control. Axonal 
sprouts were classified as silver stained processes that contacted the endplate region 
before extending beyond the acetylcholinesterase stained boundary. I also quantified 
nodal sprouts as those that branched from the axon immediately before entering the 
terminal. Examples of the terminal and nodal sprouts counted are shown in Figure 2.8. 
Counting was carried out blind to genotype, using HC PL FLUOTAR 20x/0.50 and PL 
FLUOTAR 40x/0.70 objectives on Leica DMR light microscope. 
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Figure 2.1 Cloning strategy for ALCAM Dendra (ALCAM-D) constructs 
Forward primers (green arrowheads) and stop primers (pink arrowheads) were used to 
amplify DNA fragments by PCR. Full length ALCAM was amplified (FL) or ALCAM 
fragments; signal sequence (SS), ALCAM missing one or two of its most distal 
extracellular domains (D1 or D1D2 respectively), ALCAM lacking its cytoplasmic 
domain (C), or ALCAM lacking its extracellular domain (Ec – was used to generate 
CD8-ALCAM chimera). Insert and vector are digested using appropriate restriction 
enzymes, purified and then ligated together. For constructs requiring ligation of two 
inserts, both fragments were ligated together at the same time or as a sequential 
process with firstly one digestion, ligation step and then a second digestion ligation 
step, as indicated by the dotted arrow. 
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Figure 2.2 Cloning strategy for ALCAM-His6 constructs 
The strategy used to clone the His6-tagged ALCAM extracellular domain (ALCAM-Ec) 
and cytoplasmic domain (ALCAM-C) is shown. Forward primers (green arrowheads) 
and stop primers (pink arrowheads) were used to amplify ALCAM DNA by PCR. The 
vector was digested using Nde1 and Xho1 to remove the ERCC1 insert either directly 
or sequentially. The ALCAM-Ec fragment could not be digested with Nde1, as there 
was an internal Nde1 restriction site within the ALCAM extracellular domain sequence. 
In the ALCAM-Ec start primer the Sfo1 blunt-end producing restriction site was used 
instead. Therefore, for the ALCAM-Ec construct the Nde1 digested vector had to 
undergo a sequential reaction with T4 polymerase (T4 Pol) to produce a blunt end 
before being digested with Xho1. The appropriate digested insert fragments were then 
incubated with their corresponding vector in a ligation reaction.  
Chapter 2. Materials and Methods 
 84 
 
 
 
 
 
 
Figure 2.3 Nde1 and Sfo1 restriction sites 
Arrowheads and dotted lines indicate where the enzymes Nde1 and Sfo1 cut their 
respective restriction sites. Nde1 cuts to give a 5’ overhang, while the Sfo1 enzyme 
cuts resulting in a blunt-end.  
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Figure 2.4 Coupling reaction of MION to protein 
The amide groups on the MION beads (Fe) exposed to SMCC become activated 
maleimide intermediates which can react with the sulfhydryl groups on the Hc and BSA 
proteins. This results in a disulphide bond between the proteins and the bead. 
Previously this chemistry has been used in the lab to couple the Hc fragment with 
Alexa Fluor® dyes (Lalli and Schiavo, 2002). 
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Figure 2.5 Example of box and whisker plot 
The box spans the upper to lower quartiles (representing 50% of all data values). The 
line in the centre of the box is the 50th percentile or median, and the tips of the 
whiskers are the minimum and maximum values. The box and whisker plot is a non-
parametric way of representing data without making assumptions of their underlying 
distribution. In this thesis, box and whisker diagrams have been used to represent 
ALCAM, Hc and p75NTR carrier frequency and the proportion of pausing carriers in 
transport experiments (Y-axis). 
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Figure 2.6 An example of a ALCAM488 movie kymograph 
Panel (A) shows a frame from a time-lapse imaging experiment after black an white 
conversion and inversion, so that the black puncta represent the fluorescent carriers. 
The kymograph (B) is generated by drawing a region of interest along the length of the 
axon, as shown by the dotted line in (A). Consecutive lines from the region of interest 
in (A) are stacked vertically over time to create the kymograph. Actively transporting 
vesicles are represented as puncta moving diagonally across the kymograph. The 
asterisks indicate entrance and exit points of ALCAM488 vesicles. Stationary or 
oscillating vesicles appear as vertical stripes since they do not move over consecutive 
frames, indicated by the black boxes.  
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Figure 2.7 Mouse hindlimb muscles and tendons 
Pictures were generated using the 3D mouse limb anatomy atlas 
http://www.nimr.mrc.ac.uk/3dlimb. A 3D reconstruction of the mouse hindlimb is shown. 
In the middle panel all muscles and tendons are represented and coloured as indicated 
in the lower panel. The EDL muscle alone, used in the nerve terminal sprouting study, 
is shown in the right panel. The overlying tibialis anterior muscle was cut away and the 
EDL muscle tendons exposed and the muscle removed.  
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Figure 2.8 An example of terminal and nodal sprouts from NMJ nerve 
terminal 
Endplate and nerve terminals are visualised by the combined silver-
acetylcholinesterase stain in a mouse skeletal muscle. Sprouting is induced in 
response to BoNT/A muscle paralysis. Terminal sprouts exiting the endplate region to 
contact the muscle fibre, indicated by the black arrows, were quantified. A nodal sprout 
that has branched from the nerve terminal before reaching the endplate region is also 
visible (white arrow) and were also counted in wild type and ALCAM-/- animals. Scale 
bar, 100 μm. 
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Chapter 3. ALCAM undergoes axonal retrograde 
transport with neurotrophin receptors 
3.1 ALCAM is associated with Hc containing endosomes 
As described in the introduction ALCAM was identified by mass spectrometry as a 
protein associated with the Hc-positive endosome in ventral horn neurons. In the first 
part of the study, I aimed to confirm the association between ALCAM and this axonal 
transport compartment using a variety of techniques.   
Firstly, we purified membrane compartments associated with Hc by the same method 
previously used for the mass spectrometry proteomic screen. Mouse ventral horn 
cultures were exposed to magnetic nano-beads (MIONs) conjugated with Hc. These 
modified MIONs bind to the neuronal surface and are internalised into endosomal 
compartments, as shown in Figure 1.4 and in (Deinhardt et al., 2006b). Neurons were 
harvested, passed through a cell cracker to break their plasma membrane while 
keeping intracellular organelles intact and the resulting cell-free homogenate passed 
through a magnet. Organelles containing the MIONs were retained in the magnet. 
Subsequently, proteins associated with the nano-beads were eluted, separated by 
SDS-PAGE, transferred to PVDF and blotted for ALCAM. A typical western blot from 
one of these experiments is shown in Figure 3.1. Consistently ALCAM associated 
specifically with the Hc-conjugated MIONs and not with control BSA-conjugated 
MIONs. This verified biochemically the association between ALCAM and Hc containing 
organelles that was originally indicated in the proteomic screen. 
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Figure 3.1 ALCAM associates with Hc MION beads 
A typical SDS-PAGE and western blot following MION bead purification of the Hc 
endosomal compartment is shown. The membrane has been probed for ALCAM 
(ALCAM). Two ALCAM bands are present in the ventral horn culture lysate (Input). In 
samples eluted from MION (Beads), ALCAM is only associated with the Hc beads, not 
the BSA beads. ALCAM is depleted in the flow through (FT). Interestingly, although 
both ALCAM species are associated with the beads, the lower molecular weight, less 
abundant ALCAM band is enriched in association with Hc. 
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3.2 ALCAM undergoes retrograde transport in the Hc-transport 
organelle 
I next investigated whether ALCAM underwent retrograde transport as previously 
observed with Hc, by visualisation of transport in live ventral horn neurons. To this end, 
I conjugated an antibody raised against the extracellular domain of ALCAM, to the 
fluorophore AlexaFluor®-488 (ALCAM488). The conjugated antibody can bind to the 
ALCAM extracellular domain at the plasma membrane and if the endogenous protein is 
internalised and transported, the conjugated antibody should also undergo 
internalisation and be transported. This method for following the destination of cell 
surface molecules has been extensively used to follow a variety of proteins. For 
example, an antibody directed towards the lumenal portion of synaptotagmin 1 was 
used to follow synaptic vesicle recycling in primary hippocampal neurons (Matteoli et 
al., 1992). The internalised antibody had a long half-life and did not alter the 
localisation or properties of the synaptic vesicles it labelled. Another group has used a 
monoclonal antibody to an extracellular loop of the chemokine receptor, CXCR4, to 
follow the internalisation of this protein and to monitor how this process is regulated 
(Signoret et al., 1997). However, both of these papers noted possible problems with 
the technique. In the study by M. Matteoli, evidence suggested that the antibodies 
could induce clustering of the endogenous protein in certain conditions, and this could 
alter its trafficking e.g. directing the protein into the degradative pathway. In (Signoret 
et al., 1997), it was found that the internalisation and trafficking properties of CXCR4 
were altered when the protein was transfected into chinese hamster ovary (CHO) cells, 
although this was not the case when mink lung cells were used. This finding suggested 
not only that different cell lines have different basal rates of internalisation, but also that 
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following transfection anomalous trafficking can occur. Therefore studies using 
antibodies to track transfected proteins should be treated with caution. 
To test whether the conjugated ALCAM488 retained the binding ability of the original 
antibody I conducted a competition assay. The binding of the conjugated antibody to 
ventral horn motor neurons alone was compared to that seen after pre-incubation with 
the unconjugated antibody. An experiment showing competition of ALCAM488 by the 
unconjugated antibody is shown in Figure 3.2 and confirmed that ALCAM488 bound 
to the same antigen as the original antibody. The specificity of the ALCAM488 probe 
was tested in transport experiments in ventral horn neurons isolated from ALCAM 
knockout (ALCAM-/-) mice. As expected, ALCAM488 did not bind to neurons isolated 
from ALCAM-/- mice, as shown in Figure 3.3. This result illustrated that the 
ALCAM488 probe is specific for endogenous ALCAM. 
Following characterisation of the ALCAM488 probe, I investigated whether 
internalisation and long-range transport of endogenous ALCAM occurred in primary 
ventral horn neurons. Neurons were incubated with the probe in the presence of Hc-
555 for 30 min, washed in imaging medium and transport was visualised using time-
lapse confocal microscopy in live neurons at 37°C. Onset of ALCAM488 transport 
occurred approximately one hour after initial exposure to the probe, when ALCAM-
positive vesicles could be seen moving bi-directionally. ALCAM transport was 
predominantly retrograde, and this protein was often present in transport 
compartments also containing Hc, as shown in Figure 3.4. In 3 independent 
experiments, tracked ALCAM488 vesicles were classified as containing ALCAM alone 
or ALCAM in addition to Hc and 60% of ALCAM-positive carriers quantified also 
contained Hc (n = 84 ALCAM-positive carriers, 21 axons, 3 ventral horn cultures).  
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Tracking and speed displacement analysis of live-cell imaging experiments found no 
significant difference in the speed distribution of Hc and ALCAM carriers and, as seen 
in Figure 3.5, ALCAM is transported with a similar speed distribution as Hc. This is 
consistent with the observed partial colocalisation of ALCAM and Hc during retrograde 
transport, suggesting that the two probes share a transport route when travelling 
toward the cell body. Transported ALCAM has an increased relative frequency of 
carriers with speeds between -0.2 to 0.2 μm/s when compared to Hc and this could 
suggest ALCAM carriers have an increased tendency to pause.  
The proportion of tracked ALCAM and Hc-positive vesicles that paused during 
transport was therefore quantified and is represented in Figure 3.6. A pausing carrier 
was defined as one that moved more slowly than 0.01 μm/s between 2 consecutive 
frames. There was no significant difference in the average proportion of carriers that 
paused containing ALCAM and/or Hc (p = 0.0936). Although the result did not reach 
significance, there is an increased tendency for ALCAM-positive vesicles to pause, 
shown as a shift towards more pausing carriers in the box and whisker plot Figure 3.6. 
This finding, along with the observed increase of low speed carriers observed in the 
speed distribution (Figure 3.5), suggests that ALCAM-positive carriers have an 
increased tendency to pause, when compared to Hc-positive compartments.  
The frequency of ALCAM and Hc-positive carriers transported per min was quantified 
per axon imaged, and the average frequency per ventral horn culture is represented in 
Figure 3.7. The average frequency of ALCAM488 transported per min was 
comparable to the frequency of Hc-positive carriers per min in co-transport 
experiments. 
In conclusion, ALCAM undergoes long-range axon transport toward the cell body, often 
in the presence of Hc. Furthermore, the speed and frequency of ALCAM488 transport 
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is comparable to Hc, suggesting ALCAM largely shares the same transport route (Lalli 
and Schiavo, 2002, Deinhardt et al., 2006b). Only axons that transported both ALCAM 
and Hc were analysed and because these probes are largely co-transported, 
differences in their transport kinetics, i.e. increased pausing of ALCAM-positive 
carriers, may be attributed to a pool of carriers that contained only one probe. This 
could suggest that the subset of ALCAM-positive carriers that did not contain Hc 
paused more often, and may represent another internalisation and transport route for 
ALCAM in neurons (for further discussion see 6.1.1). 
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Figure 3.2 ALCAM488 binds to endogenous ALCAM on the surface of 
ventral horn culture cells 
In the ‘competition’ condition, prior binding of endogenous ALCAM by the unconjugated 
antibody prevents ALCAM488 binding to the surface of cells, but exposure to the 
antibody alone gives a clear cell surface stain. The boxed area is shown at higher 
magnification on the right. ALCAM488 is shown to bind to neurites, as well as the cell 
body surface. Scale bar, 10μm. 
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Figure 3.3 ALCAM488 does not bind to neurons in ALCAM-/- cultures 
Ventral horn neuron cultures isolated form wild type and ALCAM-/- embryos were 
incubated with Hc-555 and ALCAM488. ALCAM488 did not bind to ALCAM-/- 
neurons, but did stain wild type axons. Hc-555 binding was not altered in neurons that 
did not express ALCAM when compared to wild type axons, and is illustrated in the 
lower panel where a similar Hc-555 signal is seen. Scale bar, 10μm. 
 
Chapter 3. Results 
 98 
 
 
 
 
Figure 3.4 ALCAM undergoes retrograde transport and partially 
colocalises with Hc containing organelles 
Consecutive frames from a transport movie obtained during live-cell imaging of Hc-555 
and ALCAM488. The arrowhead indicates a retrograde transport vesicle containing 
Hc and ALCAM moving towards the cell body (black arrow). The two probes are not 
transported exclusively in the same carriers. The stars (*) indicate Hc-positive transport 
compartments that do not contain ALCAM. Stationary vesicles that contain both Hc and 
ALCAM are seen in the centre and right hand side of the axon, while another stationary 
vesicle contains ALCAM alone (indicated by black and white  respectively). Scale bar, 
10 μm. 
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Figure 3.5 Speed distribution of ALCAM488 and Hc in co-transport 
experiments 
The relative frequency of ALCAM-positive carriers with identical instantaneous 
velocities (speed μm/s) is plotted and is comparable to that of Hc-positive carriers 
recorded in the same experiments. The two probes have a similar speed distribution (n 
= 183 ALCAM and 231 Hc carriers, recorded in a total of 38 axons from 8 ventral horn 
cultures). 
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Figure 3.6 ALCAM-positive carriers show an increased tendency to pause 
The box and whisker plot shows that a higher proportion of ALCAM488-positive 
carriers pause. Although not statistically significant, there is an increased tendency for 
ALCAM488-positive carriers to pause (p = 0.0936) when compared to Hc-positive 
organelles. Data was analysed using an unpaired t-test (n = 8 ventral horn cultures). 
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Figure 3.7 There is no significant difference in the frequency of ALCAM 
and Hc-positive carriers in co-transport experiments 
The average frequency of ALCAM488 and Hc carriers per ventral horn neuron culture 
are represented in two ways; a box and whisker plot (left) or as paired ALCAM488 
and Hc frequencies observed in the same axons (right). There is no significant 
difference in the average frequency of ALCAM488 or Hc-positive carriers per min in 
co-transport experiments. The range and maximum frequency is greater for Hc 
transport than for ALCAM488. Paired observations show that there is no consistent 
relationship between increased ALCAM488 and Hc transport frequencies. Data was 
analysed using an unpaired t-test (n = 8 ventral horn cultures). 
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3.3 ALCAM is transported in endosomes that contain 
neurotrophin receptors 
Since ALCAM transport had shown substantial overlap with Hc, we next wanted to 
confirm more directly whether ALCAM was associated with the retrograde transport of 
neurotrophins and their receptors, or whether it was transported within a distinct subset 
of Hc-labelled endosomes that did not contain these molecules. I conducted 
experiments examining ALCAM488 transport in neurons that had been co-exposed to 
a fluorophore-conjugated antibody to the p75NTR receptor (p75NTR555). 
In these experiments, axonal retrograde transport compartments were seen which 
contained both, p75NTR and ALCAM, as well as endosomes that contained either 
protein exclusively (Figure 3.8). The incidence of co-transport was quantified and 
established that 64% of ALCAM488 vesicles tracked were also p75NTR555-positive. 
Interestingly, we found that the frequency of p75NTR endosome transport was around 3 
times higher than ALCAM containing compartments as shown in Figure 3.9.  
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Figure 3.8 ALCAM is transported retrogradely in p75NTR-positive 
endosomes 
Consecutive frames from a live-cell imaging experiment with p75NTR555 and 
ALCAM488. The black arrow indicates the direction of transport towards the cell body. 
Arrowheads indicate retrogradely travelling endosomes that contain ALCAM and the 
neurotrophin receptor p75NTR. An ALCAM static endosome that does not contain the 
p75NTR is indicated by (). Scale bar, 10μm. 
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Figure 3.9 p75NTR is transported more frequently than ALCAM 
The frequency of p75NTR and ALCAM488 carriers per min was calculated in 3 ventral 
horn neuron cultures and plotted as paired observations (each line represents the 
frequency of each probe matched in each culture experiment). Although not reaching 
statistical significance, p75NTR is consistently transported at higher frequencies than 
ALCAM (around 4 fold more p75NTR is transported). Data was analysed using an 
unpaired t-test, p = 0.1757 (n = 3 ventral horn cultures). 
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3.4 Does ALCAM play a role in the regulation of retrograde 
transport? 
Considering ALCAM is retrogradely transported in the same compartment as Hc and 
p75NTR, we investigated whether it has a role in regulation of this pathway or is merely 
a cargo in these endosomes. I isolated ventral horn cultures from ALCAM-/-, ALCAM+/- 
and wild type litter mates and conducted live-cell imaging transport experiments after 
exposure to Hc-555 to investigate whether transport was altered when ALCAM was not 
expressed. As established earlier, ALCAM488 did not bind to ALCAM-/- neurons and 
was not transported in these cultures (Figure 3.3).  
Analysis of these imaging experiments found that there was no difference in the 
transport of Hc between cultures lacking ALCAM and those that expressed ALCAM. 
The speed distribution profiles in Figure 3.10 show no alteration in the overall kinetics 
of Hc transport in ventral horn cultures isolated from wild type, ALCAM+/- or ALCAM-/- 
animals. Furthermore, there is no significant difference between the genotypes in the 
frequency of Hc-positive vesicles or the proportion of vesicles that pause (Figure 3.11). 
It is noted that in ALCAM+/- ventral horn cultures analysed one culture had a particularly 
high frequency of Hc carriers that is an outlier on the box and whisker plot (Figure 
3.11). However, fewer ALCAM+/- cultures were analysed and considering that the other 
parameters quantified are the same, I concluded that Hc transport is not altered in 
heterozygote animals. In summary, Hc transport is normal in the absence of ALCAM, 
suggesting it does not play a regulatory role in this transport route. 
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Figure 3.10 Hc transport is unaltered in ventral horn neurons with or 
without endogenous ALCAM 
After tracking and speed displacement analysis of Hc transport, the speed distribution 
profiles were plotted for all three genotypes; wild type, ALCAM+/- and ALCAM-/-. We 
found no difference in the speed distribution of Hc-555 retrograde transport in ventral 
horn neurons that did not express ALCAM when compared to the transport observed in 
neurons that did express ALCAM. wild type n = 92 Hc carriers, 22 axons, 4 ventral horn 
cultures; ALCAM+/- n = 100 Hc carriers, 17 axons, 3 ventral horn cultures; ALCAM-/- n = 
101 Hc carriers, 22 axons and 4 ventral horn cultures. 
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Figure 3.11 There is no significant difference in the frequency or pausing 
of Hc carriers in ALCAM-/- cultures 
In the plots (A) the frequency of Hc carriers in wild type (wt), ALCAM+/-(+/-), ALCAM-/-(-
/-) cultures is represented (line = median). There is no significant difference in the 
frequency of Hc carriers between the genotypes. Furthermore, in (B) there is no 
significant difference in the proportion of Hc-positive carriers that pause in ventral horn 
neurons that do or do not express ALCAM. All data was analysed using an unpaired t-
test (n = 4 ventral horn cultures for wt and ALCAM-/- and 3 ventral horn cultures for 
ALCAM+/-). 
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3.5 Can ALCAM transport be modulated? 
As discussed in the Introduction, the CD6 glycoprotein is an endogenous binding 
partner of ALCAM and a soluble form of the protein has been shown to stimulate 
ALCAM internalisation in an ovarian cancer cell line (Piazza et al., 2005). I next 
examined whether exposure of ventral horn neuron cultures to CD6 could stimulate the 
retrograde transport of ALCAM. 
3.5.1 The anti-ALCAM antibody cross reacts with the CD6-Fc chimera 
Western blot analysis of ALCAM and its ligand CD6 revealed that the primary antibody 
used to detect ALCAM in my previous internalisation and transport experiments cross-
reacted with the ALCAM ligand CD6. CD6-Fc, a chimeric protein consisting of the CD6 
extracellular domain (Leu18-Gly396) fused to His6 tagged Human IgG1 was obtained 
commercially. The problem was revealed in an experiment where mouse ventral horn 
culture lysates from cells incubated with GST or CD6-Fc, were analysed by western 
blot (Figure 3.12A). A novel band of 110-120 kDa molecular weight was recognised in 
samples exposed to CD6-Fc only. To check whether this novel band was due to cross-
reaction of the anti-ALCAM antibody with CD6, the purified chimeric protein was 
analysed by western blot (Figure 3.12 B). A band was only detected in the presence of 
the anti-ALCAM primary antibody, suggesting that this antibody recognised the purified 
CD6-Fc protein. The datasheet specified that CD6-Fc should migrate at 116kDa, and 
this is the molecular weight of the band detected by the anti-ALCAM antibody. 
Endogenous ALCAM migrates at a lower molecular weight. This suggested that the 
antibody cross-reacted with the CD6-Fc protein directly rather than there being 
contamination of the chimeric protein sample with ALCAM.  
In summary, I found that a primary antibody raised against the ALCAM extracellular 
domain also reacted with purified CD6-Fc, suggesting that the commercial ALCAM 
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polyclonal antibody also could recognise the CD6 antigen. This posed a potential 
problem considering that my previous studies made extensive use of this antibody in 
transport experiments, biochemical purification and western blots. Was the protein 
recognised in previous experiments endogenous ALCAM or CD6? I therefore needed 
to confirm that CD6 is not present in the nervous system and to establish whether CD6 
is expressed in primary ventral horn neuron cultures. 
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Figure 3.12 Anti-ALCAM antibody cross-reacts with soluble CD6-Fc 
(A) Ventral horn neuron culture lysates of cells previously exposed to GST or CD6-Fc 
(CD6) were analysed by SDS-PAGE and probed for ALCAM by western blot (WB). A 
novel band appears in all conditions where CD6 has been added. In (B) and (C) 
purified CD6-Fc (10 and 100 ng) was analysed by western blot. The membrane was 
probed with an anti-goat secondary antibody alone (B) or after prior exposure to the 
anti-ALCAM primary antibody (C). Membranes exposed to the secondary antibody 
alone showed no reactivity, while CD6 protein was recognised by the anti-ALCAM 
primary antibody. 
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3.5.2 CD6 is not expressed in mouse ventral horn neuron cultures  
Firstly I tested whether pre-absorption of the anti-ALCAM antibody with soluble CD6 
altered the recognition of the ALCAM bands seen in ventral horn cultures. As shown in 
Figure 3.13, pre-absorption of the anti-ALCAM antibody with CD6 did not alter the 
recognition of both bands present in ventral horn cultures. This result suggested that 
the bands detected in primary ventral horn cultures represent endogenous ALCAM, 
rather than CD6. 
Secondly, I isolated RNA from mouse ventral horn neuron cultures, synthesised the 
corresponding cDNA using the Superscript® Vilo Kit and tested for the presence of the 
CD6 transcript by PCR. No CD6 transcript could be amplified from mouse ventral horn 
neuron culture cDNA, suggesting that endogenous CD6 is not expressed in the spinal 
cord (Figure 3.14). However, CD6 could be amplified from whole embryo cDNA as a 
control. In summary, CD6 is not expressed in the ventral horn. This finding is 
consistent with reports claiming that CD6 expression is largely restricted to the immune 
system (gene expression atlas EMBL-EBI http://www.ebi.ac.uk/gxa/gene?gid= 
Q61003).  
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Figure 3.13 Ventral horn ALCAM species recognised are not altered by 
preabsorption with CD6-Fc 
Ventral horn culture lysates from two independent experiments (A and B) were 
separated by SDS-PAGE, transferred to PVDF membrane and probed with the anti-
ALCAM antibody (ALCAM) or the anti-ALCAM antibody cross-absorbed with 3 μg of 
CD6-Fc for 90 minutes before incubation with the membrane overnight (ALCAM/CD6-
Fc). No significant change in the signal was detected after the absorption with CD6-Fc. 
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Figure 3.14 CD6 is not expressed in ventral horn cultures 
In (A) a CD6 transcript was amplified from cDNA isolated from embryonic mouse brain 
but no equivalent CD6 band was seen in cDNA isolated from wild type (WT) and 
ALCAM-/- (-/-) ventral horn cultures. In (B) the ALCAM transcript amplified from 10ng of 
ALCAM containing vector plasmid is also present in WT but not the ALCAM-/- cDNA 
isolated from the same cultures, serving as a control for the integrity of the RNA. 
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3.5.3 Is the frequency of ALCAM transport modulated in the presence of CD6? 
The discovery that the antibody cross-reacted with CD6-Fc created some 
methodological constraints when trying to investigate the effects of CD6 on ALCAM 
trafficking. Co-incubation of ALCAM488 and the soluble CD6-Fc chimera could 
produce large complexes of antibody and protein in solution that in turn could undergo 
macropinocytosis in neurons. If the internalised complexes underwent axonal transport, 
any transport visualised would then be composed of two carrier populations; those 
belonging to the characterised Hc-positive transport route, and potentially, a 
macropinocytosis-derived route.  
Endocytosis is inhibited at low temperatures so I conducted transport experiments after 
an initial binding step on ice. Cells on ice were co-exposed to CD6-Fc and 
ALCAM488 that could interact with endogenous ALCAM on the cell surface. 
ALCAM488 could bind either, or both, endogenous ALCAM or the CD6-Fc bound to 
ALCAM on the membrane. Cells were then washed, removing large complexes in 
solution and leaving only membrane-bound antibody complexes, then incubated at 
37°C for internalisation and transport. Following 60 min at 37°C, axonal transport could 
be visualised. As an additional control, soluble Human IgG Fc (Hu-Fc) was added to 
some of the cultures to investigate whether addition of a chimeric protein had any 
effect.  
The time-lapse imaging movies were tracked and the carrier speed distribution and 
carrier frequency analysed. I found that addition of Hu-Fc had no effect on transport so 
data was pooled from experiments after exposure to ALCAM488 alone or in the 
presence of Hu-Fc (alone/with Hu-Fc). The overall speed distribution profiles of 
ALCAM transport in the presence or absence of CD6-Fc are similar (Figure 3.15). To 
analyse whether these profiles are statistically different, Dr Gavin Kelly (LRI, 
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Bioinformatics and Biostatistics Service) was consulted who conducted a curve-fitting 
analysis on the tracking data. Briefly, speed distributions were generated by fitting 
curves to the raw data from each axon, data pooled from the same ventral horn culture 
and data pooled from all ventral horn cultures analysed (for a full explanation see 
section 2.2.5.5 in Materials and Methods). There was no significant difference in the 
ALCAM488 speed distribution curves with or without prior exposure to CD6-Fc. The 
position of the speed distribution peaks, i.e. the modal speeds were not significantly 
different (p=0.63) between CD6-Fc exposed and control conditions. The spread of the 
speed distribution was also not significantly different (p=0.64). This suggests that the 
time in which ALCAM reaches the cell body from the periphery does not change in 
presence of its ligand, CD6.  
A ligand could also alter the frequency at which its receptor is transported. I therefore 
quantified the frequency of ALCAM-positive carriers transported in the absence of CD6 
or after exposure to CD6-Fc. As a control, I also conducted a subset of experiments on 
ventral horn cultures co-incubated with p75NTR555 and ALCAM488 to establish 
whether CD6-Fc had a general effect on retrograde transport or whether the effect was 
specific to its binding partner ALCAM. Figure 3.16A represents the ALCAM-positive 
carrier frequency data collected from ventral horn neuron cultures exposed to 
ALCAM488 under control conditions (alone/in the presence of Hu-Fc) or after 
exposure to CD6-Fc. Neurons exposed to CD6-Fc show a tendency for increased 
ALCAM488 carrier frequency. Analysis of the proportion of ALCAM488-carriers that 
paused under control conditions or after exposure to CD6-Fc, revealed that carrier 
pausing was comparable between control and CD6 ligand stimulated conditions 
(Figure 3.16B).  
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In ALCAM and p75NTR co-transport experiments I could also estimate whether the 
presence of CD6 increased the number of axons that were transporting ALCAM. In 
these experiments, transport of either probe demonstrated the neuron was viable and 
capable of long-range transport, which allowed me to include neurons that transported 
p75NTR but not ALCAM in the analysis (i.e. axons with 0 carriers/min) and vice versa. 
The frequency of ALCAM488-carriers can be compared to p75NTR-positive carrier 
frequency in Figure 3.17A in CD6 stimulated and unstimulated conditions. I found no 
significant difference between the retrograde transport frequency of p75NTR-positive or 
ALCAM-positive endosomes in the presence of CD6-Fc or Hu-Fc. In Figure 3.17B, 
there is also a tendency towards an increased proportion of pausing ALCAM-positive 
carriers after exposure to CD6-Fc, although this was not statistically significant.  
Although I did not reveal any effect of CD6 on ALCAM transport, there is a tendency 
toward higher ALCAM transport frequencies in the presence of CD6. In contrast, no 
consistent effect of CD6-Fc on the proportion of pausing ALCAM-positive carriers was 
found (compare Figure 3.16 and Figure 3.17). All the transport experiments in the 
presence of CD6 were complicated by the cross-reactivity of the anti-ALCAM antibody 
with CD6-Fc and because ALCAM was transported at very low frequencies, making the 
detection of a small effect difficult. Perhaps, further investigation of co-transport 
experiments with p75NTR555 could establish if ALCAM-positive transport vesicles 
show increased pausing and/or frequency after exposure to an ALCAM ligand. I review 
this further in the Discussion, section 6.1.2. 
An interesting observation in these experiments is that in the absence of Hc, ALCAM 
transport is much less frequent than was seen previously (Figure 3.7). In the Hc co-
transport experiments, the mean ALCAM-positive and Hc-positive carrier frequency 
were 0.44 and 0.47 carriers per min respectively (n=9 ventral horn cultures). In the 
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ALCAM and p75NTR co-transport experiments ALCAM-positive and p75NTR-positive 
carrier frequency was 0.10 and 0.38 carriers per min respectively, in control (alone/Hu-
Fc) conditions (n=3 ventral horn cultures)(Figure 3.17A). These experiments were 
carried out at different times and on different cultures, however it suggests that 
exposure to Hc stimulates the internalisation and uptake of ALCAM in neurons. The 
ability of Hc to stimulate the transport of other proteins (i.e. p75NTR) present in the Hc 
positive endosome has been reported previously (Deinhardt et al., 2007).  
A soluble form of CD6 has been reported in human serum isolated from individuals 
with inflammatory conditions and has been suggested to have a biological role in the 
immune response as it can bind bacteria following infection (Sarrias et al., 2007). 
However, CD6 is not expressed in the nervous system, and therefore, it is unlikely that 
CD6 is a physiological ligand of ALCAM in neurons. I would suggest that the 
homologous ALCAM-ALCAM interaction is more likely to be important within the 
nervous system, acting between neurons themselves and between neurons and glia. 
Therefore, It is also worth considering several soluble forms of ALCAM have been 
described (Rosso et al., 2007, Ikeda and Quertermous, 2004) and could bind ALCAM 
in the nervous system in vivo. A schematic representing possible soluble binding 
partners for ALCAM is shown in Figure 3.18. Altogether my results suggest that 
ALCAM is loaded in a passive manner into axonal retrograde carriers, however I 
discuss the limitations of this experiment further in the Discussion, section 6.1.2.  
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Figure 3.15 Speed distribution of ALCAM and p75NTR transport does not 
change following exposure to CD6-Fc 
ALCAM (A) and p75NTR (B) speed distributions in ventral horn cultures were compared 
between control conditions (alone/Hu-Fc) or after exposure to CD6-Fc (with CD6-Fc). 
There is no significant change in the ALCAM or p75NTR transport speed distribution 
after cells were exposed to CD6-Fc (ALCAM: alone/Hu-Fc n = 109 carriers, 32 axons, 
9 cultures; CD6-Fc n = 214 carriers, 43 axons, 9 cultures; p75NTR: alone/Hu-Fc n = 157 
carriers, 21 axons, 3 cultures; for with CD6-Fc n = 111 carriers, 15 axons, 3 cultures). 
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Figure 3.16 CD6 does not significantly alter ALCAM transport frequency  
The frequency of ALCAM transport in ALCAM transport experiments with or without 
CD6-Fc is shown in (A) (n=6 ventral horn neuron cultures). The proportion of carriers 
that paused per ventral horn neuron culture is shown in (B), and is comparable 
between the alone/Human-Fc control condition or after addition of CD6-Fc.   
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Figure 3.17 ALCAM and p75 NTR transport frequency is unaltered 
A and B represent ALCAM488 and p75NTR555 co-transport experiments after 
treatment with CD6-Fc or Hu-Fc (n=3 ventral horn cultures). In (A) neither the 
frequency of p75NTR or ALCAM-positive carriers was significantly altered after 
incubation with CD6 (p = 0.9593 and 0.2647, respectively). Note that the frequency of 
p75NTR retrograde transport is approximately 3 times greater than ALCAM transport. 
The proportion of ALCAM and p75NTR carriers that pause after exposure to CD6-Fc or 
control Hu-Fc is shown in (B). ALCAM carriers have an increased tendency to pause 
after exposure to CD6 (p = 0.1779). Data was analysed using an unpaired t-test. 
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Figure 3.18 Schematic showing possible soluble proteins binding ALCAM 
ALCAM is known to bind soluble CD6 (either CD6-Fc or endogenous) via its most 
distal extracellular domains (V1). Theoretically, the most distal domains (V1 and V2) 
could also bind the soluble ALCAM fragment generated by alternative splicing, and the 
extracellular domain produced by ADAM17 cleavage in a trans-interaction. The 
cleavage product would also be able to bind in cis with membrane bound full length 
ALCAM, as shown on the right. 
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3.6 What is the fate of ALCAM-positive transport carriers? 
ALCAM is internalised and transported in neurons from the axonal plasma membrane 
towards the cell body. My experiments suggest that endosomes transporting ALCAM 
toward the cell body may contain signalling molecules such as the neurotrophin 
receptor p75NTR. Why is ALCAM transported to the cell body? ALCAM transport could 
have a role in neuronal homeostasis or the protein could merely be a passenger on the 
transport endosome. Alternatively, ALCAM could be transported back to the cell body 
to be targeted for degradation.  
To address whether ALCAM containing endosomes are part of the degradative 
pathway, I conducted co-transport experiments of ALCAM488 with LysoTracker, an 
established marker of acidic compartments (113a abstract 653 1994). I found that 
ALCAM predominantly travelled independently of acidic compartments labelled by 
LysoTracker in neurons (see Figure 3.19 and Figure 3.20). Only 12% of the ALCAM 
positive organelles, both moving and stationary, were also positive for LysoTracker. 
This is consistent with experiments that have shown Hc, neurotrophin receptors and 
other retrograde cargoes are not transported in acidic compartments (Bohnert and 
Schiavo, 2005, Lalli and Schiavo, 2002). Furthermore, I did not see colocalisation of 
ALCAM with LysoTracker in the cell body as shown in Figure 3.21. This suggests that 
ALCAM488 does not enter acidic compartments after direct internalisation in the 
soma, or after having reached the cell body following axonal transport. 
I also conducted immunofluorescence experiments on ventral horn cultures following 1-
2 h of internalisation with ALCAM488 to determine whether ALCAM was targeted to 
lysosomes labelled with the lysosome marker LAMP2 (Cuervo and Dice, 1996). As 
seen in Figure 3.22, there is little colocalisation between ALCAM488 puncta and 
LAMP2 vesicle staining. This suggests that ALCAM endosomes are not primarily 
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targeted for degradation. However, it was noted that ALCAM puncta did not 
appreciably accumulate in cells. There are alternative explanations for the limited 
colocalisation observed between degradative pathway markers and ALCAM. ALCAM 
could be degraded very rapidly, the conjugated-antibody could dissociate from the 
protein, or the Alexa-Fluor® dye could quench once it reaches acidic organelles such 
as lysosomes. Considering ALCAM-positive puncta were not abundant in cells, it could 
be difficult to visualise rapid transient events using immunofluorescence techniques 
that only represent a snapshot in time. Furthermore, the fusion of endosomes and 
sharing of their content in the cell soma could lead to the dilution of ALCAM 
concentration and decrease its signal intensity below threshold. Although, I did not 
distinguish between these alternatives I did characterise the ALCAM-containing 
endosome further.  
A type 1 glycoprotein, Coxsackievirus and adenovirus receptor (CAR) was one of the 
CAMs identified in the proteomic screen of the Hc-positive endosome (Table 1). CAR 
consists of two extracellular IgG domains, a transmembrane region and a cytoplasmic 
domain including a PDZ interaction motif. CAR has recently been shown to bind 
junctional adhesion molecule-like (JAML), and their interaction elicits cell-signalling 
events, important in the immune system for leukocyte migration and T-cell activation 
(Witherden et al., 2010, Verdino et al., 2010). As well as being identified in the Hc 
proteomic screen, CAR and the CAV-2 adenovirus have been shown to undergo 
axonal transport with Hc, neurotrophins and their receptors (Salinas et al., 2009). It 
was suggested that the CAV-2 virus utilises the innate transport of CAR and it was 
postulated that CAR transport could have a function in neurons. I conducted a co-
transport experiment of ALCAM and Hc with CAV-2 in an attempt to further 
characterise which proteins are present in the ALCAM containing transport 
compartment.  
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Co-transport of ALCAM with CAV-2 was observed suggesting that ALCAM is 
transported along the same route as CAR (Figure 3.23). It is interesting to consider the 
similarities between the cell adhesion molecules, ALCAM and CAR. In the immune 
system the interactions of ALCAM and CAR with their respective ligands, CD6 and 
JAML, are important in T-cell activation. Furthermore, both ALCAM and CAR are 
retrogradely transported with neurotrophin receptors and Hc. Interestingly, ALCAM has 
also been identified as a virus receptor (Bartee et al., 2006). The virus K5 modulator of 
immune recognition (MIR2) binds to ALCAM and targets it for degradation. The axonal 
transport of cell surface glycoproteins could be a general homeostatic mechanism, by 
which cell surface proteins enter a pleitropic compartment, also containing 
neurotrophin receptors, to travel back toward the cell body. In turn, viruses hijack the 
endogenous transport route of glycoproteins to travel to the cell body, where they have 
access to the nucleus and other organelles important for their replication. 
Another CAM previously shown to be associated with the Hc endosomal compartment 
in the proteomic screen was NCAM. To determine whether puncta containing both 
ALCAM and NCAM could be visualised, I conducted an internalisation experiment with 
ALCAM488 and p75NTR555 and then stained the intracellular domain of NCAM 
(NCAMic) using immunofluorescence. ALCAM is occasionally localised to puncta that 
contain NCAM in both neurites and soma, as shown in Figure 3.24 and Figure 3.25. In 
this experiment I cannot distinguish between NCAM present on the plasma membrane 
or present in internal vesicles. This may explain the limited colocalisation observed 
between NCAM and ALCAM488 because, following an acid wash, all the ALCAM 
visualised is internal. Another consideration is that the conjugated antibodies used to 
detect ALCAM and p75NTR induce clustering, and internalisation. NCAM internalisation 
will not have been stimulated under these conditions. Instead, in these conditions the 
majority of NCAM staining will represent the protein on the plasma membrane. Despite 
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these limitations, I did observe some colocalisation of NCAM with ALCAM in cell soma 
and neurites in these experiments. In similar experiments, I also detected limited 
colocalisation of internalised ALCAM488 vesicles with antibody staining for another Ig 
superfamily member L1 (data not shown). 
In conclusion, I found evidence that several cell adhesion molecules; CAR, ALCAM 
and NCAM are found in endosomes shared with neurotrophin receptors in ventral horn 
neurons. 
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Figure 3.19 ALCAM is not transported in LysoTracker-positive acidic 
compartment 
Consecutive frames from a co-transport experiment shows that both LysoTracker and 
ALCAM488 were transported along axons. However, they were predominantly not 
transported in the same compartment. The merged image shows that the carriers 
indicated by the white and black arrowheads are distinct carriers moving in the same 
direction back to the cell body (black arrow). Scale bar, 10 μm. 
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Figure 3.20 ALCAM488 and LysoTracker transport kymographs 
A movie taken during a ALCAM488 and LysoTracker co-transport experiment is 
represented as two kymographs. The horizontal arrow indicates the direction of 
transport toward the cell body. The kymographs are generated by drawing a line along 
the axon and aligning the single line scans vertically over time (indicated by the vertical 
arrow). For a full explanation see Material and Methods, section 2.2.5.4 and Figure 2.6. 
Two ALCAM488 carriers are seen in the upper kymograph, their entry into the frame 
indicated by asterisks. There are many LysoTracker-positive transport compartments 
moving diagonally across the kymograph, however they do not colocalise with 
ALCAM488-positive vesicles. 
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Figure 3.21 ALCAM does not colocalise with LysoTracker-positive 
organelles in the cell body 
During transport experiments ALCAM488 and LysoTracker were not found in the 
same endosomal structures in the cell body. Scale bar, 10 μm 
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Figure 3.22 ALCAM does not enter LAMP2-positive degradative 
compartments in ventral horn neuron cell bodies 
ALCAM colocalises with p75NTR in vesicles in the cell body however, there is little or no 
colocalisation of ALCAM with LAMP2. The boxed area is magnified in the lower panel 
where puncta containing both ALCAM and p75NTR but no LAMP2 are indicated by white 
arrowheads. The black arrowhead indicates a LAMP2 positive endosome that also 
contains p75NTR. Scale bars, 10 μm. 
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Figure 3.23 CAV-2 partially co-transports with ALCAM 
Consecutive frames from a transport experiment after exposure to ALCAM488, Hc-
555 and CAV-2 cy3, shows vesicles moving towards the cell body (black arrow). CAV-
2 positive endosomes were seen to colocalise with ALCAM and Hc, indicated by white 
arrowheads. The black arrowheads indicate a carrier positive for CAV-2 and Hc, but 
not ALCAM. Scale bar, 10 μm. 
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Figure 3.24 ALCAM shows limited colocalisation with NCAMic 
Ventral horn neurons allowed to internalise ALCAM488 and p75NTR555 were acid 
washed, and localisation of NCAM (NCAMIc) was assessed by immunofluorescence. 
Structures that contain ALCAM, NCAM and p75NTR can be found in cell bodies after 
internalisation and immunofluorescence staining (indicated by the large arrowhead). 
There are also organelles that contain p75NTR and NCAM but no ALCAM, an example 
is indicated by the black arrowhead. However, the predominant colocalisation is 
between ALCAM and p75NTR (small white arrowheads).  
 
Chapter 3. Results 
 132 
 
 
 
Figure 3.25 NCAM and ALCAM show partial colocalisation in neurites 
The merged image shows neurites after ventral horn neuron internalisation of 
ALCAM488 and p75NTR555 and staining for NCAM intracellular domain (NCAMic). 
The boxed region is magnified in the other panels where some, but not extensive, 
colocalisation between p75NTR555 and ALCAM488 puncta with NCAMic is seen in 
neurites. The large white arrowhead indicates a compartment with all three molecules, 
although it is noted that they do not all have the same structure. An NCAMic positive 
cluster (black-filled arrowhead) does not associate with ALCAM or p75NTR. The small 
white arrowhead indicates ALCAM488 and p75NTR colocalisation without NCAMic. 
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3.7 Summary 
ALCAM was identified as a protein associated with the Hc-containing endosome by 
mass-spectrometry. I have verified the association of ALCAM with the Hc-positive 
compartment in ventral horn neurons, biochemically and by imaging co-transport 
experiments. In living neurons ALCAM undergoes constitutive axonal transport, and is 
often transported in the presence of the neurotrophin receptor p75NTR. I found that 
exposure to the ALCAM ligand CD6 did not have a significant effect on the speed of 
ALCAM transport. Although I did not detect a significant change in ALCAM transport 
frequency, there was a consistent tendency for increased ALCAM carrier frequency 
after exposure to CD6. I found that ALCAM-containing organelles also contained other 
CAMs e.g. NCAM and CAR, perhaps suggesting CAMs travel via a general retrograde 
transport route. The function of ALCAM transport was not resolved in these 
experiments, but I did not find evidence to suggest that ALCAM transported to the cell 
body is primarily targeted for degradation. 
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Chapter 4. Characterisation of ALCAM in the 
nervous system 
From live-cell imaging and biochemical studies we confirmed the association of 
ALCAM with Hc and found that ALCAM was retrogradely transported in mouse primary 
ventral horn neurons. In western blot analysis of the magnetically purified Hc 
compartment I found two distinct forms of ALCAM were expressed in ventral horn 
cultures and interestingly, the lower form was enriched in transport endosomes. To the 
best of my knowledge, this is the first demonstration that ALCAM can exist as two 
distinct species in the ventral horn. I aimed to further characterise ALCAM expression 
in the mouse nervous system, and attempted to determine the molecular differences 
between the two species.  
4.1 ALCAM is differentially expressed in the mouse nervous 
system 
I compared the expression of ALCAM in different tissue lysates isolated from whole 
CNS tissue, primary cell cultures and cell lines.  
Initially I compared whole mouse brain lysate, purified brain synaptosomes, lysate from 
ventral horn neuron cultures that are commonly used in Hc internalisation and transport 
experiments, as well as a spinal cord astrocyte culture. I analysed ALCAM protein 
expression by western blot, probing the membrane with the same anti-ALCAM 
antibody used for the transport experiments in vitro (Figure 4.1). We found that only in 
mouse ventral horn neuron culture were two distinct forms of ALCAM expressed. In 
mouse whole brain lysate and purified synaptosomes a broad band with molecular 
weights varying between 90 and 100 kDa was recognised, which could consist of 
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several different ALCAM forms. Interestingly, purified spinal cord astrocytes expressed 
one form of ALCAM that migrated at the same molecular weight as the higher of the 
two ALCAM species observed in ventral horn neuron culture. We hypothesised that the 
existence of two ALCAM forms in these motor neuron enriched cultures is because 
they are composed of two distinct cell types, glia and neurons. Thus the high migrating 
form could be expressed on glial cells while the lower molecular weight species could 
be expressed on neurons. Consistent with this possibility, I found that the lower 
molecular weight ALCAM band was enriched in the Hc-containing axonal transport 
organelle isolated from primary ventral horn neurons (Chapter 3, Figure 3.1). Since the 
Hc-conjugated MIONs are predominantly internalised in neurons, the form of ALCAM 
associated with the Hc compartment should be that expressed on neural cells.  
Another observation consistent with, but by no means proof of, our hypothesis is that 
the relative expression of the two ALCAM species varies in different primary cultures 
(Figure 4.2). Interestingly, this difference in intensity seems to correlate with the 
relative purity of neurons to glial cells in culture. The U251MG astrocytoma cell line 
only expressed the higher molecular weight form of ALCAM similarly to what was 
observed in primary astrocytes. As shown in Figure 4.2B, I also investigated ALCAM 
expression in the Pheochromocytoma (PC12) neural cell line and the MTLN3 rat 
mammary adenocarcinoma cell line by western blot. The MTLN3 cell line expressed a 
much lower molecular weight form, consistent with the predicted molecular weight of 
ALCAM, and could represent protein that has not undergone post-translational 
modification. In the PC12 neural cell line, the anti-ALCAM antibody used does not 
recognise a specific band but many proteins in the lysate. In summary, I found that 
ALCAM is expressed differently in different cell types and this may suggest that the 
protein undergoes differential post-translational modification according to cell type. 
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As outlined in the Introduction, Figure 1.6, human ALCAM has two reported isoforms, 
Q13740-1 and Q1370-2. Q1370-2 is attributed to differential splicing resulting in the 
loss of 13 amino acids in the juxta-membrane region. The equivalent region is 
conserved in the mouse sequence, which would suggest that the same isoform exists 
in mice. However, considering only 13 amino acids have been removed, this differential 
splicing event could not account for the 10 kDa molecular weight difference observed 
in ventral horn ALCAM species. Splicing is also thought to result in a soluble fragment 
of ALCAM comprising of the most extracellular variable Ig-domain only (Ikeda and 
Quertermous, 2004). Similarly this splicing event cannot account for the ALCAM forms 
expressed in ventral horn culture lysates.  
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Figure 4.1 Distinct species of ALCAM are expressed in different tissues of 
the mouse nervous system 
Cell culture and tissue lysate samples were separated by SDS-PAGE, transferred to 
PVDF membranes, and probed with the anti-ALCAM antibody. Mouse brain and 
synaptosome fraction purified from rat brain appear to have a similar ALCAM content. 
ALCAM appears as a broad band at around 90-100 kDa. ALCAM in ventral horn 
neuron culture is expressed in two distinct forms (Ventral horn cells), one migrating at 
around 100 kDa and a second migrating around 90 kDa. Primary spinal cord astrocytes 
express only the higher molecular weight ALCAM species. 
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Figure 4.2 ALCAM expression varies in different cultures and cell lines 
Primary cell cultures and cell lines extracts were separated by SDS-PAGE and 
analysed by western blot. In (A) the relative expression of the two ALCAM forms varies 
between ventral horn neuron primary cultures isolated from different litters as can be 
seen when comparing the relative intensities of the bands in experiment I and II. The 
U251MG astrocytoma cell line expressed the higher molecular weight form of ALCAM 
only. The expression of ALCAM in the MTLN3 and PC12 cell lines is analysed by 
western blot in (B). MTLN3 cells express a low molecular weight form of ALCAM, while 
the anti-ALCAM antibody does not recognise a specific band in PC12 cells. No 
explanation for this behaviour of the anti-ALCAM antibody is currently available. 
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4.2 ALCAM is glycosylated in ventral horn neuron cultures 
Since two novel ALCAM forms were expressed in ventral horn cultures we wanted to 
characterise what could account for this difference. ALCAM can be N-glycosylated 
(Sekine-Aizawa et al., 1998) and has been identified as an O-glycosylated membrane 
protein expressed during neuronal differentiation (Sato et al., 2002). Therefore, we 
went on to examine if differential glycosylation could account for the two species 
observed.  
We investigated this by exposing ventral horn neuron culture lysates to different 
deglycosylation enzymes (Tarentino et al., 1985, Lieberoth et al., 2009). We treated the 
samples either with PNGase-F that removes all N-type glycan modifications, 
neuraminidase (recombinant from Arthrobacter ureafaciens) to remove sialic acid 
chains, or with O-glycosidase (recombinant from Streptococcus pneumonia) to remove 
O-glycan chains. The latter enzyme required co-incubation with neuraminidase to 
remove sialic acids before the O-glycosidase could remove the O-glycans. Following 
the various deglycosylating treatments, the ventral horn neuron culture samples were 
analysed by western blot as shown in Figure 4.3. 
Interestingly, ALCAM in ventral horn cultures continued to migrate as two distinct 
bands after all combinations of enzyme treatment. My findings suggest that ALCAM in 
ventral horn cultures is predominantly glycosylated on N-type glycan chains and the 
small shifts observed after neuraminidase and O-glycosidase treatments suggest that 
there are also minor sialic acid and O-type glycan chain modifications. Since ALCAM 
remained as two distinct species following all treatments, it demonstrated that 
differential glycosylation does not account for the two ventral horn ALCAM species.  
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Figure 4.3 Ventral horn ALCAM species are not the result of differential 
glycosylation 
Western blot analysis of ALCAM in ventral horn neuron culture extracts which have 
undergone deglycosylation treatments. In control conditions (no treatment) two ALCAM 
forms are observed. Upon treatment with PNGase-F there is a large shift in molecular 
weight due to the removal of N-type glycan chains, but the two bands remain distinct. 
Much smaller shifts are observed on treatment with Neuraminidase alone or in 
combination with O-glycosidase, removing sialic acid and O-type glycans respectively. 
When ventral horn lysate was treated with all three enzymes, ALCAM species 
continued to migrate as distinct bands illustrating that the two ALCAM forms are not 
due to differential glycosylation. 
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4.3 Ventral horn ALCAM species are not products of cleavage 
ALCAM can undergo ectodomain shedding and membrane cleavage by the 
metalloprotease ADAM17 (Bech-Serra et al., 2006, Rosso et al., 2007). ADAM17 
cleavage occurs in the juxtamembrane region (see Introduction, Figure 1.6). If this 
cleavage occurred in ventral horn neuron cultures it would produce a large soluble 
ectodomain fragment, corresponding to all 5 extracellular domains, and a short integral 
membrane fragment comprising of the transmembrane region and the cytoplasmic 
domain. Since the polyclonal antibody used in my previous experiments was raised to 
the extracellular domain of ALCAM, it would recognise the soluble ectodomain as well 
as the full-length protein.  
To determine whether a cleavage event could account for the 2 forms of ALCAM seen 
in ventral horn cultures, I performed a membrane stripping experiment to remove 
proteins that did not directly interact with the membrane and separated the extracts into 
membrane and supernatant fractions. Cell samples were mixed with a high KCl salt 
wash or with stripping buffer, then analysed by SDS-PAGE and western blot. A typical 
western blot is shown in Figure 4.4. Both after high salt wash, and more stringent 
carbonate stripping, the two forms of ALCAM remained associated with the membrane 
pellet of ventral horn cultures. No evidence of ALCAM was found in the supernatant 
fraction in any condition. This suggests that both ventral horn ALCAM forms are 
integral membrane proteins, and ectodomain shedding does not account for the lower 
molecular weight form. 
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Figure 4.4 Both ventral horn ALCAM species are integral membrane 
proteins 
Ventral horn culture lysate was separated into a membrane fraction (P) or supernatant 
(S) by centrifugation, either alone or after a 1 M KCl salt wash or 0.2 M Na2CO3 
stripping step (Herreros et al., 2000). Samples were analysed by SDS-PAGE and 
western blot. Both ALCAM species associate to the membrane pellet (P) in control 
membranes (Input) and after salt wash and stripping treatments. The Ponceau (lower 
panel) shows that proteins associated with the membrane fraction in non--treated 
conditions (Input) move to the supernatant after high salt wash and carbonate 
stripping. 
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4.4 Production of an antibody to recognise the cytoplasmic 
domain of ALCAM 
To further characterise the ventral horn ALCAM forms, I aimed to develop two new 
antibodies, one designed to recognise the extracellular domain and another the 
cytoplasmic domain. I hoped to investigate whether the two antibodies differentially 
recognised the two ventral horn ALCAM forms. We also hoped to use these antibodies 
to immunoprecipitate both ALCAM forms expressed in ventral horn neuron cultures, 
and then use mass spectrometry to identify the region of difference in the protein 
structure. 
I designed pET vectors that contained either the whole extracellular domain of ALCAM 
or its cytoplasmic domain fused to a 6 Histidine sequence (His6-tag) on their C-
terminus (for full explanation see Materials and Methods 2.2.1.1 and Figure 2.2). The 
ALCAM-His6 constructs were expressed in bacteria, and His-tagged proteins were 
purified on a nickel-resin column by affinity chromatography.  
The relative purity of the ALCAM extracellular domain (ALCAM-Ec) and cytoplasmic 
domain (ALCAM-C) proteins can be visualised by Coomassie Blue stain (Figure 4.5). 
The ALCAM-Ec fragment was expressed at low yield and several contaminating bands 
are present in the eluate (Figure 4.5A). Furthermore, the western blot reveals that the 
majority of the His6-tagged protein in the eluate has a molecular weight that is too small 
to comprise of the full extracellular domain. Considering there are already several 
commercial antibodies to the extracellular domain and in view of these problems with 
protein expression and purification, I decided not to pursue the production of an 
antibody directed to the extracellular domain further.  
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In SDS-PAGE, ALCAM-C migrated at 12kDa, a higher molecular weight than 3976 Da 
predicted by ApE (Universal) (Figure 4.5). However, the western blot shows that the 
majority of the purified protein is His6-tagged. Since protein migration depends on 
protein charge and SDS binding, it was reasonable to assume that the predominant 
protein seen in the coomassie gel was the tagged cytoplasmic domain of ALCAM. The 
P3 fraction contained the fewest contaminating bands and so this fraction was used for 
rabbit immunisation. We sent 1.7 mg of purified ALCAM-C in PBS to BioGenes GmbH 
(Köpenicker Straße 325, D-12555 Berlin, Germany) who then immunised 2 rabbits, 
4682 and 4683 with the purified protein fragment. The rabbits went through a sequence 
of immunisation boosts and bleeds and their serum was tested. BioGenes conducted 
an Elisa titre test on antigen-coated plates to test sera binding to ALCAM-C. The serum 
titer for rabbit 4682 was 1:100,000, while the titer for rabbit 4683 was 1:25,000.  
I tested the serum of rabbits 4682 and 4683 in western blot and the results are shown 
in Figure 4.6. Both sera 4682 and 4683 recognised the purified ALCAM-C protein and 
did not detect an unrelated His6-tagged protein (KNA). Sera 4682 and 4683 detection 
of ALCAM-C was competed by pre-absorption of the sera with soluble ALCAM-C 
protein. These results suggested both sera specifically recognised the ALCAM 
cytoplasmic domain antigen and not the His6-tag. When tested on ventral horn culture 
lysates, the serum from rabbit 4682 was more reactive than serum 4683. Furthermore 
some bands recognised in ventral horn lysate were at an appropriate molecular weight 
to be endogenous ALCAM. Some putative ALCAM bands were partially or completely 
competed by prior incubation with ALCAM-C, suggesting that this serum could 
recognise endogenous ALCAM expressed in ventral horn cultures (Figure 4.6; 
highlighted by the arrow and star). Considering the much lower titer of 4683 and its 
weaker immunoreactivity with ventral horn culture extracts I decided to pursue the 
immunisation regime with rabbit 4682 only. We also added a purification step whereby 
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the serum was passed over an ALCAM-C antigen column to specifically enrich for the 
antibodies directed against the ALCAM cytoplasmic domain. Purified 4682 antibody 
(4682 IgG) was pooled, aliquoted and frozen in 30% glycerol at -20°C. 
The purified 4682 antibody was tested on ventral horn neuron culture lysates isolated 
from wild type, ALCAM+/- and ALCAM-/- embryos to see which of the recognised bands 
would be lost in ALCAM-/- lysates (Figure 4.7). I found that 4682 IgG recognised a band 
at the molecular weight of ALCAM that was lost in cells isolated from ALCAM-/- ventral 
horn neuron cultures. This result demonstrated that antibody 4682 recognised 
endogenous ALCAM. Interestingly, the western blot suggests that two forms of ALCAM 
may be recognised, similarly to the pattern revealed by the goat anti-ALCAM antibody. 
However, the 4682 IgG immunoreactive bands were not well resolved. This suggests 
that the ALCAM species present in ventral horn cultures are recognised by the 4682 
antibody and therefore that they both contain the cytoplasmic domain. This is 
consistent with the membrane stripping experiment where both species were shown to 
be integral membrane proteins. An interesting outcome of this western blot analysis is 
that there appears to be a gene dosage effect in heterozygote animals. If the ALCAM 
signal is normalised to the total loaded (Tubulin) it appears that less ALCAM is present 
in ALCAM+/- when compared to wild type. 
I also tested whether rabbit 4682 IgG recognised overexpressed ALCAM in PC12 cells 
using both western blot and immunofluorescence analysis as shown in Figure 4.8 and 
Figure 4.9. ALCAM-D is full length ALCAM tagged with the fluorescent protein Dendra 
on its C-terminus and is described in Material and Methods, section 2.2.1 and Chapter 
5, section 5.1. As expected, 4682 IgG recognised overexpressed ALCAM in western 
blot (Figure 4.8), where it detected bands overlapping with those recognised by the 
antibody to the Dendra tag. By immunofluorescence, antibody 4682 recognised 
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ALCAM-D in the overexpressing cell, which colocalised with the Dendra signal (Figure 
4.9). Antibody 4682 can therefore recognise overexpressed ALCAM in PC12 cells. 
4682 IgG also recognised additional bands around 100 kDa that could represent 
endogenous ALCAM in PC12 cells (Figure 4.8), but their specificity has not been 
confirmed. Furthermore, in immunofluorescence (Figure 4.9) I only saw a minimal 
membrane localised stain in non-transfected cells, suggesting that either ALCAM 
expressed in PC12 cells is not recognised by the 4682 antibody or that ALCAM is 
expressed at very low levels in this cell line. Considering ALCAM has not been 
reported to display nuclear localisation, it is likely that the 4682 nuclear staining 
observed in Figure 4.9 is non-specific.  
In these experiments, a potential accumulation of 4682 IgG ALCAM signal was 
detected in neurite tips of differentiating PC12 cells. Kidins220, a scaffold protein for 
neurotrophin receptors, has been shown to localise to neurite tips in NGF-differentiated 
PC12 cells (Bracale et al., 2007). I therefore tested whether ALCAM colocalised with 
Kidins220 at neurite tips. As can be seen in the merged image in Figure 4.9, there is 
little evidence for the colocalisation of ALCAM with Kidins220 on the same structures, 
though they can be present in the same neurite. Since the accumulation of 4682 IgG in 
neurite tips was not found in all differentiated cells (both transfected and 
untransfected), it could suggest that the accumulation of ALCAM at tips is a transient 
event related to a stage of differentiation (distinct from that when Kidins220 
accumulates). However, the difference observed could also be unrelated to 
differentiation and simply due heterogeneity in protein content and distribution between 
PC12 cells. My experiments did not distinguish between these hypotheses. 
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Figure 4.5 ALCAM His-tagged construct purification 
The extracellular domain protein fragment (ALCAM-Ec) was eluted into 2 samples and 
the cytoplasmic domain (ALCAM-C) was collected as 3 samples. Two μg of each 
sample was run on two 15% Bis-Acrylamide SDS-PAGE in parallel, one gel was 
stained with Coomassie Blue (A), and the other was transferred to PVDF and western 
blotted with rabbit anti-His6 (B). The expression and purification of ALCAM-Ec was not 
efficient, there is little protein in the eluate and it is contaminated with several additional 
bands (A). Furthermore, the molecular weight of this His-tagged fragment is very 
different from the expected molecular weight (17 kDa vs. 56 kDa using ApE 
(Universal)) (B). In contrast the ALCAM-C purification worked well, with significant yield 
of recombinant protein present in the eluate, as shown in the Coomassie Blue stain. 
Crucially, the majority of protein produced is His6-tagged (B).  
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Figure 4.6 Sera 4682 and 4683 recognise the purified ALCAM-C protein but 
serum 4682 also clearly recognises endogenous protein in ventral horn 
neuron lysates 
Purified ALCAM-C (AL-C), KNA (an unrelated His6-tagged protein) and ventral horn 
neuron culture lysate (VH) were analysed by western blot with serum 4682 or 4683. 
Both sera recognise purified ALCAM-C and not KNA. Following pre-absorption of the 
sera with purified ALCAM-C (cross-abs), the ability of both 4682 and 4683 to recognise 
ALCAM-C is lost. Serum 4682 detects several bands in ventral horn lysate. One band 
migrates at an appropriate molecular weight to be ALCAM and is competed by pre-
absorption with ALCAM-C (arrow). Other bands present in ventral horn neuron culture 
are partially competed by preabsorption indicated by (*). Serum 4683 is much less 
immunoreactive with ventral horn proteins. Note that the bands on the top left of the 
4683 western blot are actually ladder proteins.  
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Figure 4.7 4682 IgG recognises a specific ALCAM band that is lost in 
knockout ventral horn neuron cultures 
Lysate from ventral horn neuron cultures isolated from ALCAM-/- mice were analysed 
by western blot. 4682 IgG recognises bands that are not present in ventral horn neuron 
cultures isolated from ALCAM-/- mice around 90-80 kDa. The two bands indicated by 
stars (*) are not well resolved. When compared to the commercial goat antibody 
against ALCAM (gt ALCAM) it can be seen that the interaction of 4682 IgG is weaker. 
Comparison of the 4682 IgG signal relative to the Tubulin loading control suggests 
there is a gene dosage effect and less ALCAM is present in ALCAM+/- cultures. 
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Figure 4.8 4682 IgG recognised ALCAM-D expressed in PC12 cells 
4682 IgG recognised a band at 130 kDa corresponding to ALCAM-D in the PC12 
lysate (I) and in the immunoprecipitate (IP) with the anti-Dendra (D) antibody. 
However it does not recognise any bands in the control rabbit IgG (IgG) 
immunoprecipitate. After immunoprecipitation ALCAM-D has been partially depleted 
from the exhausted supernatant (XS) in the anti-Dendra immunoprecipitated sample, 
but not the control IgG sample. An overlapping 130 KDa band is recognised by the 
anti-Dendra antibody using the TrueblotTM system, as seen in the lower panel.  
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Figure 4.9 Immunofluorescence showing colocalisation of ALCAM-D and 
4682 IgG signal 
PC12 cells transfected with fluorescently tagged ALCAM (ALCAM-D) and differentiated 
with NGF were stained with 4682 IgG and an antibody directed towards Kidins220 a 
membrane scaffold for neurotrophin receptors. Merge 1 and merge 2 are at different 
depths in the cell (Z planes). Merge 1 is near the substrate surface, while merge 2 is a 
slice through the cell body. The yellow signal in the merged image shows that ALCAM-
D (green) expressed in PC12 cells is recognised by 4682 IgG (red). This illustrates that 
the cytoplasmic domain of overexpressed ALCAM-D is recognised by 4682 IgG. The 
boxed region is magnified in the lower panel. Dendra and 4682 IgG are shown to 
colocalise in punctate structures in the neurite (white arrowheads). Kidins220 also 
localises to neurite tips of NGF differentiated PC12 cells but it is not present in the 
ALCAM-positive puncta. Kidins220 is also present in the non-transfected neurite (black 
arrowhead). The 4682 IgG nuclear stain (merge 2) is unspecific and of equal intensity 
in transfected and untransfected cells. Scale bar, 20 μm  
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4.5 Immunoprecipitation of ALCAM using antibody 4682 
The 4682 IgG was next tested in immunoprecipitation experiments. However, it 
became apparent that there were problems in using this 4682 antibody to 
immunoprecipitate ALCAM. Unfortunately, 4682 IgG alone migrated at the molecular 
weight of endogenous ALCAM as shown in Figure 4.10. Given the anomalous 
migration of this band in SDS-PAGE it was hypothesised that it was due to a 
particularly strong disulphide bond interaction between the two antibody heavy chains 
that did not dissociate at room temperature in Laemmli sample buffer. Boiling the IP 
samples and therefore forcing the reduction of these disulphide bonds, shifted the 
antibody bands so that they migrated at around 50 kDa. The disadvantage of this 
procedure was that boiling samples decreased the yield of ALCAM resolved by 
western blot.  
An immunoprecipitation experiment with U251MG astrocytoma cell line carried out 
under the modified conditions i.e. boiling samples for 5 minutes before SDS-PAGE 
separation, is shown in Figure 4.11. After boiling, the antibody bands no longer 
migrated between 100 and 75 KDa, but shifted to around 50 kDa (Figure 4.11, lower 
panel). Unfortunately, the western blot also shows that immunoprecipitation of ALCAM 
using antibody 4682 is very inefficient (compare input and 4682 immunoprecipitate 
signals in Figure 4.11). Considering the amount of ALCAM protein expressed in 
primary cultures, the low efficiency of immunoprecipitation and the difficultly of getting 
large amounts of primary culture extracts, we did not proceed with our initial plan of 
sending immunoprecipitated samples for a mass-spectrometry analysis. 
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Figure 4.10 Immunoprecipitation of ALCAM using the 4682 antibody 
The western blot shows an immunoprecipitation experiment with PC12 cells using the 
4682 antibody (4682 IgG) and purified rabbit immunoglobulin (Rb IgG) as a control. As 
shown previously goat anti-ALCAM (gt ALCAM) recognises many proteins in PC12 
cell lysate input (I) and in the exhausted supernatant (XS) after the 
immunoprecipitation. Prior to immunoprecipitation, lysates were precleared with beads 
and found limited evidence of protein that bound to the beads alone (Pc). A specific 
band associated with the 4682 IgG immunoprecipitation (IP) migrated at the level of 
endogenous ALCAM, but similar bands were recognised in the prebound 4682 IgG 
beads alone (Bd+4682 IgG).  
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Figure 4.11 Immunoprecipitation of ALCAM from U251MG astrocytoma 
cell line 
ALCAM is expressed in the U251MG total lysate (Input,I) detected with the goat anti-
ALCAM antibody (gt ALCAM). ALCAM is specifically immunoprecipitated (IP) with 
4682 IgG and not with the control rabbit IgG (Rb IgG). Samples were boiled so that the 
antibody bands migrated around 50 KDa, as seen in the Ponceau stained membrane in 
IP and antibody-conjugated beads (Bd) samples. No ALCAM can be seen in the 
supernatant (S) after either the IgG bead or 4682 IgG bead incubation. There is no 
explanation for this anomalous result.  
 
Experiment conducted by Claire Thomas  
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4.6 Summary 
ALCAM expression in the mouse nervous system was investigated in order to 
characterise the novel forms of ALCAM revealed in the magnetically purified Hc-
endosome. The results showed that ALCAM is differentially expressed in different 
areas of the mouse nervous system, primary cells and cell lines. ALCAM appears as a 
broad band in mouse brain and purified synaptosomes in contrast to ventral horn 
neuron cultures that express ALCAM in two distinct forms. We hypothesise that the 
higher molecular weight species is expressed on glial cells and the lower molecular 
weight species is expressed on neurons. Primary astrocyte cultures and the 
astrocytoma cell line only express the higher migrating form consistent with our 
hypothesis. The lower migrating putative neural ALCAM species is specifically enriched 
in the Hc compartment that should be specifically present in neurons. I hypothesise 
that ALCAM is recognised as a broad band in brain lysates and synaptosomes 
because both are composed of multiple neuron and glia subtypes that may express 
different forms of ALCAM. In contrast, ventral horn neuron cultures produce a unique 
co-culture system, enriched for motor neurons and containing a restricted number of 
glia types, in which distinct forms of ALCAM can be resolved.  
I attempted to characterise what could account for the difference in molecular weight 
between the two ALCAM species. I found that both ALCAM bands are glycosylated but 
differences in glycosylation did not account for the difference in their molecular weight. 
Furthermore, both ALCAM forms are integral membrane proteins, and both are 
recognised by antibody 4682 IgG directed toward the ALCAM cytoplasmic domain.  
I produced and characterised a novel antibody, 4682 IgG, directed toward the mouse 
ALCAM cytoplasmic domain that specifically recognised ALCAM in primary cultures. It 
also recognised overexpressed ALCAM in PC12 cells by immunofluorescence and 
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western blot. Unfortunately, we found that the antibody was not efficient at 
immunoprecipitating ALCAM from primary ventral horn neuron or PC12 culture 
extracts. Therefore, I did not pursue further analysis of the two forms by mass-
spectrometry, which may have provided useful information on the difference between 
the two ALCAM species. This strategy could be pursued further by optimising the 
immunoprecipitation protocol with other anti-ALCAM antibodies. 
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Chapter 5. The role of ALCAM in neurite outgrowth 
and neurotrophin signalling 
ALCAM is transported in neurotrophin-associated endosomes and it has been 
proposed that this compartment has a signalling role in neurons (reviewed in Cosker et 
al., 2008, and Zweifel et al., 2005)). It is therefore possible that ALCAM may contribute 
to neurotrophin signalling during the development and maintenance of the nervous 
system. As described in the Introduction, section 1.5, the role of ALCAM in the nervous 
system has been examined in several animal models. In chick and fish, interfering with 
ALCAM-dependent adhesion using antibodies directed towards the extracellular 
domain, can disrupt neuron outgrowth, fasciculation and neuromuscular junction 
formation (Fournier-Thibault et al., 1999, Ott et al., 2001, Avci et al., 2004). 
Furthermore, zebrafish show aberrant retinal ganglion cell (RGC) differentiation and 
axon outgrowth following morpholino knockdown of Neurolin A and B, the zebrafish 
orthologs of ALCAM (Diekmann and Stuermer, 2009).  However, ALCAM-/- mice have a 
limited neurological phenotype, suggesting that other proteins can functionally 
compensate for the loss of ALCAM during development in higher vertebrates (Weiner 
et al., 2004). In this chapter, I investigated the role of ALCAM in neurite outgrowth, and 
whether it cooperated with neurotrophin signalling. 
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5.1 ALCAM overexpression potentiates neurite outgrowth in 
response to NGF 
Full-length ALCAM was cloned and tagged with the fluorescent protein Dendra to its 
cytoplasmic domain (ALCAM-D) (for full explanation see Materials and Methods, 
section 2.2.1 and Figure 2.1). Dendra is a monomeric fluorescent protein derived from 
Dendronepththya sp. that can undergo photoconversion from green to red fluorescent 
states (Gurskaya et al., 2006). It is not only capable of stable photoconversion with UV-
violet light, similar to earlier generation photoactivatable fluorescent proteins, but also 
by visible blue light which is less phototoxic to cells (Gurskaya et al., 2006). ALCAM-D 
was transfected into PC12 cells that could be differentiated in the presence of NGF. 
Examples of Dendra or ALCAM-D transfected cells are shown in Figure 5.1 and Figure 
5.2 respectively. I found ALCAM-D was expressed on the surface of PC12 cells in 
culture where it was recognised by an antibody directed towards the ALCAM 
extracellular domain (Figure 5.2). Interestingly, ALCAM was found in clusters on the 
plasma membrane and in internal puncta that were not stained by the antibody to the 
extracellular domain in non-permeabilising conditions. ALCAM-D photoconverted by a 
405 nm laser was used to follow the protein in transfected cells. This permitted 
visualisation of the protein under conditions that did not require antibody binding and 
therefore, clustering of ALCAM on the plasma membrane. I found that the majority of 
ALCAM in PC12 cells was slowly diffusing, and puncta did not undergo vectorial long-
range transport, as shown in Figure 5.3 and Figure 5.4. 
A study that analysed PC12 cell gene expression profiles after 12 h treatment with the 
differentiation stimuli, NGF or dbcAMP, found that ALCAM transcript levels increased 
between 2 and 3 fold in both conditions (Ng et al., 2009). Further evidence that 
regulation of ALCAM expression is coupled to neuronal differentiation came from a 
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study that identified ALCAM as a protein whose glycosylation was induced upon 
Neuro2A cell differentiation (Sato et al., 2002). Since ALCAM expression is modulated 
upon differentiation and that it is involved in axonal outgrowth during development in 
chick and fish, I wanted to investigate whether ALCAM played a role in neurotrophin-
induced differentiation in PC12 cells.  
The percentage of cells that displayed neurite outgrowth at both 1 and 3 days after 
transfection with ALCAM-D or Dendra and treatment with NGF was calculated (Figure 
5.5). Neurite outgrowth was quantified by counting the number of cells whose longest 
neurite was at least two times or more the length of the cell body at its widest point. I 
found that ALCAM-D expression significantly increased the percentage of PC12 cells 
that displayed neurite outgrowth. This suggested that ALCAM overexpression in PC12 
cells cooperated with NGF-signalling during differentiation.  
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Figure 5.1 NGF differentiated PC12 cells transfected with Dendra 
Immunofluorescence showing differentiated PC12 cells transfected with Dendra. Cells 
transfected and kept in differentiation medium with 100 ng/ml NGF have clearly visible 
neurite extensions 3 days after transfection.  The boxed region is magnified in the 
upper right panel (mag) and Dendra can be seen present throughout the cell 
cytoplasm. An anti-ALCAM antibody (ALCAM) shows weak interaction with both the 
untransfected and transfected PC12 plasma membrane and could reflect low levels of 
endogenous ALCAM. Scale bar, 10 μm. 
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Figure 5.2 NGF differentiated PC12 cells transfected with ALCAM-D 
Immunofluorescence showing PC12 cells transfected with ALCAM-D and differentiated 
in the presence of 100 ng/ml NGF for 3 days. ALCAM-D is predominantly seen on the 
plasma membrane (Dendra). In non-permeabilising conditions ALCAM-D on the 
surface of the cell is recognised by the anti-ALCAM antibody (ALCAM). The boxed 
area is enlarged in the upper right panel (mag) and shows that ALCAM-D is present on 
internal vesicular structures (arrowheads), as well as on the plasma membrane. 
Staining is similar to that observed with 4682 IgG in Chapter 4, Figure 4.8. Scale bar, 
10 μm.  
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Figure 5.3 Photoactivation of ALCAM-D 
ALCAM-D could be photoconverted from green to red channel by irradiating the boxed 
region with 10% 405 nm laser power for 5 iterations. Scale bar,10 μm. 
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Figure 5.4 ALCAM-D is predominantly static on the surface of PC12 cells 
Frames from a live-cell imaging experiment of PC12 cells transfected with ALCAM-D. 
Over two minutes no movement of ALCAM-D along the surface of a differentiated 
PC12 cell neurite could be detected. Scale bar, 10 μm. 
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Figure 5.5 ALCAM-D significantly increased the percentage of PC12 cells 
that displayed neurite outgrowth 
PC12 cells were differentiated with NGF after transfection with Dendra or ALCAM-D for 
1 or 3 days post transfection (DPT). The percentage of cells whose longest neurite was 
at least two times the length of the soma was calculated (% of cells with neurite 
outgrowth). ALCAM-D significantly potentiated the percentage of cells that displayed 
neurite outgrowth at 3 days post transfection (p=0.0059). Data analysed using unpaired 
t-test. (n = 3 experiments, error bars = SEM). 
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5.2 ALCAM’s extracellular domain is necessary and sufficient 
for potentiation of neurite outgrowth in PC12 cells 
I next investigated which domains of ALCAM were important for its ability to potentiate 
NGF-induced neurite outgrowth. For this I designed and cloned four ALCAM constructs 
that lacked different functional domains, similar to those used previously to investigate 
the role of human ALCAM in cancer (van Kempen et al., 2001). Constructs were 
generated similarly to the full-length ALCAM-D, (for a full explanation see Material and 
Methods, 2.2.1 and Figure 2.1). 
A schematic illustrating all the Dendra-tagged ALCAM constructs is shown in Figure 
5.6. I generated two extracellular domain truncation mutants; D1-ALCAM-D, lacked 
the more distal variable immunoglobulin (V1) domain, and D1D2-ALCAM-D lacked the 
two V1V2 domains. These two constructs lack one or both of the variable 
immunoglobulin domains that are required for trans-binding in both homophilic and 
heterophilic interactions (van Kempen et al., 2001, Bowen et al., 1997). The signal 
sequence of 27 amino acids was fused to the start of the truncated domains because it 
is required for protein folding and delivery onto the plasma membrane. A construct 
generated that lacked this signal sequence was found to accumulate in the 
endoplasmic reticulum (ER) (data not shown). I also generated C-ALCAM-D that 
lacked the short cytoplasmic domain after amino acid 553. Lastly, I produced a 
chimeric protein consisting of the ALCAM transmembrane and cytoplasmic domain and 
the extracellular portion of CD8 (a kind gift of Prof. M. Seaman, University of 
Cambridge). CD8 is a type 1 transmembrane glycoprotein expressed in T-cells that has 
been used to generate reporter constructs to test whether cytoplasmic domains of 
proteins of interest contain targeting information (Seaman, 2004). The CD8 luminal and 
transmembrane portions have no intrinsic role in trafficking and therefore can be fused 
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to specific cytoplasmic tails to investigate their targeting and localisation. The CD8-
ALCAM-D construct would address whether the ALCAM transmembrane and 
cytoplasmic domains had intrinsic neurite outgrowth potentiating ability.  
I transfected these constructs into PC12 cells and differentiated them for 3 days in 100 
ng/ml NGF. Figure 5.7 shows PC12 cells expressing the various proteins. All the 
ALCAM constructs were localised on the plasma membrane and all cells retained the 
ability to differentiate.  
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Figure 5.6 Schematic illustrating the truncated ALCAM proteins generated 
Full length ALCAM-D comprises the signal sequence required for translocation in the 
ER lumen and sorting on the plasma membrane, followed by two variable 
immunoglobulin domains (V1 and V2) required for binding in trans, three membrane 
constant type-2 proximal domains (C1C2C3) required for cis-interactions followed by a 
trans-membrane region, and a carboxy terminal cytoplasmic domain. The carboxy 
terminal was tagged with Dendra (D). ALCAM truncation and chimeric proteins are 
represented below. Ec extracellular; Ic intracellular. 
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Figure 5.7 NGF differentiated PC12 cells expressing ALCAM fluorescent 
constructs 
Images show that ALCAM-D truncation mutants were expressed at similar levels and 
localised to the plasma membranes of PC12 cells in culture. Cells transfected with the 
ALCAM-D constructs were still capable of differentiating in response to NGF exposure. 
Nuclei are stained with DRAQ5 in blue. Scale bar, 40μm. 
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5.2.1 ALCAM extracellular domains engaged in cis and trans interactions 
contribute to potentiating NGF-induced neurite outgrowth in PC12 cells.  
Quantification of neurite outgrowth was carried out 3 days after transfection and 
differentiation with NGF for PC12 cells transfected with the ALCAM constructs and is 
shown in Figure 5.8. Truncations of the most distal extracellular domains (V1 and V2) 
decreased the ability of transfected ALCAM to potentiate NGF-induced neurite 
outgrowth. The effect of losing both domains was additive because cells that 
expressed ALCAM lacking V1V2 showed less neurite outgrowth than those without V1. 
This suggests that binding of ALCAM in trans contributes to the potentiation of neurite 
outgrowth seen in transfected PC12 cells. Interestingly, the truncations did not abolish 
this potentiation completely. Indeed, D1-ALCAM-D and D1D2-ALCAM-D increased 
neurite outgrowth in response to NGF above control Dendra transfected cells. This 
suggests that cis interactions within the membrane maintained in these mutants also 
contribute to the potentiation effect.  
Interestingly, an ALCAM construct that lacked the cytoplasmic domain (C-ALCAMD) 
potentiated neurite outgrowth to the same extent as the full-length protein. This could 
suggest that ALCAM does not contribute to neurotrophin signalling by direct 
downstream signalling. As described in the Introduction, section 1.5, the cytoplasmic 
tail of ALCAM is the least conserved region when compared to its V1V2C1C2C3 family 
members, MCAM and BCAM, which suggests the cytoplasmic region has not been 
under strong selective pressure during evolution. The other family members have 
much larger cytoplasmic regions with known interaction motifs, while the ALCAM 
cytoplasmic domain has no known motifs and interactions have only been 
demonstrated for ubiquitin and actin (Thelen et al., 2008, Te Riet et al., 2007). The 
latter interaction has been shown to contribute to ALCAM adhesion (Zimmerman et al., 
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2004). However, it is not possible to conclude that the cytoplasmic domain is not 
required for neurite outgrowth potentiation from my findings because PC12 cells may 
express endogenous ALCAM (reviewed in Discussion, section 6.3.3). In PC12 cells 
transfected with C-ALCAM-D, endogenous ALCAM could compensate for the 
truncation mutant through cis-interactions by transmitting any relevant signals or 
cytoskeletal alterations required to cause the increase in neurite outgrowth observed.  
The CD8-ALCAM-D chimera comprised of the CD8 ectodomain fused to the juxta-
membrane, trans-membrane and cytoplasmic domain of ALCAM was incapable of 
increasing neurite outgrowth. This result corroborated the findings obtained with the 
other constructs. Firstly, that the ectodomain of ALCAM was required to potentiate 
NGF-induced neurite outgrowth, and secondly, that the cytoplasmic domain did not 
contribute to this effect. Importantly, this also illustrated that the observed potentiation 
of neurite outgrowth was not a general response to the overexpression of a cell surface 
plasma membrane protein.  
These results are particularly interesting considering the proposed segregation of 
function within the extracellular domains of ALCAM discussed in the Introduction, 
section 1.5 and (van Kempen et al., 2001). Swart and colleagues have previously 
shown that ALCAM has two functional modules; domains V1V2 are responsible for 
binding in trans while domains C1C2C3 are responsible for binding in cis-interactions. 
Manipulations of these two modules can have cooperating and opposing effects. 
Expression of a N-ALCAM (equivalent to my D1D2 construct) was found to interfere 
with homophilic cell adhesion by altering ALCAM avidity. Furthermore, it was found that 
cells expressing this dominant negative form of ALCAM showed increased ability to 
metastasise while displaying decreased metalloprotease activity (van Kempen et al., 
2004). Cells treated with a soluble form of ALCAM, comprising of the V1 domain alone, 
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also showed inhibition of metalloprotease activity but showed decrease in migration 
and metastasis (van Kilsdonk et al., 2008). It is suggested that metalloprotease 
activation relies on an intact ALCAM network, which is inhibited by both N-ALCAM 
and soluble ALCAM. However, the difference in migration and metastasis is thought to 
occur because N-ALCAM expression causes upregulation of L1-CAM, while soluble 
ALCAM does the opposite (van Kilsdonk et al., 2008). The mechanism behind the 
differential effects on L1-CAM expression is not yet understood. These studies 
demonstrate that manipulations of ALCAM binding and analysis of the effects caused 
by the overexpression of ALCAM truncation forms are complex to interpret.  
ALCAM can be expressed on the sending and receiving cell, and can function 
bidirectionally, both in cis and in trans. In my experiments disruption of clustering, 
requiring both trans and cis interactions, abrogates the potentiation of neurite 
outgrowth seen on overexpression of full-length ALCAM.  
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Figure 5.8 Potentiation of NGF-induced differentiation of PC12 cells 
requires the extracellular domains of ALCAM 
Quantification of PC12 cells with neurites at least two times the length of the soma (% 
of cells with neurite outgrowth) transfected with a variety of ALCAM mutants and 
differentiated with 100 ng/ml NGF for 3 days. Truncations D1-ALCAM-D and D1D2-
ALCAM-D inhibited the potentiating effect of ALCAM on neurite outgrowth, however 
both constructs were still capable of potentiating NGF-induced differentiation above 
control levels. C-ALCAM-D, lacking the cytoplasmic domain, was capable of 
potentiating neurite outgrowth equivalently to expressing full length ALCAM-D. CD8-
ALCAM-D, that lacked the entire ALCAM extracellular domain did not potentiate neurite 
outgrowth above control Dendra transfected cells. Data analysed using 1 way ANOVA 
with Bonferroni’s Multiple Comparison Test; * p<0.05 *** p<0.001 (n = 3 to 8 
experiments, error bars = SEM). 
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5.2.2 The ALCAM extracellular domain is sufficient to potentiate neurite 
outgrowth in PC12 cells 
To complement the truncation studies I next tested whether addition of the soluble 
ALCAM ectodomain could potentiate the NGF-induced differentiation in PC12 cells. 
ALCAM-Fc was added to the NGF-differentiation medium at either 1 μg/ml or 10 μg/ml. 
As a control, the chimeric protein human immunoglobulin IgG1 (Hu-Fc) was added to 
differentiation medium at the same concentrations tested. Neurite outgrowth of Dendra 
expressing PC12 cells was measured 3 days after transfection.  
Addition of soluble ALCAM-Fc at 1 μg/ml was found to significantly potentiate neurite 
outgrowth in response to NGF (Figure 5.9). This complements my previous findings 
(Figure 5.8), suggesting that the extracellular domain was necessary to potentiate 
neurite outgrowth in response to NGF. Furthermore, this is consistent with PC12 cells 
expressing endogenous ALCAM with which the ALCAM-Fc can bind. However, I 
cannot exclude that ALCAM-Fc may also bind another unidentified, heterophilic binding 
partner on the surface of PC12 cells, through which it could modulate neurotrophin 
signalling.  
It is noted that ALCAM-Fc at 10 μg/ml did not significantly potentiate neurite outgrowth 
in response to NGF above control levels. However, this can be attributed to an 
anomalous increase in neurite outgrowth seen in the presence of 10 μg/ml Human-Fc. 
The explanation for this was not investigated further, however upon addition of 10 
μg/ml of soluble protein (ALCAM-Fc or Human-Fc) cell adhesion was compromised 
and cells were often lost during staining and mounting. This could explain why 
potentiation of neurite outgrowth at this concentration did not reach significance. 
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I went on to test whether addition of the heterophilic ALCAM ligand, CD6, would have 
the same effect as addition of soluble ALCAM-Fc. In axonal transport experiments 
(Chapter 3; Figure 3.16 and Figure 3.17), addition of CD6-Fc showed a tendency 
towards increasing the retrograde transport frequency of ALCAM-positive carriers but 
did not alter their average speed. I tested whether addition of 1 μg/ml CD6-Fc or Hu-Fc 
would alter NGF-induced neurite outgrowth in PC12 cells transfected with ALCAM-D or 
Dendra. Quantification of neurite outgrowth found no evidence to suggest that the 
soluble CD6-Fc could potentiate neurite outgrowth in response to NGF in either Dendra 
or ALCAM-D expressing cells three days after transfection (Figure 5.10). Interestingly, 
this suggests that though CD6 can increase internalisation in cancer cell lines and 
shows a tendency towards modulating ALCAM transport frequency, the same stimulus 
has no effect on neurite outgrowth.  
Remarkably, the different effects of CD6-Fc and ALCAM-Fc illustrate that even though 
both ligands bind the variable immunoglobulin domains in trans, they have different 
physiological properties. Importantly, ALCAM-Fc should also be capable of binding 
endogenous ALCAM in cis and therefore would more closely replicate the 
overexpression of the full-length protein (for schematic representation of binding 
configurations of soluble ALCAM refer to Chapter 3, Figure 3.18). My findings therefore 
suggest that the ability of ALCAM to potentiate neurotrophin signalling requires binding 
in cis.  
Lastly, it is noted that overall decreased levels of neurite outgrowth were observed 
following addition of soluble proteins to the differentiation medium (Figure 5.10). In 
these experiments neurite outgrowth was displayed in around 40% of cells compared 
to 60% observed in the original experiments involving transfection of full-length protein 
(compare Figure 5.5 and Figure 5.8 to Figure 5.9 and Figure 5.10). This suggests that 
Chapter 5. Results 
175 
addition of soluble proteins to the medium, especially at higher concentrations, may 
interfere with adhesion and differentiation.  
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Figure 5.9 Addition of soluble ALCAM potentiates NGF-induced neurite 
outgrowth in PC12 cells 
The histogram shows quantification of the percentage of cells whose longest neurite 
was two times or greater than the length of the soma (% of cells with neurite outgrowth) 
three days after transfection in response to 100 ng/ml NGF in the presence of soluble 
ALCAM-Fc or human-Fc (Hu-Fc). Neurite outgrowth was quantified in Dendra-
transfected cells. A significant difference was found between the percentages of cells 
displaying neurite outgrowth after exposure to 1 μg ALCAM-Fc when compared to 1 μg 
Hu-Fc (P=0.0285). There is no significant difference between ALCAM-Fc and Hu-Fc at 
the higher concentration used (10 μg). Data analysed using unpaired t-test; * p <0.05 
(n = 4 experiments, error bars = SEM). 
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Figure 5.10 Addition of the soluble ALCAM ligand CD6 does not potentiate 
neurite outgrowth in PC12 cells 
The histogram shows the percentage of cells that displayed neurite outgrowth (those 
that had neurites at least two times the length of the soma) in response to NGF in the 
presence of 1 μg/ml human-Fc (Hu-Fc) or soluble CD6-Fc three days after transfection. 
There is no significant potentiation of neurite outgrowth in the presence of CD6-Fc in 
either Dendra or ALCAM-D transfected cells. Data analysed using unpaired t-test 
analysis (n = 3 experiments, error bars = SEM). 
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5.3 ALCAM overexpression potentiates specific differentiation 
stimuli in PC12 cells 
I next examined whether ALCAM overexpression was having a general potentiative 
effect on neurite outgrowth or whether it was specific to the differentiation stimulus. I 
compared neurite outgrowth in PC12 cells expressing Dendra or ALCAM-D in various 
differentiation conditions. Cells were analysed in the presence of NGF as a positive 
control and after serum withdrawal but in the absence of a specific differentiation 
stimulus. PC12 cell neurite outgrowth was investigated in response to glial cell line-
derived neurotrophic factor (GDNF), a growth factor that is not in the neurotrophin 
family, and to dibutyryl cAMP (dbcAMP), a cyclic AMP analogue known to induce 
neurite differentiation in a variety of cell lines (Ng et al., 2009). Figure 5.11 shows 
transfected PC12 cells in each of these conditions. 
Quantification of neurite outgrowth in ALCAM-D and Dendra-expressing PC12 cells in 
various conditions found that ALCAM overexpression only significantly potentiated 
NGF-induced differentiation (Figure 5.12). In the absence of differentiation stimuli, 
ALCAM-D expression had no effect on neurite outgrowth, suggesting that ALCAM does 
not initiate differentiation per se, but can either potentiate the stimulus itself or the 
process of neurite extension once it has been initiated. Interestingly, ALCAM did not 
potentiate neurite outgrowth in PC12 cells in response to dbcAMP at either 
concentration tested. This demonstrates that ALCAM potentiation of neurite outgrowth 
is not a general effect on differentiation but is specific to the stimulus. Analogues of 
cAMP act intracellularly where they mimic an increased concentration of the secondary 
messenger cAMP and therefore act downstream of membrane signalling. Along with 
the previous experiments using truncation mutants, this finding suggests that ALCAM 
potentiation of neurite outgrowth may occur at the level of the plasma membrane. In 
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this experiment the dbcAMP treatment essentially bypassed the requirement of 
extracellular receptor activation, by directly activating the signalling cascade required 
for neurite outgrowth, downstream of ALCAM. 
Interestingly, there is a trend to suggest that ALCAM-D transfection could potentiate 
neurite outgrowth in response to GDNF, although the difference between ALCAM-D 
and Dendra-transfected PC12 cells is not significant. This could suggest that the 
mechanism by which ALCAM potentiates growth factor signalling is more influential in 
the NGF than GDNF signalling pathways. Alternatively, it could be merely a 
methodological issue. GDNF is a weak inducer of neurite outgrowth in comparison to 
NGF (around 20% or 50% of cells respectively). Perhaps with more experiments the 
smaller percentage difference may become significant.  
PC12 cells do not express the GDNF co-receptor, GFR, that cooperates with RET 
and/or NCAM in activating differentiation signalling (see Introduction, section 1.4, and 
(Paratcha et al., 2003)). To induce neurite outgrowth in these experiments it is 
necessary to add a soluble form of GFR to the GDNF differentiation medium. I 
therefore also tested whether ALCAM-D could replace the requirement for soluble 
GFR in these experiments. However no neurite outgrowth was observed in response 
to GDNF without GFR but in the presence of ALCAM-D (data not shown). This 
suggests that ALCAM does not interact with RET or NCAM directly in a similar way to 
the co-receptor GFR. 
In summary, these experiments analysing PC12 neurite outgrowth suggest that 
ALCAM potentiates neurotrophin signalling and that this requires the ALCAM 
extracellular domain. Furthermore, ALCAM itself appears not to directly activate 
downstream signalling cascades, but acts as a modifier, altering specific differentiation 
signals at the membrane.  
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Figure 5.11 Analysis of neurite outgrowth in response to a variety of 
differentiation signals in PC12 cells expressing Dendra or ALCAM-D 
PC12 cells transfected with Dendra or ALCAM-D are shown in the different treatment 
conditions. In the absence of differentiation stimuli (no stimulus), very few neuritic 
protrusions are seen. On dbcAMP and GDNF treatment some transfected cells have 
neuritic extensions, however the differentiation is less extensive than following NGF 
treatment (compare to Figure 5.7). Nuclei are stained with DRAQ5 in blue. Scale bar, 
40 μm. 
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Figure 5.12 ALCAM-D potentiates specific PC12 differentiation stimuli 
The histogram summarises the quantification of neurite outgrowth (cells with neurites 
two times or greater in length than the soma) in experiments investigating the PC12 
cell response to the presence or absence of specific differentiation stimuli. ALCAM-D 
did not induce neuronal differentiation in the absence of differentiation stimuli (-). 
ALCAM-D did not potentiate differentiation induced by exposure to dbcAMP 5 days 
after transfection (5DPT) at either 0.1 mM or 0.5 mM. PC12 cells transfected with 
ALCAM-D differentiated with GDNF showed a tendency for increased neurite 
outgrowth at both time points tested (5DPT or 7DPT), but this was not statistically 
significant. ALCAM-D transfection significantly potentiated neurite outgrowth in 
response to NGF 3 days after transfection (3DPT). Data analysed using 1 way ANOVA 
with Bonferroni’s Multiple Comparison Test; p<0.001 (n = 4 experiments, error bars = 
SEM). 
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5.4 ALCAM overexpression potentiates TrkA phosphorylation 
in response to NGF 
I then went on to assess whether ALCAM-D overexpression directly alters the 
neurotrophin-signalling pathway in PC12 cells. Differentiated ALCAM-D or Dendra 
transfected PC12 cells were starved of serum and neurotrophins for 5 hours and then 
treated with NGF.  Activation of the neurotrophin signalling pathway was assessed by 
western blotting for phosphorylated components of the NGF-signalling cascade. Cells 
were harvested in boiling high SDS buffer, to inactivate proteases and phosphatases. 
Samples were run on SDS-PAGE, transferred to PVDF membranes and analysed by 
western blot to compare the levels of specific phosphorylated proteins after NGF 
treatment. I analysed the levels of phosphorylation of the NGF receptor, TrkA, and the 
MAPK, ERK1/2 (Figure 5.13). The intensity of phosphorylated protein (TrkA or ERK1/2) 
was normalised to the total amount of protein per sample, and phosphorylation levels 
were normalised to activation 3 min after NGF treatment in Dendra cells (see Materials 
and Methods). The time course represented in Figure 5.14 shows that NGF increased 
phosphorylation of TrkA and ERK1/2 peaking at 3 minutes and 15 minutes 
respectively. ALCAM-D cells had increased TrkA and ERK1/2 phosphorylation at all 
timepoints, consistent with the downstream increase in neurite outgrowth observed in 
PC12 cells.  
However, upon Lipofectamine transfection, ALCAM-D or Dendra is only expressed in 
30-40% of PC12 cells and therefore we assumed that we would only be able to 
observe a small change in phosphorylation by western blot because of the contribution 
of non-transfected cells to the sample. Furthermore, the phosphorylation intensities 
obtained varied between experiments i.e. due to different cell preparations, as well as 
between the different time points after NGF exposure. This variability decreased the 
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power with which I could assess the small differences in phosphorylation by 
conventional statistical tests.  
To take these issues into account we consulted with Dr Gavin Kelly, a statistician (LRI, 
Bioinformatics and Biostatistics Service). The raw intensity data values were 
transformed on a log scale (to reflect relative differences rather than absolute values), 
and a model that assumed the individual phosphorylation intensities had dependencies 
on experiment and timepoint after NGF treatment was fitted. This model was used to 
produce individual intensity values with the experiment and time-trend effect removed 
for TrkA and ERK1/2 phosphorylation and these values are shown on the box plot 
(Figure 5.15). This allowed us to pool individual phosphorylation values across all 
timepoints and all experiments, so that we could analyse whether there was an effect 
of transfection. ANOVA was used to determine whether the difference between the 
Dendra and ALCAM-D predicted phosphorylation intensity values was larger than that 
ascribbable to noise. The difference between TrkA predicted phosphorylation 
intensities is significantly different between Dendra and ALCAM-D conditions 
(p=0.00038), but is not significant for ERK1/2 (p=0.19). The ANOVA also indicates that 
phosphorylation was significantly different between experiments and between 
timepoints after NGF stimulation (p<1e-6). 
In summary, my results show that ALCAM-D significantly increased TrkA 
phosphorylation intensity. I also found a significant effect on phosphorylation with time 
after NGF stimulation, as well as between experiments. The ERK1/2 phosphorylation 
observed was much more variable than TrkA phosphorylation. ERK1/2 is downstream 
of many stimuli (e.g. cell stress), which are more problematic to control between 
experiments. This variation limited our ability to resolve an effect of ALCAM-D on 
ERK1/2 phosphorylation (reviewed further in the Discussion, section 6.3.1). 
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Figure 5.13 TrkA and ERK1/2 phosphorylation in PC12 cells stimulated 
with NGF 
A typical western blot showing phosphorylated TrkA and ERK1/2 at 0, 3, 5 and 30 
minutes after addition of 100 ng/ml NGF. ALCAM-D expressing PC12 cells show 
higher TrkA phosphorylation than Dendra-expressing cells in response to NGF. 
ERK1/2 is also phosphorylated after addition of NGF.  
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Figure 5.14 ALCAM-D expressing PC12 cells showed increased TrkA and 
ERK1/2 phosphorylation in response to NGF 
The histograms represent protein phosphorylation levels for TrkA and ERK1/2 (n=4 
experiments). For each experiment, phosphorylated levels were adjusted to the total 
TrkA or ERK1/2 per sample. Phosphorylation was then normalised to the average 
phosphorylation intensity of Dendra cells 3 minutes after NGF exposure across all 
experiments analysed. ALCAM-D expression shows a tendency towards potentiation of 
TrkA and ERK1/2 phosphorylation at all time points after exposure to NGF. Using 1 
way ANOVA TrkA phosphorylation is significantly different (p = <0.0004) but not 
between transfection conditions using Bonferroni’s Multiple Comparison Test (n = 4 
experiments). 
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Figure 5.15 ALCAM-D significantly increased TrkA phosphorylation 
Box and whisker plots of TrkA and ERK1/2 phosphorylation (au - arbitrary units) after 
adjustment to remove variability attributed to different experiments and timepoints after 
NGF stimulation. A significant increase in TrkA phosphorylation in ALCAM-D 
transfected cells is shown in comparison to Dendra transfected cells (A) (*** p<0.001). 
In contrast, no significant difference in ERK1/2 phosphorylation intensity in Dendra and 
ALCAM-D transfected cells is observed (B). Data was analysed with the help of Dr 
Gavin Kelly, using ANOVA to compare the predicted phosphorylation values in Dendra 
versus ALCAM-D transfected conditions for TrkA and Erk1/2 across all experiments 
and timepoints (n = 4 experiments). 
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5.4.1 ALCAM-D does not directly interact with TrkA 
ALCAM overexpression could alter NGF signalling through interactions with the NGF 
receptor TrkA. To test whether ALCAM directly interacted with the neurotrophin 
receptor I tried to co-immunoprecipitate the two proteins in various conditions, using 
endogenous protein in primary ventral horn cultures, and transfected ALCAM-D in 
PC12 cells after differentiation. As explained in Chapter 4, section 4.5, the 
immunoprecipitation of endogenous ALCAM was inefficient in the conditions tested. 
However, I identified conditions in which immunoprecipitation of overexpressed 
ALCAM-D was possible. 
I did not find any evidence of an interaction between ALCAM and TrkA when either 
protein was immunoprecipitated. As can be seen in Figure 5.16, ALCAM-D 
immunoprecipitated by the Dendra antibody was not associated with TrkA. 
Furthermore, immunoprecipitation of endogenous TrkA revealed no evidence of 
association with endogenous or overexpressed ALCAM in PC12 cells. This would 
suggest that the way in which ALCAM overexpression modulates TrkA-NGF signalling 
is not due to direct transactivation of TrkA. 
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Figure 5.16 ALCAM and TrkA do not directly interact 
PC12 cells transfected with ALCAM-D, undifferentiated or differentiated with NGF 
(NGF – or + respectively) were used in an immunoprecipitation experiment. Cell 
lysates (I) were pre-cleared with beads alone (Pc), then immunoprecipitated with 
antibodies directed against ALCAM-D (IP Dendra) or to TrkA (IP TrkA). Samples of cell 
lysates (I) and exhausted supernatant (XS) after removal of IP beads are also shown. 
In IP Dendra samples ALCAM-D was immunoprecipitated with the anti-Dendra 
antibody (D) but not the control Rabbit IgG (Rb), and is recognised by western blotting 
(WB) with 4682 IgG antibody for ALCAM or Dendra. However there is no evidence for 
association of TrkA with the ALCAM-D immunoprecipitate (IP). In IP TrkA, it can be 
seen that TrkA was successfully immunoprecipitated by a monoclonal antibody (B3) 
but not by an unrelated monoclonal (M). It can be seen that more TrkA was pulled 
down in the differentiated (+ NGF) condition. However there is no evidence of ALCAM-
D also being pulled down with TrkA when the membrane was probed with 4682 IgG 
directed to ALCAM. 
 
 
Chapter 5. Results 
 189 
5.4.2 ALCAM-D modulates the association of p75NTR to detergent resistant 
membranes 
A possible way in which ALCAM could indirectly alter NGF receptor signalling would be 
by altering the association of neurotrophin receptors to detergent-resistant membranes 
(DRMs), also known as lipid rafts. TrkA and p75NTR have been shown to localise to lipid 
rafts, and this relates to their signalling function (Limpert et al., 2007, Gil et al., 2007). 
For example, it has been found that on laminin binding to ganglioside GM1, TrkA 
residence in DRMs is altered, leading to potentiation of TrkA signalling and neurite 
outgrowth (Ichikawa et al., 2009).  Furthermore, the cell adhesion molecule NCAM has 
different signalling partners and subsequent downstream signalling, depending on 
whether it is present in DRMs or detergent-soluble membranes (reviewed in Maness 
and Schachner, 2007). To determine whether ALCAM could affect neurotrophin 
receptor localisation I isolated DRMs from PC12 cells transfected with ALCAM-D or 
Dendra differentiated with NGF for 3 days.  
Detergent resistant membranes were isolated and analysed by western blot for 
markers of lipid rafts, neurotrophin receptors and ALCAM (Figure 5.17). Lipid rafts 
were successfully isolated from both ALCAM-D and Dendra-expressing cells, shown by 
fractions 2-5 containing Thy-1.1, a GPI-anchored protein which accumulates in DRMs 
(Madore et al., 1999). ALCAM-D was present in the non-raft associated membrane 
fractions. Over several experiments, we saw no major alteration in Thy-1.1 DRM 
distribution between PC12 cells expressing ALCAM-D or Dendra. Furthermore, there 
was no difference in the distribution of full length TrkA in cells that overexpressed 
ALCAM-D or Dendra.  This suggests that the increase in TrkA phosphorylation (seen in 
Figure 5.13 and Figure 5.14) was not due to an alteration in the amount of TrkA 
associated with DRMs.  
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However, the distribution of the other PC12 neurotrophin receptor p75NTR was shifted 
toward those DRM fractions containing Thy1.1 in ALCAM-D cells. The alteration in the 
membrane localisation of p75NTR could affect its downstream signalling. Interestingly, a 
second band was observed around 25 kDa in the p75NTR western blot, although its 
membrane association is not altered between ALCAM-D and Dendra-transfected 
conditions. The lower band was not recognised by an antibody to the p75NTR 
extracellular domain consistent with the idea that it could be the p75NTR C-terminal 
fragment (data not shown). It is also noted that an unknown band migrating at 50 kDa 
recognised by TrkA antibodies, (both  phosphoTrk and  panTrk), and which changes 
its distribution between ALCAM-D and Dendra expressing cells. A possible explanation 
for the 50 kDa band, is that it represents the truncated C-terminal domain of the TrkA 
receptor which has been shown to be constitutively active (Diaz-Rodriguez et al., 
1999). Perhaps ALCAM overexpression alters the activity of the proteases responsible 
for neurotrophin receptor cleavage. A recent paper found that p75NTR processing by -
secretase generates an intracellular fragment capable of potentiating TrkA signalling in 
PC12 cells (Ceni et al., 2010). In turn, if there were alterations in processing it could 
explain how ALCAM overexpression influences TrkA signalling indirectly (see 
Discussion, section 6.3.2). 
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Figure 5.17 DRMs are not altered in ALCAM-D expression 
PC12 Dendra and PC12 ALCAM-D cell lysates (I) and detergent-resistant membrane 
(DRM) fractions were separated (1-12/13) and analysed by western blot. Thy1.1 is 
present in DRMs and is not altered between Dendra and ALCAM-D transfected cells. 
Both Dendra at 26 KDa and ALCAM-D at 130 kDa are detected in soluble membrane 
fractions (10-12/13). TrkA is detected in soluble membrane fractions in both Dendra 
and ALCAM-D expressing cells. The distribution of p75NTR is shifted toward DRMs in 
ALCAM-D expressing cells. The asterisks highlight unknown bands detected by the Trk 
and p75NTR antibodies. Similar results were obtained in 2 experiments. 
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5.5 The role of ALCAM in nerve terminal sprouting in vivo at 
the mouse neuromuscular junction (NMJ) 
Since overexpression of ALCAM potentiated NGF-induced neurite outgrowth in a 
neural cell line, we next examined the potential role of ALCAM in axonal outgrowth in 
vivo. To do this I investigated whether ALCAM-/- mice displayed decreased axonal 
outgrowth in response to an insult that normally induces sprouting of nerve terminals at 
the NMJ. As described in the Introduction section 1.5, ALCAM-/- animals have a mild 
neurological phenotype and it was hypothesised that upregulation of proteins with 
related functions compensated for the loss of ALCAM during development. In the adult 
nervous system axonal outgrowth occurs in response to injury, for example nerve 
transection (for example Moscoso et al., 1998). Since ALCAM is expressed in the 
immune system, we wanted to avoid using a procedure that caused inflammation 
because recovery could be affected by loss of ALCAM in immune cells e.g. 
macrophages, as well as in the neurons themselves. Nerve crush injury has been 
associated with macrophage invasion (Omura et al., 2005). However, muscle paralysis 
is known to be a potent inducer of nerve terminal sprouting (Angaut-Petit et al., 1990) 
but has not been reported to involve an immune response.  
In this study muscle paralysis was induced by intramuscular injection of botulinum toxin 
type A (BoNT/A). In response to muscle paralysis nerve terminals sprout from the axon 
terminal to neighbouring regions of the muscle in an attempt to functionally innervate 
the inactive muscle fibres (de Paiva et al., 1999). During the early phase of recovery, 
when nerve stimulation again elicits muscle contraction, it has been shown that areas 
where the nerve sprouts contact the muscle fibre are the only sites of synaptic vesicle 
turnover and are responsible for neurotransmission (de Paiva et al., 1999). The 
process of nerve terminal sprouting is then followed by their retraction and removal 
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once the original terminals reacquire full functionality and become capable of vesicle 
turnover.  
I analysed the sprouting response to BoNT/A injection in the extensor digitorum longus 
(EDL) hindlimb muscle in adult wild type and ALCAM-/- littermates. Electrophysiological 
recordings performed by Jim Dick in the laboratory were used to determine if the 
BoNT/A treatment was effective in producing complete muscle paralysis. An in vivo 
assessment of isometric twitch and tetanic force was performed in an anaesthetised 
wild type mouse following BoNT/A treatment of the EDL hindlimb muscle, using the 
contralateral untreated limb as a control. As can be seen in Figure 5.18, seven days 
after BoNT/A treatment the EDL muscle was completely paralysed. 
To examine the extent of nerve terminal sprouting, animals were sacrificed 3 weeks 
after BoNT/A treatment, the EDL muscles in the BoNT/A treated leg and the 
contralateral untreated leg were removed, fixed and sectioned. Then axons and 
neuromuscular junctions were visualised using a combined acetylcholinesterase silver 
staining protocol (modified from Namba et al., 1967). Terminal sprouts, extending from 
within the endplate region into surrounding muscle, and nodal sprouts, where axons 
branched immediately before entering the endplate, were quantified. Examples of 
terminal and nodal sprouts observed in response to BoNT/A treatment are shown in 
Figure 5.19. Quantification of endplate sprouting was conducted blind to the genotype 
on a light microscope.  
The same analysis was also conducted on the levator auris longus (LAL) muscle, 
which has been used extensively in the study of the response to BoNT/A-induced 
paralysis (Angaut-Petit et al., 1987, Angaut-Petit et al., 1990). The LAL muscle does 
not require sectioning and was stained as a whole mount preparation using the same 
combined cholinesterase silver stain. We sacrificed the animals 3 weeks after injection 
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of 0.5 pg of BoNT/A subcutaneously into the head and sprouting was quantified by the 
same method as for the EDL.  
I found that loss of ALCAM in vivo had no effect on the nerve terminal sprouting in 
response to BoNT/A observed after 3 weeks. There was no difference in the 
percentage of endplates with nerve terminal sprouts (terminal and/or nodal) in either 
EDL or LAL muscles (Figure 5.20). The number of sprouts in untreated EDL and LAL 
muscles was also comparable between wild type and ALCAM-/- mice. Furthermore, as 
illustrated by the frequency distribution of the number of sprouts quantified, the ability 
of motor axons to extend more than one sprout from an endplate did not differ between 
wild type or ALCAM-/- littermates (Figure 5.21). In summary, no difference in nerve 
terminal sprouting at the NMJ was detected in ALCAM-/- animals either in normal 
conditions or in response to BoNT/A induced paralysis. The ALCAM-/- animals may 
have compensatory mechanisms similar to those proposed to exist during development 
that allowed the animals to respond normally to BoNT/A induced muscle paralysis. 
Alternatively these in vivo results may suggest that the increased neurite outgrowth 
seen in vitro in PC12 cells are due to ALCAM overexpression, rather than reflecting a 
function of the endogenous protein. Knockdown of ALCAM in PC12 cells is necessary 
to determine whether endogenous ALCAM has a role in neurite outgrowth in PC12 
cells. I will discuss these issues further in the Discussion, section 6.3.3.  
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Figure 5.18 BoNT/A caused complete paralysis one week after injection 
Injection of 2 pg of BoNT/A into the mouse hindlimb caused complete paralysis in EDL 
muscles as illustrated by electrophysiological recording. Four stimuli were used; a 
single 10 volt stimulation for 0.05 s (twitch tension), or successive stimulations at 40 
Hz, 80 Hz and 100 Hz (tetanic stimulation). Indirect stimulation via the nerve is shown 
in A while direct stimulation of the muscle directly is shown in B. The injected muscle 
(red trace) does not contract in response to nerve stimulation, however the untreated 
leg (blue trace) showed both a twitch response to the single stimulation (single peak 
trace) and sustained contraction on tetanic stimulation at high frequency stimulations 
(broad trace). The lower panel shows that the muscle was still functional because it 
responds to direct electrical stimulation of the muscle. The experiment confirmed that 
the dose of the toxin used was sufficient to completely prevent signal transduction from 
nerve to muscle i.e. induce muscle paralysis 7 days after treatment. Performed by J 
Dick. 
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Figure 5.19 Nerve terminal sprouts were observed in EDL muscles 3 
weeks after BoNT/A injection 
Nerve terminals labelled by silver can be seen contacting endplates labelled by 
acetylcholinesterase. No nerve terminal sprouts are seen in an ALCAM-/- uninjected 
EDL muscle in image (A). Terminal sprouts were defined as a neurite branch that 
extended beyond the cholinesterase stained region after entering the endplate (black 
arrows) and are seen in wild type and ALCAM-/- muscles in (B). Nodal sprouts, defined 
as those that branched from the axon immediately before it reached the endplate, were 
also quantified (white arrowhead). Scale bar 50 μm. 
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Figure 5.20 Loss of ALCAM did not alter sprouting in response to BoNT/A 
The percentage of endplates that possessed terminal or nodal sprouts in BoNT/A 
treated (+ BoNT/A) and control muscles (- BoNT/A) were quantified in EDL and LAL 
muscles of wild type and ALCAM-/- mice and is represented as a histogram. In EDL 
muscles approximately 50% of endplates possessed sprouts in BoNT/A treated 
muscles in both wild type and ALCAM-/- animals, while only 10% of endplates in 
untreated muscles had sprouts. In the LAL muscle a similar pattern was seen with no 
difference between wild type and ALCAM-/- animals. Both showed a sprouting response 
after BoNT/A treatment (For EDL muscles n = 3 litters, 3 wild type and ALCAM-/- 
BoNT/A treated muscles, 1 wild type and 2 ALCAM-/- untreated muscles; average of 47 
endplates counted per muscle. For LAL muscle analysis n = 2 litters and 2 wild type 
and 2 ALCAM-/- muscles with and without BoNT/A treatment; average of 30 endplates 
counted per muscle). Data was analysed by 1 way ANOVA and the means are 
significantly different (p = 0.0303). There was a significant increase in sprouting in 
injected versus uninjected muscles but there was no difference between wild type and 
ALCAM-/- muscles (error bars = SEM). 
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Figure 5.21 The frequency distribution of the number of sprouts per 
endplate is comparable in EDL muscles of ALCAM-/- and wild type 
littermates 
The percentage of endplates with 0 to 5 sprouts is plotted for BoNT/A treated EDL 
muscles from wild type and ALCAM-/- animals. There is no apparent change in the 
frequency distribution of endplates with more than one sprout. (n = 3 animals per 
genotype; total of 131 neuromuscular junctions in wild type animals and 150 
neuromuscular junctions in ALCAM-/- animals were quantified). 
 
 
 
 
Chapter 5. Results 
 199 
5.6 Summary 
In this chapter, I have shown that ALCAM can potentiate neurite outgrowth in PC12 
cells. Through the use of a soluble ALCAM extracellular domain and a variety of 
truncation mutants, I demonstrated that the ability of ALCAM to potentiate neurite 
outgrowth upon NGF-induced differentiation was dependent on its extracellular 
domain. The ALCAM cytoplasmic tail and transmembrane region was ineffective in 
inducing neurite outgrowth. Since PC12 cells express endogenous ALCAM, which 
could compensate for truncation of the cytoplasmic domain, it was not possible to 
determine whether the cytoplasmic domain was necessary to potentiate NGF-induced 
neurite outgrowth. Overexpression of the extracellular domain truncation mutants were 
capable of disrupting the extracellular ALCAM network, and ALCAM function, even in 
the presence of endogenous ALCAM. CD6-Fc binding in trans was incapable of 
potentiating neurite outgrowth and suggests that binding in cis is required for ALCAM 
to potentiate NGF stimulated differentiation. My findings suggest that ALCAM does not 
take part in direct signal transduction via its cytoplasmic domain upon ligand binding. 
Instead the difference observed between CD6-Fc and ALCAM-Fc suggests that the cis 
interaction and resulting increased avidity is required to potentiate neurite outgrowth.  
ALCAM did not cause neurite outgrowth when overexpressed in the absence of other 
differentiation signals, suggesting that ALCAM is a modifier rather an initiator of the 
process. Interestingly, ALCAM did not potentiate all differentiation stimuli, it did not 
potentiate outgrowth in response to the downstream messenger dbcAMP and this 
again suggests that ALCAM does not directly activate downstream signalling cascades 
that could cooperate with other downstream stimuli. My results indicate that ALCAM 
potentiates specific membrane initiated differentiation signals. I found that ALCAM also 
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alters GDNF induced differentiation suggesting it may not be TrkA specific and ALCAM 
potentiation may extend to other growth factor receptors.  
I attempted to determine the mechanism by which ALCAM-D potentiated neurite 
outgrowth. There was a consistent increase in the phosphorylation of TrkA after 
ALCAM-D transfection. No direct interaction between TrkA and ALCAM was identified 
by immunoprecipitation experiments suggesting that it was not due to direct 
transactivation of the receptor. Following isolation of DRMs, it appeared that ALCAM-D 
did not localise to DRMs, and did not alter the overall distribution of Thy-1.1, or full-
length TrkA. The distribution of p75NTR was however shifted toward DRMs, which could 
alter p75NTR function. Considering ALCAM has already been shown to be involved in 
regulation of metalloprotease activity in cancer cell lines (van Kilsdonk et al., 2008, 
Lunter et al., 2005), it would be interesting to investigate whether ALCAM 
overexpression alters metalloprotease activity in neural cells, especially considering 
that anomalous smaller TrkA and p75NTR forms were observed (discussed further in the 
Discussion, section 6.3.2). 
There is no difference in neurite sprouting in response to BoNT/A-induced muscle 
paralysis in animals that did not express ALCAM. My results suggest that ALCAM does 
not play a role in nerve terminal sprouting in response to paralysis of LAL and EDL 
muscles in vivo. I propose that the ALCAM network at the plasma membrane can 
influence growth factor signalling at the level of the receptor-ligand interaction. 
Currently we have not determined whether this is a property of ALCAM expressed at 
endogenous levels or a PC12 specific mechanism. Possible explanations that warrant 
further investigation will be considered further in the Discussion. 
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Chapter 6. Discussion 
6.1 ALCAM undergoes retrograde transport in ventral horn 
neurons. 
6.1.1 Characterisation of the ALCAM retrograde transport endosome 
The results presented in this thesis show that endogenous ALCAM on the surface of 
ventral horn neurons undergoes axonal retrograde transport and is transported in 
endosomes that also contain the atoxic fragment of the tetanus toxin (Hc). ALCAM is 
not associated with a distinct subset of Hc-positive endosomes but is co-transported 
with known retrograde cargoes entering this axonal compartment, such as the cell 
adhesion molecule CAR and the neurotrophin receptor p75NTR. Considering the 
substantial percentage of ALCAM-containing endosomes that also contained Hc and 
p75NTR  (60% and 64% respectively), my results strongly suggest that the ALCAM 
transport compartment associates with the same motor proteins and Rab GTPases 
characterised previously for Hc-positive endosomes. Transport of Hc depends on the 
retrograde motor cytoplasmic dynein, as well as myosin Va (Lalli et al., 2003b). On 
expression of GFP-Rab5 and GFP-Rab7, Rab5 was found to localise on stationary or 
oscillating structures in the axon while Rab7 was found on long-range bi-directional 
moving puncta (Deinhardt et al., 2006b). This is particularly interesting since my results 
showed that the ALCAM transport speed distribution had two distinct peaks. This 
suggested that there are two types of ALCAM carriers, one slow moving with frequent 
pauses and a second faster retrograde transport carrier. It would be interesting to 
investigate this further in co-transport experiments in neurons expressing GFP-Rab5 
and GFP-Rab7. I hypothesise that ALCAM vesicles with slow transport kinetics would 
associate with Rab5, while those with faster transport would instead associate with 
Rab7. Perhaps the ALCAM transport observed with slower kinetics in neurons, could 
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be comparable to the short range ALCAM recycling reported in ovarian cancer cell 
lines (Piazza et al., 2005). 
The slow ALCAM transport component was not observed in the experiments assessing 
the effect of the ALCAM ligand CD6-Fc on transport. This may, however, be accounted 
for by methodological differences between these experiments and the original Hc co-
transport experiments. Firstly, the initial experiments were conducted in the presence 
of the atoxic Hc fragment, which is capable of modifying transport of other retrograde 
cargoes. Indeed, in the absence of neurotrophins, p75NTR can be directed to the 
retrograde route by Hc (Deinhardt et al., 2007), and Hc triggers Trk signalling in the 
absence of neurotrophins (Gil et al., 2003). This suggests that ALCAM sorting to the 
retrograde transport route could have been altered in the presence of Hc. Secondly, in 
the CD6-Fc experiments ventral horn neurons were exposed to the fluorescently 
labelled antibody against ALCAM (ALCAM488) on ice before moving to 37°C for 
internalisation and transport. Hypothetically this could result in a wave of internalisation 
that would saturate the sorting machinery so that a homogeneous population of 
antibody labelled carriers were at a similar stage of trafficking while being imaged. In 
contrast, in the initial experiments the probes were internalised throughout the 
incubation period allowing antibody-labelled endosomes at both early and late stages 
of internalisation and trafficking to be imaged simultaneously. It would be interesting to 
perform ALCAM transport experiments on ventral horn neurons isolated from the same 
mouse litter in the presence or absence of Hc and after exposure to the probes at both 
37°C and 4°C. This could resolve whether either of these working hypotheses account 
for the difference observed or whether it was merely due to the biological variability of 
different neuronal cultures. It would also be interesting to analyse my co-transport 
experiments in more detail, by separating the transport information of ALCAM-positive 
Hc-positive endosomes from those that were ALCAM-positive but Hc-negative. This 
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could reveal whether the speed distribution of ALCAM endosomes that also contained 
Hc had different transport dynamics from those that did not.  
6.1.2 Modulation of ALCAM transport 
I used ALCAM488 to follow transport of the endogenous protein in living ventral horn 
neurons. This involved antibody binding to ALCAM at the plasma membrane, which 
would cause clustering of the protein on the cell surface. This strategy for following 
protein transport may alter the subsequent trafficking route of the protein of interest as 
discussed in Chapter 3.2. It would have been interesting to follow photoactivated 
ALCAM-D in transfected neurons to determine if ALCAM clustering is a pre-requisite 
for its subsequent internalisation and transport. Although this would involve the 
overexpression of a tagged protein it would have allowed me to address whether 
transport was altered in response to stimuli that induce clustering, such as addition of 
ALCAM ligands or antibody cross-linking. Initial experiments examining ALCAM-D 
transport in differentiated PC12 cells yielded limited information because I found no 
evidence of vectorial transport of ALCAM along neurites. It would have been interesting 
to follow ALCAM-D transport in primary ventral horn neurons, however this strategy 
was hampered by the low efficiency of ALCAM-D expression after electroporation and 
the poor health of the electroporated neurons. 
In my experiments I did not detect a significant effect of CD6-Fc on the speed or 
frequency of ALCAM488-endosome transport. This could suggest that ALCAM 
transport is not modulated by ligand engagement. However, there were some practical 
issues in performing these experiments that may have made detection of small 
differences difficult. As described in Chapter 3, section 3.5.1, the ALCAM488 cross-
reacted with CD6-Fc and therefore these experiments had to be conducted with the 
constraint of incubating the neurons at 4°C. This additional manipulation may have 
contributed to the low frequency of ALCAM transport observed in these cultures and 
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this in turn made it difficult to get substantial numbers of carriers to analyse. Another 
factor that probably contributed to the low transport frequency observed in these 
experiments is that they were performed in the absence of Hc. However, this was 
necessary because it was unclear whether Hc modifies ALCAM transport and, if this 
was the case, the effect of ALCAM ligand stimulation may have been masked. 
Considering ALCAM is transported at low frequency and that sampling from each 
culture is low (only a few axons can be imaged during an individual experiment), the 
data analysis was inherently variable between different cultures. This made the 
detection of small differences difficult using statistical methods. Furthermore, my 
strategy assumed that ALCAM488 would be able to bind ALCAM molecules bound to 
CD6-Fc directly or to endogenous ALCAM associated in cis with ALCAM-CD6-Fc 
complexes. However, if this was not the case e.g. ALCAM488 and CD6-Fc competed 
for ALCAM binding, then the ALCAM488 probe would not have been capable of 
detecting the pool of carriers that contained ALCAM-ligand complexes.  
Although there is certainly not a large ligand-dependent effect on ALCAM transport as 
there is for p75NTR after exposure to neurotrophins (Deinhardt et al., 2007), several 
observations suggest that further examination of a ligand-dependent modulation of 
ALCAM transport is warranted. There was a consistent tendency towards an increase 
in the frequency of ALCAM carriers after exposure to CD6. It would be interesting to 
examine whether addition of ALCAM-Fc would alter ALCAM488 transport. 
Considering ALCAM-Fc and CD6-Fc have differential effects on neurite outgrowth, the 
ligands could also affect ALCAM transport differently. Furthermore, mimicking 
homophilic binding may be more physiologically relevant when examining the effect of 
ligand stimulation in neurons because CD6 is not expressed in the central nervous 
system but ALCAM is (discussed previously in Chapter 3, section 3.5.3).  
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6.1.3 The fate of ALCAM after axonal retrograde transport 
The biological reason for retrograde transport of ALCAM was not resolved in my 
experiments. However, following axonal transport to the neural cell body it is known 
that other retrograde transport cargoes can be degraded, be transcytosed to the 
dendrite/cell body plasma membrane via recycling endosomes or secreted as 
exosomes (reviewed in von Bartheld, 2004).  
6.1.3.1 Is transported ALCAM degraded? 
ALCAM vesicles showed little colocalisation with lysosomal markers, both in living 
neurons during transport or in immunofluorescence of ALCAM puncta in the cell body. 
However, my conclusions rely on the assumption that the ALCAM488 probe does not 
dissociate from the endogenous protein, nor lose fluorescence once in acidic 
compartments. In support of my findings, studies on other endocytosed CAMs in 
neurons have shown they do not primarily colocalise with degradative compartments, 
using both fluorescently tagged proteins and antibody-based approaches (Yap et al., 
2008, Diestel et al., 2007). NCAM localised to both Rab4 and Rab11 labelled 
endosomes, as well as those containing transferrin, suggesting that NCAM is targeted 
to recycling endosomes and then back to the plasma membrane (Diestel et al., 2007). 
Yap and colleagues (2008) found that NgCAM endocytosed in the dendritic/cell body 
compartment traffics via endosomes containing neuron-enriched endosomal protein of 
21 kDa (NEEP21) before being transcytosed to the axonal plasma membrane. It would 
be interesting to investigate the nature of the ALCAM-containing compartment in the 
soma further. Since ALCAM puncta in ventral horn neurons are not as numerous as 
NgCAM or NCAM puncta reported in these papers, it may be necessary to stimulate 
internalisation e.g. in the presence of Hc or an ALCAM ligand. This would increase the 
number of ALCAM-containing puncta in the soma necessary for proper quantification of 
colocalisation with endosomal markers (e.g. Rab proteins) by immunofluorescence. 
Preliminary experiments however, did not show a significant colocalisation with Rab21-
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positive compartments that have been previously associated with integrin recycling 
endosomes (Pellinen et al., 2006).  
As discussed in the Introduction section 1.5, an independent investigation in neurons 
has reported endocytosis of DM-GRASP, the chick orthologue of ALCAM (Thelen et 
al., 2008), however, with conclusions that partially contrast with my results. Thelen and 
collaborators (2008) found that the cytoplasmic tail of DM-GRASP could bind ubiquitin, 
and was also a site for ubiquitination. They found that DM-GRASP was mono-
ubiquitinated on the plasma membrane and suggested that internalised DM-GRASP in 
retinal ganglion cells (RGCs) was degraded after internalisation. In contrast, I found no 
evidence of ALCAM being targeted to degradative compartments in neurons. There are 
several reasons why Thelen et al (2008) have drawn different conclusions on the fate 
of internalised ALCAM/DM-GRASP from those presented here. Firstly, they assumed 
that DM-GRASP was targeted for degradation because they found DM-GRASP in large 
vesicles in cells overexpressing ubiquitin. Only vesicle size was used to indicate that 
the DM-GRASP-containing puncta after ubiquitin overexpression were of a degradative 
nature. In contrast, I used lysosomal markers, including LysoTracker in transport 
experiments and LAMP2 in immunofluorescence studies. Secondly, their experiments 
analysing the degradation of DM-GRASP were conducted on DM-GRASP transfected 
undifferentiated Neuro2A cells, while the DM-GRASP immunoprecipitation of ubiquitin 
was performed in transfected HEK cells. In sharp contrast, I examined the transport 
and destination of endogenous ALCAM in primary ventral horn neurons. In fact, in the 
study by Thelen et al (2008), it was observed that DM-GRASP accumulated in the 
central domain of RGC growth cones 15 minutes after antibody-stimulated 
internalisation, and interestingly, DM-GRASP-positive puncta decreased by 30 
minutes. Although, DM-GRASP degradation could account for this observation, 
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another interesting possibility consistent with my findings is that DM-GRASP 
underwent long-range axonal transport.  
Thelen et al (2008) concluded that the mono-ubiquitination was not responsible for 
internalisation because endocytosis of DM-GRASP was unaffected upon 
overexpression of ubiquitin. However, the effect of ubiquitin depletion was not tested in 
these experiments, and therefore, they cannot exclude the possibility that endogenous 
levels of ubiquitin are sufficient for steady state endocytosis of ALCAM/DM-GRASP. To 
date it has not been demonstrated whether the internalisation, transport or degradation 
of ALCAM is altered upon depletion of ubiquitin, or expression of ALCAM forms 
incapable of being ubiquitinated. Mono-ubiquitination of ALCAM would be a particularly 
interesting phenomenon to investigate in more detail because ALCAM lacks any known 
endocytosis motifs in its cytoplasmic tail, but mono-ubiquitination has been shown to 
regulate the endocytosis of NCAM in cortical neurons (Diestel et al., 2007). 
6.1.3.2 Does ALCAM undergo transcytosis? 
Considering the evidence showing that NCAM and NgCAM/L1 can be recycled back to 
the plasma membrane, it would be interesting to investigate if ALCAM can undergo 
recycling and transcytosis. I attempted to examine transcytosis of ALCAM in ventral 
horn cultures in compartmentalised chambers but the results of these experiments 
were inconclusive. Microfluidic devices currently produced in our laboratory have two 
channels separated by microgrooves (adapted from Park et al., 2006). These 
microgrooves do not allow cells to cross but are permissive for axon growth and 
therefore there is separation between the neuronal cell bodies in one channel and the 
axons in the other. In these experiments the ALCAM488 probe was allowed to 
internalise in the axonal compartment and be transported via the axon to the cell body. 
The cell body compartment was then incubated with the appropriate secondary 
antibody so, if ALCAM reached the cell surface, it would be labelled. Motor neurons are 
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a notoriously sensitive neural cell type to handle and in my experiments very few axons 
crossed the microgrooves to the axonal side in the microfluidic devices. I believe that to 
investigate this further, it would be necessary to characterise ALCAM transport in 
another neural cell type that can be cultured in this compartmentalised system e.g. 
dorsal root ganglia (DRG). L1/NgCAM accumulates on the axon plasma membrane 
and therefore the ratio of NgCAM fluorescence on the axon versus in the 
dendritic/soma compartment is used as a read-out for transcytosis efficiency (Yap et 
al., 2008). ALCAM is expressed on the neuron cell body, neurites and the axon, which 
means that I could not use the relative accumulation of ALCAM in the central 
compartment as a read-out of transcytosis efficiency.  
Transcytosis of ALCAM is however an attractive hypothesis to account for ALCAM’s 
retrograde transport in a non-degradative endosome. It has been shown that 
neurotrophins, their receptors and various toxins and viruses undergo transcytosis 
(reviewed in von Bartheld, 2004, Rind et al., 2005). I observed extensive colocalisation 
of ALCAM with p75NTR in the soma, and this could suggest that ALCAM is sorted with 
this neurotrophin receptor to the plasma membrane of the soma and/or dendrites after 
reaching the cell body. After transcytosis, a protein can be reinserted into the plasma 
membrane to function similarly as it did in the origin membrane (reviewed in von 
Bartheld, 2004). Alternative possible fates include, that the protein is used as a vehicle 
to release its ligand into the extracellular environment (either directly or by receptor 
ectodomain shedding), or secretion of the protein into the extracellular medium e.g. L1 
can undergo ectodomain shedding and secretion in exosomes (Stoeck et al., 2006). 
There is evidence that ALCAM can be released in exosomes from lung endothelial 
cells (King et al., 2008). ALCAM transcytosis is a legitimate and interesting hypothesis 
to test since ALCAM has several properties that are consistent with this possibility: (i) it 
can be cleaved, (ii) it has been found in exosomes, and (iii) it is known to interact with 
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other proteins that undergo transcytosis e.g. NgCAM (DeBernardo and Chang, 1996) 
and p75NTR (unpublished results from our laboratory). 
6.2 ALCAM expression in the nervous system 
In ventral horn neuron cultures, ALCAM is expressed as two distinct forms that are 
both membrane-bound and glycosylated. To the best of my knowledge, this is the first 
report showing the existence of two distinct ALCAM forms within the nervous system. I 
propose that these two forms in ventral horn neuron cultures are comprised of a higher 
migrating glial form, equivalent to that seen in U251MG cultures, and a smaller neural 
form, which is associated with the Hc axonal retrograde transport compartment.  
Alternative forms of ALCAM have been reported previously, but these can be attributed 
to differential glycosylation or membrane cleavage. In Fournier-Thibault et al (1999) 
neural ALCAM isolated from the spinal cord migrated on SDS-PAGE at a lower 
molecular weight than that observed in muscle lysates and epithelial cells. Pourquie 
and colleagues (1992), reported that ALCAM/BEN has at least 3 distinct forms: a 
heavy 110 kDa epithelial form, an intermediate 100 kDa haematopoietic form and a 95 
kDa neural form. However, all three forms collapsed into a 75 kDa band after 
deglycosylation with PNGase-F and therefore the difference in protein migration is 
attributed to differential glycosylation. The two novel ALCAM forms observed in this 
study in ventral horn neuron cultures cannot be attributed to differential glycosylation.  
Unfortunately, it was not possible to determine what accounts for the difference in 
migration of the two forms of ventral horn ALCAM. To address this, I plan to investigate 
if two transcripts are amplified by RT-PCR from RNA of ventral horn neuron cultures. It 
would be particularly interesting to establish whether the neural and glial ALCAM forms 
differ in their primary sequence, and whether this could reflect differences in function. 
Other important CAMs expressed in the nervous system express specific isoforms in 
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neurons and glia. For example, differential splicing of L1 in neurons results in inclusion 
of a sequence that is responsible for L1 endocytosis in growth cones, while the GPI-
anchored form of NCAM is expressed in glia (reviewed in Maness and Schachner, 
2007). Optimisation of ALCAM immunoprecipitation using different antibodies would 
also be warranted in order to determine whether the two forms associate with different 
proteins. Antibodies directed toward human ALCAM have been shown to 
immunoprecipitate the native protein. Based on the high degree of conservation of 
ALCAM in vertebrates, it is reasonable to hypothesis that these antibodies could be 
exploited to immunoprecipitate mouse ALCAM.  
I did not find evidence of ALCAM cleavage in ventral horn cultures or ALCAM-D PC12 
cells. For example, I did not detect a membrane bound C-terminal fragment as a 
product of cleavage in cell lysates or evidence of the ectodomain in the cell culture 
medium by western blot analysis (data not shown). However, in previous work 
examining ALCAM cleavage, ALCAM ectodomain fragments have been 
immunoprecipitated from cell lysates and culture medium (Rosso et al., 2007). 
Therefore, if ALCAM immunoprecipitation were optimised I would conduct these 
experiments again. Furthermore, it would be interesting to examine whether ALCAM 
cleavage and ectodomain shedding would be stimulated by neurotrophin stimulation in 
PC12 cells and ventral horn neurons, in analogy to the EGF-dependent cleavage 
observed in ovarian cancer cells (Rosso et al., 2007).  
6.3 ALCAM potentiates NGF-induced neurite outgrowth 
My results showed that ALCAM significantly potentiates neurite outgrowth in response 
to NGF in PC12 cells. Analysis of NGF-induced differentiation after transfection of 
truncation mutants or after addition of soluble ALCAM-Fc, revealed that this effect was 
dependent on the ALCAM extracellular domain. Expression of the transmembrane and 
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cytoplasmic domain alone had no effect on NGF-induced differentiation. Importantly, 
ALCAM alone did not induce PC12 differentiation, remarkably suggesting that ALCAM 
acts as a modifier of other signals and not as an initiator of neurite outgrowth. ALCAM’s 
role in neurite outgrowth was specific to the stimuli used. ALCAM overexpression 
increased NGF-differentiation of PC12 cells only but did not potentiate dbcAMP-
mediated neurite outgrowth. This suggests that ALCAM does not activate an 
intracellular signalling cascade directly because ALCAM overexpression did not 
synergise with dbcAMP stimulation. In contrast, ALCAM overexpression showed only a 
non-significant potentiation of GDNF-dependent neurite outgrowth, further supporting 
the specificity of its effect on neurite outgrowth.  
In light of these results, the findings presented in this thesis are compatible with the 
model of ALCAM function proposed by Prof. G Swart and colleagues and shown 
schematically in the Introduction, Figure 1.8. Indeed, truncation of the N-terminal of 
ALCAM abrogated the potentiation of neurite outgrowth seen upon overexpression of 
the full-length protein. This suggests that intact ALCAM binding can increase growth 
factor signalling and this is partially inhibited when trans binding is interrupted. The 
soluble ligand CD6-Fc that is only capable of trans binding, and in this respect behaves 
similarly to the isolated V1 domain alone, disrupted the endogenous ALCAM network 
resulting in no potentiation of neurite outgrowth. However, ALCAM-Fc, which is 
capable of cis as well as trans-interactions, was able to potentiate neurite outgrowth. 
This suggested that it is binding in cis and clustering on the membrane that is important 
in ALCAM mediated potentiation of NGF signalling. Previous work in vitro and in vivo 
has shown that ALCAM is involved in neurite outgrowth in many neuron types 
(DeBernardo and Chang, 1995, Avci et al., 2004, Ott et al., 2001), however my work, 
as outlined above, has provided molecular information on how this process may occur.  
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A critical difference between my studies and previous work is that I examined neurite 
outgrowth within cells overexpressing various forms of ALCAM, whereas previous 
studies have looked at the effect of ALCAM/DM-GRASP substrates on neuron 
outgrowth (Kawauchi et al., 2003, DeBernardo and Chang, 1995). Interestingly Avci 
and colleagues (2004), found that RGCs on a DM-GRASP/laminin substrate showed 
increased neurite outgrowth when compared to RGCs on laminin alone. In this study, 
the authors also showed that a DM-GRASP/polylysine substrate did not promote 
neurite outgrowth. Interestingly, I found that transfection of ALCAM did not potentiate 
neurite outgrowth alone but required a differentiation stimulus, e.g. NGF. In this 
context, my interpretation of the findings of Avci et al (2004) is that the laminin 
substrate has acted as the initiator of differentiation, similarly to NGF, and ALCAM has 
potentiated the subsequent neurite outgrowth as a modifier of the differentiation signal. 
If ALCAM can cooperate with laminin functioning as an initiator, it suggests that 
ALCAM cooperates with integrin signalling as has already been shown with other 
CAMs (Chen et al., 2010). Avci et al (2004) did not investigate whether NgCAM 
modulated integrin signalling directly, but this would be interesting to examine further 
considering my finding that ALCAM can potentiate NGF-signalling and differentiation.  
Since, my analysis of neurite outgrowth was restricted to ALCAM transfected cells, my 
results shed light on a cell-autonomous function for ALCAM in neurite outgrowth rather 
than a non-cell autonomous function as a substrate as previously described by others. 
Since ALCAM-D was only transfected in around 30% of cells, most cells with which 
these transfected cell came into contact with would have been untransfected. 
Therefore the differences in the neurite outgrowth observed is likely to be the result of 
ALCAM expression within the transfected cell analysed, rather than the result of 
interactions in trans from an adjacent cell. However, it is possible, although less likely, 
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that the alterations in neurite outgrowth were influenced by secretion of the ALCAM 
ectodomain into the medium, which could therefore function similarly to ALCAM-Fc. 
My experiments did not address whether ALCAM internalisation and transport related 
to ALCAM’s role in neurite outgrowth. In a previous study it was claimed that 
endocytosis of DM-GRASP was required for RGC preference for DM-GRASP 
substrates, but this study only showed that a general clathrin inhibitor abolished RGC 
preference for DM-GRASP/laminin substrates (Thelen et al., 2008). This approach did 
not formally prove that DM-GRASP endocytosis is important for RGC axon growth 
preference because the inhibitor used abolished general endocytosis and therefore the 
recycling of many plasma membrane proteins.  
6.3.1 Modulation of NGF-signalling 
I also examined whether ALCAM modulated the NGF signalling response by looking at 
the phosphorylation levels of TrkA and ERK1/2 in control and ALCAM-D transfected 
PC12 cells. ALCAM overexpression significantly increased the phosphorylation of the 
TrkA receptor. Unfortunately, I did not observe a statistically significant increase in 
ERK1/2 phosphorylation. However, this kinase is downstream of many other stimuli 
including stress factors and these are hard to control experimentally, as described in 
Chapter 5, section 5.4. I decided to analyse the phosphorylation of ERK1/2 because 
this signalling cascade is thought to be responsible for PC12 differentiation in response 
to NGF and I had seen a potentiation of neurite outgrowth in ALCAM-D transfected 
cells. However, different kinases are responsible for distinct responses downstream of 
NGF (reviewed in Klesse and Parada, 1999). It would be interesting to investigate 
whether the signalling cascade mediated through PI3K and Akt, which is responsible 
for PC12 cell survival, is also modified in ALCAM overexpressing cells.  
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6.3.2 Possible mechanisms by which ALCAM could potentiate NGF-induced 
differentiation 
I was unable to determine the precise mechanism by which ALCAM overexpression 
potentiates NGF-induced differentiation and TrkA phosphorylation in PC12 cells. I 
could not detect a direct interaction between TrkA and ALCAM by immunoprecipitation. 
Alternatively, ALCAM could potentiate NGF-signalling by altering the stoichiometry of 
neurotrophin receptor complexes on the plasma membrane. Therefore, I also 
investigated whether ALCAM interacts with p75NTR or sortilin, the p75NTR co-receptor, 
but no direct interactions were detected in ALCAM immunoprecipitations (data not 
shown). However, in view of the overall low immunoprecipitation efficiency, I can only 
tentatively conclude that ALCAM does not interact with these proteins.  
To clarify if NGF receptor activation is required as proposed or whether ALCAM 
interacts directly with NGF, it would be necessary to analyse the effect of ALCAM 
transfection on neurite outgrowth in PC12 cells that lack NGF receptors (e.g. 
knockdown of p75NTR or using PC12nnr that lack TrkA). Alternatively I could use a 
pharmacological approach and assess ALCAM potentiation of NGF-induced neurite 
outgrowth in the presence of the inhibitor K252a, to inhibit tyrosine kinase activity. I did 
not find evidence to suggest that ALCAM can bind to NGF directly by 
immunoprecipitation (data not shown) but perhaps a cell surface binding and 
interference experiment similar to that described in Piazza et al (2005) could be 
undertaken. Comparison of NGF binding to cells expressing ALCAM (but not TrkA or 
p75NTR) would need to be compared to cells that are null for all three proteins. Cells 
would need to be exposed to fluorescently labelled NGF-Fc prior to fluorescence-
activated cell sorting analysis (FACs analysis). 
Several alternative mechanisms could account for the potentiation of NGF-induced 
differentiation observed in this thesis. These include altered membrane localisation of 
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neurotrophin receptors, which I investigated in experiments that isolated detergent 
resistant membranes (DRMs - also referred to as lipid rafts) from ALCAM-D expressing 
cells. ALCAM transfection did not alter the association of Thy1.1 (a marker for DRMs), 
full length TrkA or its phosphorylated form within DRMs. ALCAM-D was found in 
detergent soluble membranes, but its expression appeared to alter the distribution of 
p75NTR toward Thy1.1-containing fractions. This could have functional consequences 
for p75NTR-dependent NGF signalling by changing the association of p75NTR with TrkA, 
its proximity to other effectors or its localisation to specific membrane subdomains. 
Another possible mechanism by which ALCAM overexpression could potentiate 
neurotrophin signalling is by altering the regulated proteolysis of membrane receptors. 
TrkA , p75NTR and ALCAM are all processed by ADAM17, and regulated proteolysis 
has been associated with altering signal cascade activation (Diaz-Rodriguez et al., 
1999, Ahmed et al., 2006, Rosso et al., 2007). Subsequently p75NTR can undergo -
secretase cleavage in endosomes (Urra et al., 2007) to generate an intracellular 
domain capable of potentiating TrkA signalling in response to NGF. The p75NTR 
intracellular domain is generated in response to NGF treatment in PC12 cells and it 
was shown that p75NTR cleavage induced by TrkA activity, in turn potentiated TrkA 
signalling (Ceni et al., 2010). Therefore, if ALCAM could increase p75NTR cleavage it 
could also potentiate TrkA signalling. It would be interesting to examine whether p75NTR 
cleavage is altered upon NGF stimulation in Dendra or ALCAM-D transfected cells by 
western blot. If this cleavage were confirmed, it would be interesting to test if 
potentiation of neurite outgrowth in response to ALCAM overexpression was altered 
following inhibition of ADAM17 or -secretase. This experiment would determine if the 
potentiation of NGF-signalling upon ALCAM overexpression required protease activity. 
To determine which ADAM17 substrate mediated this effect, it would be required to 
see whether potentiation of NGF-induced neurite outgrowth was inhibited in PC12 cells 
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transfected with p75NTR, TrkA and ALCAM mutants resistant to cleavage. I am aware 
that a possible explanation for the potentiation of NGF-signalling observed is that 
ALCAM overexpression could upregulate ADAM17 activity and in turn this could lead to 
an increase in cleavage of other ADAM17 substrates like p75NTR and TrkA. Although 
this could mean that the effects observed in this study are a consequence of 
overexpression, rather than a property of endogenous ALCAM, it could still be 
physiologically important considering that ALCAM is found overexpressed in several 
forms of cancer (Ofori-Acquah and King, 2008). 
It should be noted that several of the Hc endosome cell-surface proteins have 
properties relating to ectodomain shedding and metalloprotease regulation. Firstly, one 
metalloprotease itself, ADAM10, was found in this proteomic screen. Secondly, 
ALCAM has been shown to regulate metalloprotease activity e.g. matrix 
metalloprotease MMP-2 and membrane type 1 matrix metalloprotease MT1-MMP (van 
Kilsdonk et al., 2008, Lunter et al., 2005). Furthermore, another of the IgCAMs 
identified in this Hc-containing compartment is CD147, also known as extracellular 
matrix metalloproteinase (MMP) inducer (EMMPRIN) (see Introduction, Table.1). As 
well as these metalloprotease regulators, several of the Hc-endosome cargoes are 
known to undergo metalloprotease cleavage e.g. TrkA, p75NTR and NCAM (Diaz-
Rodriguez et al., 1999, Urra et al., 2007, Hinkle et al., 2006). This could suggest that 
regulation of metalloprotease activity is an important process in these retrograde 
carriers. This possibility is consistent with growing evidence suggesting that membrane 
proteolysis often happens on endosomes and this can relate to their signalling function 
(Urra et al., 2007). 
6.3.3 Issues relating to ALCAM depletion 
All my experiments examining the role of ALCAM in NGF-dependent neurite outgrowth 
in PC12 cells used overexpression of ALCAM. To determine whether the potentiation 
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of NGF-signalling observed is a property of endogenous ALCAM it is necessary to 
perform ALCAM knockdown experiments. By western blot and immunofluorescence I 
could not detect any endogenous ALCAM expressed in PC12 cells. However, I 
amplified an ALCAM transcript from PC12 cDNA by PCR. This result was in agreement 
with previous findings that demonstrated that the ALCAM transcript significantly 
increased in PC12 cells upon differentiation by NGF and dbcAMP (Ng et al., 2009). It is 
therefore likely that endogenous ALCAM was expressed in PC12 cells in my neurite 
outgrowth experiments, limiting the conclusions I could draw from my studies. For 
example, I could not conclude whether the cytoplasmic domain was required for 
potentiation of neurite outgrowth when I overexpressed ALCAM lacking the C-terminal 
tail because endogenous ALCAM may have been sufficient in transmitting signals in 
these cells.  
I attempted to knockdown ALCAM in PC12 cells but using immunofluorescence and 
western blot analysis I could not determine whether the protein had been depleted. It 
would be necessary to establish the efficiency of ALCAM knockdown using RT-PCR if I 
were to repeat these experiments. Furthermore, the interpretation of ALCAM 
knockdown experiments can be further complicated by mechanisms compensating for 
loss of ALCAM in knockdown cells. In Lunter et al (2005) ALCAM depletion decreased 
basal metalloprotease activity, however it had no effect on concanavalin A stimulated 
metalloprotease activity, a stimulator of the proteolytic cascade that bypasses the need 
for cell-matrix interactions. In contrast, ALCAM N-terminal truncation mutants (N-
ALCAM) inhibited both basal and concanavalin A stimulated metalloprotease activity in 
this study. This suggests that pharmacological stimulation can restore metalloprotease 
activity and relieve its dependence on ALCAM in ALCAM knockdown cells. In contrast, 
ALCAM truncation mutants inhibit metalloprotease activity under basal and stimulated 
conditions, suggesting that in the presence of a defective ALCAM network 
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metalloprotease activity remained ALCAM-dependent in both conditions. This suggests 
that ALCAM acts as a conditional switch in regulation of this pathway; if ALCAM is 
present a functional network is required to activate the metalloprotease cascade, but in 
the absence of ALCAM cells can compensate and activate metalloproteases via 
different mechanisms.  
ALCAM is expressed in many different tissues during development (reviewed in Swart, 
2002). I found ALCAM expressed in all cell types tested including PC12 cells, 
U251MG, primary ventral horn cultures, primary astrocytes, brain and muscle lysates. 
Undifferentiated Neuro2A cells have been used in previous studies as a cell system 
that lacks endogenous ALCAM (Thelen et al., 2008). However, upon differentiation with 
retinoic acid ALCAM was identified as a protein that became modified with a disialic 
acid epitope in Neuro2A cells (Sato et al., 2002). This suggests that once 
differentiated, these cells express ALCAM, and I confirmed this by amplifying the 
ALCAM transcript from differentiated Neuro2A cDNA (data not shown). Since my 
experiments were looking at the role of ALCAM in differentiation I could not use 
Neuro2A cells as an ALCAM null system. An alternative way to analyse the effect of 
ALCAM on neurite outgrowth in a null system would have been to express my 
constructs in ALCAM-/- ventral horn neurons.  However, primary ventral horn neurons 
are notoriously difficult to transfect and as already described, electroporation of ventral 
horn neurons was unsuccessful.  
6.4 Nerve terminal sprouting in vivo in response to BoNT/A 
was unaffected in ALCAM-/- animals 
I found that ALCAM-/- and wild type mice showed comparable nerve terminal sprouting 
in response to BoNT/A induced paralysis at the neuromuscular junction (NMJ) in vivo. 
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Although this suggests that ALCAM is not involved in this process, there are several 
considerations to be taken into account when interpreting this result. Firstly, the precise 
mechanism by which BoNT/A-induced sprouting at the NMJ occurs is unknown. It has 
been suggested that the muscle secretes factors that induce sprouting, such as insulin-
like growth factors (IGF) (Caroni and Schneider, 1994). Since I have shown that 
ALCAM exhibits specificity in modulating growth factor signalling and no phenotype 
was observed in vivo, this could suggest that the growth factors involved in sprouting 
after BoNT/A-induced paralysis activate pathways that are not potentiated by ALCAM. 
Another possible reason why absence of ALCAM did not alter the sprouting response 
in ALCAM-/- animals, is that upregulation of other CAMs may have compensated for the 
loss of ALCAM function. As described in the Introduction section 1.4, the IgCAM family 
is very large and there is known functional redundancy between its members. For 
example in cell lines, interference with endogenous ALCAM function can upregulate L1 
expression (van Kilsdonk et al., 2008). Interestingly, the V1V2C1C2C3 family member 
BCAM is also localised to the neuromuscular junction (Nishimune et al., 2008) and 
therefore it may compensate for ALCAM function in the knockout animals. It would 
have been interesting to investigate whether ALCAM-/- ventral horn cultures showed 
increased L1 or BCAM expression in western blot analysis from ventral horn cultures, 
brain and muscle lysates.  
Although NCAM and L1 have proven important functions in the nervous system, 
animals in which these genes have been knocked out have surprisingly mild 
phenotypes (see Introduction 1.4). Despite NCAM being expressed on muscle, motor 
neurons and terminal Schwann cells, NCAM-/- mice were found to have surprisingly 
normal NMJs (Moscoso et al., 1998). Only an in-depth electrophysiological analysis 
found subtle alterations in NMJ function (Polo-Parada et al., 2001). The knockout mice 
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have abnormal synaptic vesicle recycling, which results in increased transmission 
failures at high stimulation frequencies. Behaviourally, this cellular phenotype 
manifests as poor performance on a rota-rod test at high speeds when compared to 
wild type animals (Polo-Parada et al., 2001). Perhaps in-depth electrophysiological 
analysis of ALCAM-/- animals could reveal similar subtle changes in NMJ function. 
As outlined above, the relatively mild phenotype of NCAM-/- mice is proposed to be a 
consequence of functional redundancy between members of the IgCAM superfamily 
and the upregulation of proteins with related function during development (Moscoso et 
al., 1998). NCAM expression is restricted to the NMJ in adulthood but is re-expressed 
along nerves and muscle fibres in response to injury. Many genes expressed during 
development of the peripheral nervous system are not re-expressed after injury and 
therefore, Chipman and collaborators (2010) investigated whether a role for NCAM in 
synaptic stability could be revealed after injury when compensation by upregulation of 
other proteins may not occur. The authors analysed the recovery of NMJ function at 1, 
3 and 6 months after a tibial nerve crush in NCAM-/- mice. They found that NCAM-/- 
animals re-innervate normally after nerve injury. However, it was revealed that 3 and 6 
months after injury the reinnervated NMJ axons retracted in NCAM-/- mice, which in 
turn resulted in a progressive muscular atrophy. This study revealed that NCAM is 
required to maintain synaptic function after reinnervation and suggested NCAM has a 
role in long-term stability and maintenance of the NMJ that only becomes evident after 
injury when expression of other proteins cannot compensate for loss of its function. 
Interestingly, ALCAM is also dynamically regulated during NMJ formation and is 
upregulated in response to injury (described in the introduction section 1.5 and see 
Fournier-Thibault et al., 1999). ALCAM, therefore, may have a similar role to NCAM in 
maintenance of the NMJ. It would be interesting to conduct a similar study on ALCAM-/- 
mice examining the long-term stability of the NMJ after nerve injury. In this thesis the 
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NMJ was only examined at a relatively short period (three weeks), after induction of 
BoNT/A-induced paralysis. Taking into account the changes observed in NCAM-/- 
animals months after reinnervation, it would be interesting to also look at later time 
points after BoNT/A treatment, to establish if there would be long-term deficits in NMJ 
stability after recovery from muscle paralysis. 
Retinal ganglion cells in ALCAM-/- animals show misprojections from the temporal part 
of the retina to the superior colliculus (Buhusi et al., 2009). Since ALCAM is also 
expressed in a population of motor neurons, I think that it would also be interesting to 
map whether there is aberrant patterning of motor neurons and interneurons circuits in 
the spinal cord of ALCAM-/- animals. Behavioural monitoring of the ALCAM-/- mice 
showed that some adult knockout mice showed subtle hind limb clasping defects, 
which could suggest they had abnormal connectivity of neurons in their spinal cord 
which control these reflexes. The mistargeting of RGCs in ALCAM-/- mice reported by 
Buhusi et al (2009) was not observed in all animals analysed e.g. of 14 mice analysed 
11 had abnormal projections as well as normal, one had only abnormal projections 
while 2 were equivalent to wild type. This supports my observation of an abnormal 
clasping phenotype in only some ALCAM-/- mice, possibly because there is variability in 
the patterning defects observed, and perhaps normal connectivity exists in parallel to 
the aberrant circuits in many animals. A possible way to analyse whether motor 
neurons have aberrant projections in the spinal cord of ALCAM-/- mice would be to 
conduct a similar retrograde tracing study as reported by Buhusi et al (2009). Injecting 
tagged tetanus toxin, cholera toxin or viruses into muscles of ALCAM-/- animals could 
reveal if the neurons had an abnormal circuitry within the spinal cord, which could 
account for their abnormal clasping reflex. 
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6.5 Concluding remarks 
In this thesis, I have characterised the cell adhesion molecule ALCAM as a novel cargo 
of retrograde axonal transport in primary ventral horn neurons. I have shown that 
ALCAM is transported in a non-degradative compartment with other cell adhesion 
molecules and neurotrophin receptors. However, further work on the fate of ALCAM 
once it reaches the neuron cell body is required. I reported two novel ALCAM forms 
expressed in the nervous system that are likely to represent glial and neural isoforms. 
Importantly, my findings revealed a novel role for ALCAM in neurite outgrowth as a 
modulator of growth factor signalling. ALCAM overexpression potentiates NGF 
differentiation signalling and neurite outgrowth in PC12 cells. Molecular 
characterisation of ALCAM’s ability to potentiate neurite outgrowth revealed that the 
ALCAM extracellular domain is necessary and sufficient to increase PC12 
differentiation in response to NGF. A model for ALCAM function initially proposed in 
cancer cells (Swart et al., 2005) is consistent with my findings of ALCAM function in 
neurons. An intact ALCAM network can potentiate neurite outgrowth and the effect is 
predominantly dependent on cis-interactions. I propose that ALCAM can modulate 
specific growth factor signalling, although I did not determine the mechanism 
responsible for this phenomenon. I saw an alteration in p75NTR membrane localisation 
in detergent-resistant membranes, which could influence p75NTR signalling ability. An 
attractive hypothesis to test is that ALCAM regulates ADAM17 metalloprotease activity 
and therefore p75NTR cleavage. An increase in the cleavage and in turn in the 
concentration of the soluble p75NTR intracellular domain could potentiate TrkA 
signalling. Unfortunately, due to problems knocking down ALCAM and probable 
compensation by upregulation of proteins with related functions in vivo, I was unable to 
prove that ALCAM expressed at endogenous levels also contributes to growth factor 
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signalling. In the Discussion, I have described several ways in which to address some 
of these problems.  
The data presented in this thesis illustrates the complicated and intimate relationship 
between cell adhesion molecules and classical receptors at the membrane. Over 
recent years, work on signalling molecules at the membrane has shown that the 
boundaries between cell adhesion molecules and receptors are increasingly blurred. 
My results are consistent with work on other IgCAM family members that have been 
shown to cooperate with integrin and growth factor signalling. I have characterised the 
role of ALCAM in neurite outgrowth in molecular detail unlike previous studies. My 
results suggest that ALCAM is not merely a permissive substrate for neuron outgrowth, 
but that it can act cell-autonomously to potentiate neurotrophin signalling.  
The finding that ALCAM overexpression can potentiate growth factor signalling may 
have important implications for the study of cancer. ALCAM is found upregulated in 
many forms of cancer (Ofori-Acquah and King, 2008) where it has been correlated with 
disease progression and poor prognosis. My results show that overexpressed ALCAM 
potentiated neurotrophin signalling in neural cells. This implies that ALCAM 
overexpression in cancer, as well as regulating metalloprotease activity and adhesion, 
could have an additional role potentiating growth factor signalling. Importantly, it has 
been demonstrated that NGF and TrkA are overexpressed in epithelial ovarian cancer 
cells (Campos et al., 2007), which also overexpress ALCAM (Rosso et al., 2007). 
Therefore, overexpression of ALCAM in epithelial ovarian cancer may be of particular 
physiological importance because it could potentiate TrkA signalling, which has been 
linked to increased vascular endothelial growth factor (VEGF) expression and tumour 
progression in this cancer. Furthermore, Swart et al (2005) performed a gene 
expression profile analysis of ALCAM-positive metastatic melanoma cell lines versus 
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ALCAM-negative non-metastatic cell lines. The authors found that ALCAM 
overexpression not only correlated with the upregulation of the plasminogen activation 
cascade, but also the overexpression of several growth factors including bFGF, PDGF-
A and VEGF that may suggest that ALCAM could also play a role in these growth 
factor signalling cascades. In the future, it would be interesting to explore whether 
ALCAM overexpression cooperates with these growth factor signalling pathways, to 
promote tumour growth and progression in these cancers. 
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